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Chemical protein synthesis, via solid-phase peptide synthesis and 
chemoselective ligation of peptides, is a powerful approach for preparing 
peptides and proteins. These techniques enable complete atomic control over 
protein composition with both mechanistic and practical applications for 
biochemistry. 
The foundation of this dissertation is formed by two ambitious chemical 
protein synthesis projects: DapA (Chapter 2) and Dpo4 (Chapter 5). DapA is a 
312-residue protein whose folding depends on the well-studied chaperone 
GroEL/ES. The successful synthesis of DapA (in both L- and D- chirality) was 
used to demonstrate cross-chiral folding by GroEL/ES—a fundamental biological 
insight and potential tool for future mirror-image synthetic biology research.  
However, the record-breaking synthesis of DapA was an arduous process 
requiring tremendous human and technical resources. The lessons from this 
project were then applied to the synthesis of our next target, Dpo4 (352 
residues). Dpo4 is one of the shortest DNA/RNA polymerases, providing an 
accessible synthetic tool to amplify DNA/RNA for future synthetic biology studies. 
A new concept termed DOPPEL (Diversity-based Optimization of Peptide 
Properties to Enhance Ligations) was used to simplify this synthesis. 
Furthermore, various synthesis strategies and general advice for completing 
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mega-synthesis projects in the future are detailed in this chapter. 
In both the DapA and Dpo4 projects, one of the most prominent 
challenges was the handling of poorly soluble peptide segments. These poorly 
soluble peptides can lead to dramatic yield losses and additional complexities. 
In the third major synthesis project of this thesis, GroES, we overcame an 
even greater insolubility challenge. This 97-residue protein could not be 
synthesized due to extreme solubility challenges with its C-terminal half. In 
response to this challenge, a new chemical tool was developed to link a 
solubilizing peptide (“Helping Hand”) to the C-terminal half of the protein. Key to 
this approach is a new synthetic building block, Fmoc-Ddae-OH, which is easy to 
synthesize, incorporate, and cleanly remove once the solubilizing function is 
complete. 
Overall, this dissertation pushes the limits of chemical peptide and protein 
synthesis, and provides exciting directions for the next wave of biochemists 
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INTRODUCTION TO CHEMICAL PROTEIN SYNTHESIS 
 
1.1 The Advantages of Chemical Protein Synthesis 
Chemical Protein Synthesis (CPS) can be simply defined as the total 
chemical synthesis of proteins without any recombinantly expressed 
components. This dissertation discusses the application and simplification of 
CPS toward studying interesting biological problems. There are three key 
advantages that CPS provides over classical recombinant expression: 
(1) Direct accessibility to mirror-image D-peptide and proteins: Peptides and 
proteins composed of D-amino acids are attractive therapeutics due to their 
resistance to natural L-proteases1. D-peptides are the foremost research 
interest of the Kay lab, where they have developed a trimeric D-peptide 
inhibitor of HIV entry that possesses pM potency2. This group is also currently 
developing inhibitors to Ebola3 and other viruses with similar mechanisms of 
cell entry4. The critical method that is needed to develop targeted, mirror-
image D-peptide inhibitors is mirror-image phage display5. In this method, the 
target of interest is prepared in D-chirality and then screened against a 
natural (L-) phage library. The selected phage that bind the target are then 
sequenced. These peptide sequences are next synthesized in D-chirality. 
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Based on the law of symmetry, these D-peptides will bind to the natural L-
target. A critical first step to using this method is the total chemical synthesis 
of the D-target. There is currently no other reliable method for producing D-
proteins, although recombinant incorporation of individual D-residues into 
proteins has been achieved (review of methods for genetic code expansion6). 
Another notable application of D-proteins is the versatility that it can add to 
crystallization conditions. As has been reviewed7, the availability of racemic 
protein mixtures provides access to an extended array of achiral space 
groups, in particular the P1 space group. Several examples from the Kent lab 
have highlighted this advantage for protein crystallization8. 
(2) Preparation of site-specifically modified proteins for biological studies: 
Although the preparation of full-length proteins (>300 aa) by total chemical 
synthesis is not yet routine (see discussion below), an interesting work-
around to this challenge has been developed: expressed protein ligation 
(EPL)9. With this technology10, semisynthetic proteins can be prepared by 
reaction of recombinantly expressed proteins with synthetic segments. Some 
recent demonstrations include fundamental studies with ubiquitin11, alpha-
synuclein12, histones13,  and membrane proteins14. Although this intriguing 
method has been highly successful, this dissertation focuses on the 
challenges and applications of total chemical synthesis. 
(3) Preparation of proteins with entirely new topologies: In addition to facilitating 
the incorporation of site-specific modifications, CPS provides an approach for 
creating new protein topologies. Specifically, protein domains can be stitched 
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together in new ways analogous to those used in polymer chemistry. For 
example, scaffolds or templates can be prepared that then anchor several 
protein domains via chemoselective and site-specific attachment15.  
The current standard approach for performing CPS combines two 
technologies: (1) solid-phase peptide synthesis (SPPS)16 to produce peptide 
segments followed by (2) a chemoselective ligation strategy17 to connect the 
peptide segments. In SPPS, peptides are prepared using couple-deprotection 
cycles for sequential introduction of individual protected amino acids (building on 
a solid support from the C- to N-terminus). Final deprotection and cleavage from 
resin is typically achieved using either a moderate or strong acid, depending on 
the particular protecting groups and resin. The repetitive nature of SPPS makes it 
amenable to automation, greatly accelerating the rate of peptide production. 
However, the accumulation of byproducts (e.g., terminations, deletions, and 
modifications) during synthesis generally limits SPPS to ~50 aa18, although some 
prominent, highly-optimized examples have reported the successful synthesis 
(and purification) of 18819 and 140 residue peptides20. 
Importantly, peptides produced by SPPS must be purified to a high degree 
and be well-characterized by analytical HPLC and MS. To routinely advance 
beyond the ~50 aa limit of SPPS, chemoselective methods17, 21 are needed to 





1.2 Native Chemical Ligation: The Critical Advance in CPS 
The original attempts to ligate peptides required protection of all internal 
reactive groups, so that selective amide formation could be performed at the 
peptide termini. However, this approach was significantly hindered by the poor 
solubility of protected peptide fragments22. The solubilities of protected peptides 
can be hard to predict; in some cases, protected peptides are totally insoluble23. 
Other challenges associated with ligating protected peptides included 
racemization at the activated ligation site24 and the obvious difficulty of 
performing high-resolution purification on poorly soluble intermediates21b. A key 
discovery toward overcoming this challenge was the development of the 
“chemical ligation principle”, where unprotected peptide segments could be 
chemoselectively ligated. Here, a peptide containing a C-terminal thioacid was 
selectively reacted with a peptide containing an N-terminal bromoacetyl group to 
form a chemically analogous thioester bond product. Although this approach 
provided an important advance to achieving soluble and purifiable ligation 
products, the reaction product contained a non-native thioester bond. 
The key discovery in 1994 of Native Chemical Ligation (NCL) by Dawson 
and Kent solved these handling problems with protected peptides25. Fig 1 shows 
the mechanism of NCL. Here, a peptide containing a C-terminal thioester can 
react with another thiol by reversible thiol-thioester exchange. In the presence of 
another peptide with an N-terminal thiol group, a reversible peptide-peptide 
thioester intermediate forms. This peptide-peptide intermediate can then undergo 
an irreversible S ->N acyl shift (likely via 5-membered ring intermediate) to form a 
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natural amide product. 
Some key benefits of NCL include: 
• The use of highly solubilizing and denaturing conditions, which (generally) 
allows for relatively high concentrations (several mM) of the starting 
peptides, making the reaction highly kinetically favorable, 
• Straightforward HPLC and MS methods (generally) can be used to purify 
and analyze the stable ligation product, 
• The two reacting peptides can be prepared, and then stored, in a relatively 
easy fashion. The peptide with an N-terminal Cys can be directly prepared 
by SPPS, while preparation of the C-terminal thioester peptide is also 
achievable directly by Boc-SPPS26. Preparation of the thioester peptides 
by Fmoc-SPPS is more challenging and will be discussed below in detail. 
Thus, the development of NCL was critical to the field of peptide 
synthesis, as it provides an effective and clean procedure for producing synthetic 
proteins. However, as detailed in the next sections below, several challenges 
remain for the production of synthetic proteins to become routine. 
 
1.3 Dependence of NCL on an N-terminal Terminal Cysteine 
As introduced, NCL25 possessed a significant limitation in its dependence 
on a Cys residue at the ligation site—as Cys is the least common residue in 
proteins. This dependence on Cys is a bottleneck, as many proteins do not 
contain Cys residues. Alternatively, some proteins that do contain Cys residues 
possess long stretches (>100 aa) that lack these residues. This problem has 
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been addressed in two general ways: the ligation-desulfurization strategy and a 
removable auxiliary approach. In the less common auxiliary approach27, a C-
terminal peptide is generated with an N-terminal auxiliary group (typically on a 
Gly residue) containing a thiol for reaction in NCL. Following the NCL reaction, 
the auxiliary group is then removed to generate a native peptide. The lower utility 
of this method is likely due to the slower kinetics observed in these ligations. 
On the other hand, the ligation-desulfurization approach (pioneered by 
Dawson) has proven to be a reliable method for expanding NCL sites28. In the 
first iteration of this concept, NCL is still performed using Cys-based junctions; 
however, following ligation, the reaction site cysteine is desulfurized to an Ala 
residue using Ni metal. In other words, this method expands the suite of NCL 
sites to include Ala junctions. Danishefsky later refined this procedure by 
developing more gentle and robust metal-free reaction conditions by applying a 
free radical mechanism29. 
Addition of Ala to the NCL suite provided a huge benefit to the field, but 
even broader utility was provided in the next iteration of the ligation-
desulfurization concept. As suggested in Dawson’s original paper28, even more 
ligation sites could be gained by introducing non-natural β- or γ-mercapto-thiol 
amino acids, which could then be desulfurized back to a native residue following 
ligation. This concept was first applied using a β-mercapto-phenylalanine30. It has 
since expanded31 to several residues including Asp, Glu, Lys, Leu, Pro, Gln, Arg, 
Thr, Val, and Trp; however, the preparation of these building blocks is chemically 
demanding, with most requiring 7-16 synthetic steps. Unfortunately, only two of 
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these custom non-natural residues are commercially available: penicillamine 
(thio-Valine)32 and thio-proline33. Thus, at this stage, significant progress has 
been made to expand past the dependence on Cys junctions, but much of this 
work is still relatively inaccessible. 
 
1.4 Facile Preparation of Peptide Thioesters by Fmoc-SPPS 
The preparation of thioesters by Boc-SPPS is relatively straightforward by 
simple incorporation of a mercaptopropionic acid building block on-resin followed 
by subsequent thioester formation34. This thioester is stable during the synthesis 
and cleavage steps.  However, Boc-SPPS, compared to Fmoc-SPPS, is not ideal 
for routine laboratory use for the following reasons: 
(1) Boc-SPPS requires trifluoroacetic acid (TFA) handing at every 
deprotection step of the synthesis (in contrast to just one time for cleavage 
in Fmoc-SPPS), 
(2) Boc-SPPS requires highly corrosive and toxic hydrogen fluoride (HF) 
during the cleavage step26, 
(3) The harsh acidic conditions needed for Boc-SPPS (both for deprotection 
and cleavage) limits its use in the preparation of glycosylated and other 
custom amino acids35. 
Thus, we (and most other peptide labs) employ Fmoc-SPPS for routine 
peptide synthesis. However, at this time, thioesters cannot be routinely prepared 
using Fmoc-SPPS due to their instability to Fmoc deprotection conditions36. To 
address this problem, various crypto thioester/surrogate methods have been 
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developed (recently reviewed37,38). However, most of these methods suffer from 
one of two problems: very slow kinetics to generate the thioester species or the 
requirement for specialized chemical syntheses to generate the thioester device. 
In contrast, the recently developed peptide hydrazide method39 has provided a 
robust approach to preparing peptide hydrazides. In the peptide hydrazide 
method, thioesters are not directly assembled on-resin. Instead, they are later 
formed by activation of the hydrazide into an azide followed by in-situ thiolysis to 
generate a thioester in solution. This method has become the routine technique 
for all Kay lab synthesis projects. Additional details on the strengths and 
weaknesses of these methods are elaborated in great detail throughout the 
chapters. 
 
1.5 Dissertation Overview 
The primary goal of this dissertation has been to push the limits of 
chemical peptide and protein synthesis for studying interesting biological 
problems. However, along the way to pushing the limits, new tools and strategies 
were developed for simplifying the entire chemical synthesis process. 
Indeed, Chapter 2 (“Synthesis and Folding of a Mirror-image Enzyme 
Reveals Ambidextrous Chaperone Activity”) starts with the description of our first 
successful protein chemical synthesis project (the 312-residue DapA protein). 
This published report describes how the natural chaperone GroEL/ES is 
ambidextrous, in that it is capable of folding both L- and D- chemically 
synthesized versions of DapA, a model chaperone client protein.  
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Next, Chapter 3 (“Design and Characterization of Ebolavirus GP 
Prehairpin Intermediate Mimics as Drug Targets”) provides a detour to shorter 
peptide-based approaches to D-peptide inhibitors of Ebolavirus cell entry. 
Returning to CPS, Chapter 4 (“’Helping Hands’ for Simplifying Chemical 
Protein Synthesis: Preparation of the Challenging GroES”) introduces the 
synthetically challenging 97-residue GroES protein. The foundation of this 
challenge is the very poorly soluble C-terminal region of the protein, which could 
not be adequately purified in order to achieve the total synthesis. This problem 
was solved by the development of a straightforward method for temporarily 
introducing, and then cleaving, a solubilizing peptide (“Helping Hand”). This new 
tool for introducing helping hands, termed Fmoc-Ddae-OH, should be highly 
useful in the field. 
Lastly, Chapter 5 (“Towards the Total Chemical Synthesis of a 352-
residue DNA Polymerase”) details the sophisticated development of a six-piece 
synthesis strategy. Full-length synthetic protein was achieved using a methodical 
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Mirror-image proteins (composed of D-amino acids) are promising
therapeutic agents and drug discovery tools, but as synthesis of
larger D-proteins becomes feasible, a major anticipated challenge
is the folding of these proteins into their active conformations. In
vivo, many large and/or complex proteins require chaperones like
GroEL/ES to prevent misfolding and produce functional protein.
The ability of chaperones to fold D-proteins is unknown. Here
we examine the ability of GroEL/ES to fold a synthetic D-protein.
We report the total chemical synthesis of a 312-residue GroEL/ES-
dependent protein, DapA, in both L- and D-chiralities, the longest
fully synthetic proteins yet reported. Impressively, GroEL/ES folds
both L- and D-DapA. This work extends the limits of chemical pro-
tein synthesis, reveals ambidextrous GroEL/ES folding activity, and
provides a valuable tool to fold D-proteins for drug development
and mirror-image synthetic biology applications.
peptide synthesis | protein folding
All known living organisms use proteins composed of L-aminoacids. Mirror-image proteins (composed of D-amino acids)
are not found in nature and are promising therapeutic agents
due to their resistance to degradation by natural proteases (1, 2).
D-peptide inhibitors that target particular protein interfaces can
be identified by mirror-image phage display (3, 4), in which a li-
brary of phage bearing L-peptides on their surface is screened
against a mirror-image (D-) protein target. By symmetry, D-peptide
versions of the identified sequences will bind to the natural L-target.
Because D-protein targets must be chemically synthesized, this dis-
covery method has thus far been limited to relatively small targets.
Through rigorous application of recent advances in chemical
protein synthesis (reviewed in ref. 5), the production of larger
synthetic D-proteins is becoming increasingly feasible [e.g., 204-
residue D-VEGF dimer (6) and 84-residue D-MDM2/MDMX
(7)]. However, many proteins are prone to misfolding, especially
as their size and complexity increase (8). Molecular chaperones,
such as the extensively studied GroEL/ES, mediate folding by
preventing aggregation of many cellular proteins (9, 10). GroEL/ES
is thought to interact with these diverse substrates via nonspecific
hydrophobic interactions, but it is unknown whether it can fold
mirror-image proteins. If natural chaperones cannot fold mirror-
image proteins, then the folding of large/complex D-proteins into
their active conformations will be a major challenge (in the absence
of mirror-image chaperones, which are currently inaccessible).
The binding of substrates by GroEL is an intriguing instance of
promiscuous molecular recognition. GroEL has been shown to
interact transiently with ∼250 cytosolic proteins in Escherichia
coli under normal growth conditions (8, 11). A subset of these
proteins exhibit an absolute requirement for GroEL and its
cochaperone GroES to avoid aggregation and fold into their
native state (8, 12). Interestingly, sequence analysis of known
GroEL/ES obligate substrates reveals no obvious consensus
binding sequence (11), although structurally they are enriched in
aggregation-prone folds (12).
Several lines of evidence suggest the predominant interactions
between GroEL/ES and substrate proteins are hydrophobic.
Protein substrates trapped in nonnative states have been shown
to present hydrophobic surfaces that are otherwise buried in the
core of the correctly folded protein, and a hydrophobic binding
model is supported by the thermodynamics of binding of these
nonnative states to GroEL (13). Additionally, the GroEL apical
domain residues implicated in substrate binding are largely hy-
drophobic (14). Finally, previous studies on the basis of substrate
interaction with GroEL using short model peptides have con-
cluded that the most important determinant of substrate binding
is the presentation of a cluster of hydrophobic residues (15–17).
The only evidence addressing the chiral specificity of GroEL/
ES comes from a study that qualitatively demonstrated binding
of a short D-peptide to GroEL (16). However, this NMR study
required peptide concentrations that greatly exceed physiologic
levels and did not localize the interaction to the substrate-
binding region of GroEL. Only recently has it become feasible
to directly test the stereospecificity of the GroEL/ES folding
reaction by synthesizing the mirror-image version of a chaperone-
dependent protein.
Due to great interest in mirror-image proteins as targets for
drug discovery (6, 7, 18, 19) and mirror-image synthetic biology
(20, 21), we were intrigued by the possibility that natural (L-)
GroEL/ES could assist in the folding of D-proteins. Thus, we
synthesized a D-version of a substrate protein and evaluated its
folding by GroEL/ES. Furthermore, because most GroEL/ES sub-
strate proteins are large (>250 residues), this project provided
an excellent opportunity to demonstrate the power of chemical
synthesis methodologies for producing previously inaccessible
synthetic proteins.
Significance
This paper addresses a fundamental question: Can natural
chaperones fold mirror-image proteins? Mirror-image proteins
(composed of D-amino acids) are only accessible by chemical
synthesis, but are protease resistant and therefore have tre-
mendous potential as long-lived drugs. Many large/complex
proteins depend on chaperones for efficient folding. Here we
describe the total chemical synthesis of a 312-residue chaper-
one-dependent protein (DapA) in natural (L-) and mirror-image
(D-) forms, the longest fully synthetic proteins yet reported.
Using these proteins we show that the natural bacterial GroEL/
ES chaperone is “ambidextrous”—i.e., it can fold both natural
and mirror-image proteins via nonspecific hydrophobic inter-
actions. Our study also provides proof-of-concept for the use of
natural GroEL/ES to fold D-proteins for mirror-image drug dis-
covery and synthetic biology applications.
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Selection of DapA as Model Protein.We began our investigation by
searching for the smallest model protein that requires GroEL/ES
for folding under physiologic conditions and has a robust activity
assay that does not depend on complex chiral reagents (e.g.,
cofactors or other enzymes that would also require mirror-image
synthesis). The E. coli DapA protein [4-hydroxy-tetrahy-
drodipicolinate synthase (EC 4.3.3.7)] (Fig. 1) meets these cri-
teria. DapA is a 31-kDa protein that forms a homotetramer (22)
and catalyzes the stereoselective (23) condensation of L-aspartate-
β-semialdehyde and pyruvate to (4S)-4-hydroxy-2,3,4,5-tetrahydro-
(2S)-dipicolinic acid (24–26), a key step in the biosynthesis of lysine
and diaminopimelic acid, a cell-wall precursor.
DapA is highly enriched in GroEL/ES complexes under nor-
mal growth conditions (8) and is aggregated or degraded in
GroEL-depleted cells (8, 12). In E. coli GroEL-depletion strains,
cell death occurs via lysis due to loss of DapA activity, further
demonstrating the dependence of DapA on GroEL/ES to adopt
its native structure (27). Indeed, in vitro, DapA is absolutely
dependent on GroEL/ES for proper folding in physiologic buffer
at 37 °C (8). An added benefit of DapA as a model protein is that
although it depends on chaperones for folding under physiolog-
ical conditions, a chemical-folding procedure has been reported
using 0.5 M arginine (8), providing an important positive control
for enzyme activity independent of chaperone-mediated folding.
Although a chemical refolding protocol for DapA was reported,
many complex proteins cannot be folded by known chemical
means, e.g., E. coli METK (28) and METF (8, 29).
Synthesis of L- and D-DapA. Because D-proteins can only be
accessed through chemical synthesis, a synthetic route to DapA
was devised. Synthetic peptides are routinely made using solid-
phase peptide synthesis (SPPS), but a project of this magnitude
(312 residues) is well outside the capability of current SPPS
technology (generally ∼50 residues). To access larger synthetic
assemblies, chemoselective ligation techniques, especially native
chemical ligation (30), are used to assemble peptide segments
into larger constructs (reviewed in refs. 5, 31, and 32). Recent
noteworthy synthetic proteins include tetraubiquitin [alone (33)
and as part of a semisynthetic tetraubiquitinated α-synuclein
(34)], covalent HIV protease dimer (35), L-/D-snow flea anti-
freeze protein (36), glycosylated EPO (37, 38), and the γ-subunit
of F-ATPase (39).
For synthesizing DapA, we used a recently developed method
to join peptide segments via native peptide bonds formed be-
tween a peptide with a C-terminal hydrazide (for selective con-
version to a thioester) and a peptide with an N-terminal Cys (40–
43). We selected this chemistry because of the convenient route
to peptide hydrazides via Fmoc SPPS (less hazardous and more
compatible with acid-sensitive modifications than Boc chemis-
try), the robustness of the native chemical ligation reaction (30,
44), and the ease of carrying out convergent protein assembly
(vs. linear C- to N-assembly).
Our retrosynthetic analysis began by locating all Cys residues
(potential ligation junctions) in DapA (Fig. 1A), all of which are
located at acceptable ligation junctions (see refs. 40 and 45 for
discussions of unacceptable junctions). This information allowed
us to break the protein into six segments, leaving two segments
>50 residues. To expand the range of potential ligation junc-
tions, we used a free radical-based desulfurization reaction that
enables selective conversion of unprotected Cys to Ala (46, 47).
This technique allows one to substitute a Cys for a native Ala
residue during peptide synthesis (for use in ligation) and then












































Fig. 1. Total chemical synthesis of 312-residue DapA. (A) Target amino acid sequence, including N-terminal half (DapA 1–4, green), C-terminal half (DapA 5–8,
blue), N-terminal His tag and thrombin cleavage site (italics), cysteines (red), ligation sites (bold and underline), and A77C mutation (red arrow). (B) Final
synthetic strategy, including peptide segments (DapA 1–4, green and DapA 5–8, blue) with ligation hydrazide and cysteine residues indicated. Oxidation
(hydrazide to azide), native chemical ligation (NCL), and acetamidomethyl (ACM) cysteine deprotection steps are also indicated.
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this method, we introduced two additional junction sites at A77
and A211, resulting in eight segments overall, ranging in size from
27 to 50 residues (DapA 1–8; Fig. S1). Using optimized SPPS
reaction conditions and RP-HPLC column selection (Materials
and Methods), we synthesized and purified all eight peptides.
Our initial strategy for the assembly of these eight segments
required 12 steps (seven ligations, two desulfurizations, and
three Acm removals; Fig. S1) and their associated purifications.
Acm was used as an orthogonal Cys protecting group that pre-
vents cyclization/polymerization of peptides containing both an
activated C-terminal hydrazide and an N-terminal Cys, and also
prevents Cys desulfurization. Following this scheme, we assembled
the C-terminal segments (DapA 5–8), but were unable to assem-
ble the N-terminal segments (DapA 1–4). A significant compli-
cation was the His thioester on DapA 2 (H76), which was highly
susceptible to hydrolysis, leading to low reaction yields during the
DapA 2/3 ligation step (Fig. S2). This difficulty, coupled with the
large number of manipulations (and concomitant sample losses),
resulted in a failure to assemble DapA 1–4 in usable yield.
We reasoned that we could simplify the assembly if we elim-
inated the desulfurization step necessary to convert the Cys to
native Ala at the DapA 2–3 junction. Toward this end, we de-
termined locations in our protein that would likely tolerate
permanent mutation to Cys. BLAST analysis of the E. coli DapA
identified the 1,000 most-similar homologs (>69% conserva-
tion, >49% identity), which were aligned to determine positions
where Cys residues naturally occur. Fortuitously, 12% of the
aligned sequences contained Cys at position 77, site of the DapA
2–3 junction (Fig. 2A). Next, we analyzed the DapA crystal
structure to determine the likelihood of the A77C mutation to
disrupt protein structure/function. The side chain of residue 77 is
surface-exposed and not in close proximity to the active site or
any native Cys residues (>12 Å to the nearest Cys; Fig. 2B). This
analysis suggested that introduction of the A77C mutation would
likely be well tolerated. Indeed, this mutation affected neither
recombinant protein activity (Fig. 2C) nor its dependence on
GroEL/ES for folding under physiological conditions (Fig. 2D
and Table S1). We ultimately selected a final assembly strategy
that incorporated both the A77C mutation and a unified DapA
7–8 segment (we were not able to produce high-quality DapA 1–2,
3–4, or 5–6 unified peptides). This final strategy yielded a seven-
segment assembly scheme (Fig. 1B) that removed four synthetic
steps (and associated purifications) from the initial scheme.
Following this simplified strategy, we successfully assembled
the 312-residue synthetic DapA A77C (hereafter referred to as
“DapA”) in both L- and D- chiralities (Fig. 3 and SI Text), the
longest synthetic peptides reported to date. The peptides were
synthesized at milligram scale (1.1 and 1.7 mg of L- and D-DapA,
respectively; Figs. S3 and S4). The synthetic L- and D-peptides
behave identically to recombinant DapA on a C4 RP-HPLC
column (Fig. 3A), and the major products possess the correct













































































Fig. 2. Validation of the DapA A77C mutation. (A) Natural sequence diversity at position 77 from Protein BLAST analysis. (B) Structure of DapA tetramer (PDB
ID code 1DHP) showing, on one subunit, the surface-exposed alanine at position 77 (cyan), natural cysteine residues (green), and catalytic lysine at position
181 in the active site (red). (C) Enzyme activity of recombinant native WT and A77C DapA. Error bars indicate SD of at least three measurements. (D) GroEL/ES-
mediated refolding of recombinant WT and A77C DapA.














Fig. 3. Analysis of synthetic unfolded L- and D-DapA. (A) Analytical RP-HPLC of recombinant (black), synthetic L- (red), and synthetic D-DapA (blue) on C4
column (linear gradient 5–100% buffer B over 30 min; buffer A, 0.1% TFA in water; buffer B, 0.1% TFA in 10% water/90% acetonitrile). (B and C) LC-MS
analysis of the synthetic L- and D-DapA, respectively. Observed masses were calculated using the Bayesian Protein Reconstruct tool in Analyst 1.5.1 software
(AB Sciex) over the charge states covering 650–1,050 Da. See SI Appendix for larger, detailed mass spectra of the final synthetic products and HPLC and LC-MS
characterization of all synthetic intermediates.










Our initial efforts to fold these synthetic peptides using
GroEL/ES resulted in measurable enzymatic activity, albeit at
relatively low levels (∼20–40%; Table S1), likely due to micro-
heterogeneity in the synthetic peptides (SI Appendix). Because
active DapA assembles as a tetramer, we reasoned that we could
enrich for “foldable” protein by using a chemical refolding pro-
cedure followed by size-exclusion chromatography (SEC).
Chemical-Mediated Folding of DapA. Chaperone-independent folding
of DapA has been described using 0.5 M L-arginine (8), a protein
refolding additive (48). This method was validated at 13 °C using
recombinant DapA and works equally well with D-arginine (Fig.
S5). Thus, L-arginine can be used to fold both L- and D-DapA.
Importantly, this procedure also provides a chaperone-independent
means to evaluate the activity of our synthetic constructs.
After arginine-assisted folding of synthetic L- and D-DapA, we
isolated tetrameric protein using SEC (Fig. S6). Following SEC,
both the L- and D-DapA synthetic proteins have the expected CD
spectra (Fig. 4A) and are enzymatically active (Fig. 4B), dem-
onstrating that both L- and D-synthetic proteins are correctly
folded and functional. As hoped, the SEC purification generated
synthetic proteins with high specific activity (∼80% compared with
recombinant protein). However, the Arg-assisted refolding/SEC
purification resulted in a substantial (>10-fold) yield loss, largely
due to precipitation during dialysis and concentration steps.
Chaperone-Mediated Folding of DapA. With folded and equally
active synthetic L- and D-DapA in hand, we were poised to
perform the definitive experiment comparing the refolding of
our synthetic L- and D-DapA by GroEL/ES. This experiment
answers the question of whether GroEL/ES is ambidextrous
(i.e., Can it fold a mirror-image protein?). The SEC-purified
proteins were denatured for 1 h in denaturation buffer (con-
taining 6 M GuHCl) and then diluted 100-fold into refolding
buffer with or without GroEL/ES at 37 °C to initiate refolding.
At specific time points, refolding was quenched by Mg chelation
[1,2-diaminocyclohexanetetraacetic acid (CDTA)] followed by
measurement of enzyme activity using a colorimetric assay (8).
Interestingly, GroEL/ES refolded both synthetic L- and D-DapA,
as demonstrated by the recovery of significant enzymatic activity
(Fig. 5 and Table S1).
Discussion
The results presented here demonstrate that GroEL/ES is able
to fold a D-protein and therefore does not manifest strict ste-
reospecificity in folding its substrates. This result supports a
substrate binding mechanism via nonspecific hydrophobic inter-
actions followed by sequestration in the GroEL/ES cage (9, 10).
Our study also provides proof-of-concept for the use of natural
(L-) GroEL/ES to fold D-proteins for mirror-image drug dis-
covery and synthetic biology applications.
To determine if the ability of GroEL/ES to fold D-proteins is
universal, the most definitive approach would be the total
chemical synthesis of D-GroEL (548 residues) and D-GroES (97
residues), followed by screening of a suite of well-characterized
recombinant L-substrates in refolding assays. Though we ob-
served no difference in the activity of chemically refolded syn-
thetic L- vs. D-DapA, there was a noticeable difference in their
chaperone-mediated refolding. More detailed folding studies
(49) requiring additional material will be needed to determine
whether this difference reflects a general chiral preference in the
recognition and/or extent/rate of folding.
Although the synthetic proteins show high specific activity
(∼80% of recombinant protein; Fig. 4B), it will be important to
improve their quality and yield to expand application of this work
to even larger synthetic proteins. We speculate that subtle syn-
thetic defects in our proteins include single-residue deletions,
racemization (50), and aspartamide formation (51, 52).
Ultimately, the ability to chemically synthesize proteins of
interest not only serves to advance mirror-image drug discovery
efforts by making larger targets available, but also provides al-
luring possibilities for mirror-image synthetic biology (20) and
complements efforts to synthesize other large biomolecules (e.g.,
synthetic genomes) (53). An intriguing prospect is the assembly
of a mirror-image in vitro translation apparatus (including mir-
ror-image ribosomal proteins in combination with mirror-image
rRNAs; all but one of the 70S subunits are <300 residues), an
effort that we have dubbed the “D. coli” project (18). Such a tool
would not only provide a facile route to the production of mir-
ror-image biomolecules for drug discovery, but would also fa-
cilitate the structural/biochemical study of highly toxic agents in
(nontoxic) mirror-image form.
Materials and Methods
Peptide Synthesis and Ligation. Peptides were synthesized via Fmoc–SPPS on
a commercial peptide synthesizer (Prelude; Protein Technologies, Inc). Pep-
tide hydrazides were prepared on 2-hydrazine chlorotrityl resin (ChemPep).




























































Fig. 4. Structural and functional characterization of synthetic folded L- and
D-DapA. (A) Circular dichroism spectra of Arg-folded and SEC-purified
recombinant (black), synthetic L- (red), and synthetic D-DapA (blue). (B) En-
zyme activity of Arg-folded and SEC-purified synthetic L- and synthetic
D-DapA compared with native recombinant DapA. Error bars indicate SD of
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Fig. 5. GroEL/ES-mediated refolding of synthetic L- and D-DapA. Refolding of
recombinant (black), synthetic L- (red), and synthetic D-DapA (blue) (250 nM)
in the presence (closed circles) or absence (open circles) of 7 μM GroEL/ES.
Data are normalized to the maximum point in the GroEL/ES refolding of
recombinant DapA.
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pH 3.0 (5–20 mM NaNO2) at −20 °C for 20 min. Peptides were then ligated in
6 M GuHCl, 200 mM 4-mercaptophenylacetic acid (MPAA), 200 mM sodium
phosphate, pH adjusted to 7.0–7.2, at 25 °C for 5–20 h. Ligation reactions were
quenched by addition of freshly prepared tris(2-carboxyethyl)phosphine to
∼130 mM and incubated for >10 min.
Peptide Purification and Characterization. Analytical reverse-phase HPLC was
performed using Phenomenex Jupiter 4-μm Proteo C12 90 Å (150 × 4.6 mm)
or Phenomenex Jupiter 5-μm C4 300 Å (150 × 4.6 mm) columns. Preparative
reverse-phase HPLC of crude peptides was performed on either Phenomenex
Jupiter 4-μm Proteo C12 90 Å (250 × 21.2 mm) or Phenomenex Jupiter 10-μm
C4 300 Å (250 × 21.2 mm) column. Semipreparative reverse-phase HPLC of
ligation products was performed on a Phenomenex Jupiter 10-μm C4 300 Å
(250 × 10 mm) column. Purified peptides were analyzed by LC/MS on
a Phenomenex Aeris WIDEPORE 3.6-μm C4 (50 × 2.1 mm) column on an AB
Sciex API 3000 LC/MS/MS system. The major observed deconvoluted masses
from mass spectrometry were calculated using Bayesian Peptide and Protein
Reconstruct Tools in Analyst 1.5.1 Software (AB Sciex). See SI Appendix for
full characterization of all peptides.
Enzyme Activity Assay. Ten-microliter samples of DapA (250 nM) were added
to 240 μL of DapA assay buffer [200 mM imidazole (pH 7.4), 35 mMNa pyruvate,
4 mM DL-aspartate-β-semialdehyde, 0.5 mg/mL o-aminobenzaldehyde, 12.5 mM
CDTA] to initiate the enzyme activity assay (10 nM final enzyme concen-
tration). The assay is quenched after 15 min of agitation at room temperature
on a microplate shaker (800 rpm) by the addition of 50 μL 2 M HCl, developed
by continuing the agitation for 1 h at room temperature, followed by mea-
suring absorbance at 562 nm. Under these conditions, this assay demonstrates
good linearity (A562 < 0.4 for WT recombinant DapA; saturation occurs at
A562 >1.5).
Arginine-Assisted Folding. DapA constructs (both recombinant and synthetic)
were dissolved in denaturation buffer [6 M GuHCl, 20 mM MOPS (pH 7.4),
100 mM KCl, 10 mM MgCl2, 10 mM DTT] with 0.5 M arginine and diluted to
final concentration of ∼37 μM. Samples were incubated at room temperature
for 40 min, 13 °C for 20 min, and then dialyzed [Slide-A-Lyzer minidialysis
cassettes 3500 molecular weight cutoff (MWCO)] against 100× volume of
refolding buffer [20 mM MOPS (pH 7.4), 100 mM KCl, 10 mM MgCl2, 10 mM
sodium pyruvate, 1 mM DTT] with 0.5 M arginine for 2.5 h at 13 °C. Samples
were then further dialyzed against 100× volume 100 mM ammonium bi-
carbonate (pH 8) for 1 h. The dialyzed sample was used directly in functional
assays (post-Arg and pre-SEC) or concentrated by Vivaspin 500 10,000 MWCO
centrifugal concentrators and further purified by SEC (Superdex 200 10/30;
GE Healthcare) in 100 mM ammonium bicarbonate (pH 8) running buffer
with a flow rate of 0.75 mL/min (post-Arg and post-SEC). Following SEC,
samples were again concentrated and prepared for structural (CD spec-
troscopy) and functional assays (direct activity and GroEL/ES refolding).
Chaperone Refolding Assay. The DapA refolding assay (to evaluate GroEL/ES
chaperone activity) was adapted from ref. 8. Twenty-five micromolar stocks
of DapA were prepared from lyophilized powder (pre-SEC) or buffer ex-
changed (post-SEC) into denaturation buffer [20 mM MOPS (pH 7.4),
100 mM KCl, 10 mMMgCl2, 10 mM DTT, 6 M GuHCl] and allowed to denature
for 1 h at 25 °C. Refolding was initiated by diluting 100× into 37 °C refolding
buffer [20 mM MOPS (pH 7.4), 100 mM KCl, 10 mM MgCl2, 10 mM sodium
pyruvate, 5 mM ATP] with or without 7 μM GroEL monomer and 7 μM GroES
monomer. Final DapA concentrations used in refolding assays were 250 nM.
At specific time points, 10-μL aliquots of the refolding reaction were added
to 240 μL of DapA assay buffer, which simultaneously quenches chaperone-
mediated refolding and initiates assay of enzyme activity (measured as
described above).
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SI Materials and Methods
Recombinant DapA Proteins. The coding region of DapA was PCR
amplified from Escherichia coli BL21 (DE3) (Novagen) genomic
DNA using two primers:
• DapA_fwd: TGACCATATGTTCACGGGAAGTATTGTCG
• DapA_rev: TGACGGATCCTCCCTAAACTTTACAGCAAACC
Amplified product was then inserted into the pET14b vector
(Novagen) between NdeI and BamHI restriction sites, yielding
a construct with an N-terminal hexahistidine tag and thrombin
cleavage site (pET14b_DapA). The A77C mutant of DapA,
pET14b_DapA_A77C, was generated by mutating position 77
from GCT to TGC using the Q5 Site-Directed Mutagenesis Kit
(NEB) with pET14b_DapA as the template, using two primers:
• DapAmut_fwd: TGACGAACATTGCGATGTGGTGATGATG
• DapAmut_rev: TGATTTAAGGTAGCGGAC
Mutation was confirmed by sequencing of the entire gene.
Proteins were expressed in BL21 (DE3) cells (Novagen).
Cultures were grown in autoinduction media (1) in shake flasks at
37 °C to an OD600 of 0.7–1 and then allowed to grow for an
additional 14–18 h at 19 °C. Cell pellets were suspended in buffer
A [50 mM Tris (pH 7.3), 300 mM NaCl, 5 mM imidazole, 5%
glycerol] and disrupted by sonication. Samples were clarified by
centrifugation, and protein was isolated from the supernatant by
applying to His-Select Ni-affinity resin (Sigma), thoroughly wash-
ing with buffer A, and eluting in buffer A containing 250 mM
imidazole. Purified fractions were pooled, dialyzed against buffer
A without imidazole, spin concentrated to ∼8 mg/mL, aliquoted,
flash-frozen, and stored at −80 °C. A portion of the material was
further purified via RP-HPLC and lyophilized for use in re-
folding studies. The amino acid sequence of the recombinantly
expressed DapA used in the paper is identical to the synthetic
DapA constructs described below.
Recombinant GroEL and GroES.GroEL and GroES were expressed
in E. coli DH5α from the pBRE-groESL+ plasmid [gift from
C. Georgopoulos (University of Utah, Salt Lake City)], which
contains the E. coli groE operon. Cultures were grown at 37 °C in
shake flasks to an OD600 of 0.6. An equal volume of 55 °C media
was added and the cultures were shifted to 43 °C for 3 h to in-
duce expression of groE. Cell pellets were resuspended in buffer
[50 mM Tris (pH 8), 1 mM EDTA, 1 mM DTT] containing 0.17
mg/mL PMSF and lysed by incubation with lysozyme, followed
by sonication and centrifugation. GroEL and GroES were pu-
rified as described in ref. 2 with a 5-mL HiTrap Q HP column
(GE Healthcare) used instead of a DE-52 column. Eluted frac-
tions containing GroES were dialyzed at 4 °C into 25 mM Tris
(pH 8 at 4 °C), 0.5 mM EDTA, 1 mM DTT. One-molar NaOAc
(pH 4.6) was added to 75 mM and the sample was stirred on ice
for 15 min, filtered through a 0.2-μm pore-size membrane, and
then purified on a 1-mL HiTrap SP XL column (GE Healthcare)
with a NaCl gradient (0–500 mM over 15 column volumes) in
50 mM NaOAc, 0.5 mM EDTA, 2 mM DTT (pH 4.6). Fractions
containing GroES as judged by SDS/PAGE and liquid chroma-
tography (LC)/MS analysis were pooled, dialyzed against 25 mM
Tris (pH 7.5; pH 8 at 4 °C), 0.5 mM EDTA, 1 mM DTT, and
concentrated in an Amicon Ultra-15 centrifugal concentrator.
Concentrations were determined by absorbance at 280 mm
(GroES) or Bradford method (GroEL). Glycerol was added to
10%, and aliquots were flash-frozen and stored at −80 °C.
Peptide Synthesis. Peptides were synthesized via Fmoc–SPPS on
a commercial peptide synthesizer (Prelude instrument; Protein
Technologies, Inc). L-amino acids were from AAPPTec; D-amino
acids were from Peptides International and CBL Patras; and
both L- and D-Val-Ser(ψMe,Mepro)-OH pseudoproline dipeptides
(incorporated in peptide segments DapA 2 and 5) were obtained
from AAPPTec. Multiple batches of each peptide were synthe-
sized at ∼15-μmol scale. Peptides containing the C-terminal region
of DapA, i.e., DapA 8 and DapA 7–8, were synthesized on TentaGel
R RAM resin (0.19 mmol/g, RAPP Polymere) to generate
C-terminal peptide amides. All other peptides were synthesized on
2-hydrazine chlorotrityl resin (ChemPep) to generate C-terminal
peptide hydrazides. For each hydrazide peptide, the first residue
was manually attached to the resin to a desired density between
0.05 and 0.1 mmol/g by dissolving 0.075 mmol amino acid and
0.075 mmol Oxyma Pure (Novabiochem) in 1 mL 1:1 dime-
thylformamide (DMF):DCM, followed by activation with 0.08
mmol N,N′-diisopropylcarbodiimide for 10 min before addition to
180 mg of resin for 2 h. The resin was then washed with DMF, and
unreacted sites were capped by treatment with 1/1 acetic anhydride/
0.6 M N-methylmorpholine (NMM) in DMF for 15 min. After
capping, the density of the first amino acid (desired 0.05–0.1 mmol/g)
was confirmed by measuring Fmoc release, after 30-min treat-
ment with 20% piperidine in DMF (assuming Fmoc e301 =
7,800 M−1·cm−1), using a spectrophotometer.
Automated peptide synthesis was performed with the following
parameters. For Fmoc deprotection: (i) 2 mL of 20% piperidine
in DMF; (ii) mix 3 × 3 min (new solvent delivered for each
mixing cycle). For amino acid coupling: (i) 0.66 mL of 200 mM
Fmoc-protected amino acid in NMP; (ii) 0.66 mL of 198 mM
HATU in DMF; (iii) 0.5 mL of 600 mM NMM in DMF; and (iv)
mix 1 × 25 min. For DMF washing (performed between de-
protection and coupling steps): (i) 2 mL of DMF; (ii) mix 6 × 30 s
(new solvent delivered for each mixing cycle). Upon completion
of the peptide chain, resins were washed with DCM and dried
(using vacuum) for >10 min and then cleaved for 2.5 h using
a TFA mixture specific to the peptide sequence. Peptides con-
taining Cys: 3.7 mL TFA, 100 μL water, 100 μL TIS, 100 μL EDT;
peptides containing Met (±Cys): 3.7 mL TFA, 100 μL water,
100 μL TIS, 100 μL EDT, 60 mg NH4I.
Following cleavage, the mixture was isolated from the resin via
filtration, precipitated (and washed 3×) with cold diethyl ether, and
peptide was collected by centrifugation. Pelleted peptides were
dried overnight in a vacuum desiccator before HPLC purification.
HPLC and LC/MS. Analytical reverse-phase HPLC was performed
on crude and purified peptides using Phenomenex Jupiter 4-μm
Proteo C12 90 Å (150 × 4.6 mm) and Phenomenex Jupiter 5-μm
C4 300 Å (150 × 4.6 mm) columns at 1 mL/min with a water/
acetonitrile gradient in 0.1% TFA. The initial crude peptide
analytical HPLC traces were used to scout the column (either
C12 or C4) and gradient method to be used for the preparative-
scale purification. Analytical HPLC runs were also used to
present the purity of the peptide segments and ligation products
(see SI Appendix).
Preparative reverse-phase HPLC of crude peptides was per-
formed on either Phenomenex Jupiter 4-μm Proteo C12 90 Å
(250 × 21.2 mm) or Phenomenex Jupiter 10-μm C4 300 Å (250 ×
21.2 mm) at 10 mL/min with a water/acetonitrile gradient in
0.1% TFA. Semipreparative reverse-phase HPLC of ligation
products was performed on a Phenomenex Jupiter 10-μm C4
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300 Å (250 × 10 mm) at 5 mL/min with a water/acetonitrile
gradient in 0.1% TFA.
Fractions collected from preparative and semipreparative runs
(30-s intervals) were analyzed by LC/MS on a Phenomenex Aeris
WIDEPORE 3.6-μm C4 (50 × 2.1 mm) column at 0.4 mL/min
with a water/acetonitrile gradient in 0.1% formic acid on an AB
Sciex API 3000 LC/MS/MS system. Fractions containing correct
product (based on LC/MS) were pooled and lyophilized.
Analytical reverse-phase HPLC traces of purified peptides
were normalized to the maximum intensity point of the trace. The
major observed deconvoluted masses from mass spectrometry
were calculated using Bayesian Peptide and Protein Reconstruct
Tools in Analyst 1.5.1 Software (AB Sciex). The analytical gra-
dients used for each peptide are listed in the SI Appendix.
Peptide Ligation. For a typical ligation reaction, the N-terminal
peptide segment (containing C-terminal hydrazide for in situ
conversion to azide and then thioester) was dissolved (0.8–3.0mM)
in activation buffer [6 M GuHCl, 100 mM sodium phosphate
(pH 3.0)] and prechilled to −20 °C for 10 min. Next, hydrazide
activation (conversion of hydrazide to azide) was performed by
adding sodium nitrite to a final concentration of 5–20 mM (lower
concentrations were found to diminish hydrolysis of DapA 2
thioester) from a 200-mM stock in water (pH adjusted to 3.8–
4.2), mixing, and incubating at −20 °C for 20 min. The molar
ratio of NaNO2 to peptide hydrazide should be greater than 10
(3) to achieve sufficient activation. During the activation step,
the C-terminal peptide segment (containing N-terminal cysteine)
was dissolved in ligation buffer [6 M GuHCl, 200 mM 4-mer-
captophenylacetic acid (MPAA) (4), 200 mM sodium phosphate,
pH adjusted to 7.0–7.2]. Typically, a 2× molar ratio of the
C-terminal peptide segment (cysteine peptide) over the N-terminal
peptide segment (hydrazide peptide) was used in the ligations,
except in the final ligation where an excess of DapA 1–4 over
DapA 5–8 was used. In ligations involving DapA 2, 3, and 6
peptides, it was found that increasing the initial GuHCl con-
centration to 8 M improved solubility (final GuHCl concen-
tration was ∼7 M). Following activation of the N-terminal
segment, the solutions containing N- and C-terminal segments
were combined, pH adjusted to 6.8–7.0 with 2 M or 6 M NaOH
(using rapid mixing), and allowed to react at 25 °C for 5–20 h.
This final pH adjustment should be done carefully to prevent
thioester hydrolysis at pH values >7.0 (5). Accordingly, it was
found that this pH adjustment step could be conveniently sim-
plified by using activation and ligation buffers of different sodium
phosphate concentrations. Here, the pH 3 activation buffer was
100 mM sodium phosphate, and the pH 7 buffer was 200 mM
sodium phosphate. This approach ultimately reduced the amount
of NaOH needed to adjust the final ligation pH to 6.8–7.0 after
mixing the two buffers together.
Following ligation, reactions were quenched by addition of
freshly prepared tris(2-carboxyethyl)phosphine (TCEP) to
∼130 mM and incubated for >10 min. Addition of TCEP is es-
sential to reduce all MPAA in the solution; inadequate reduction
with TCEP led to dramatic precipitation problems during workup.
Further, the TCEP reduction should be performed at pH >5 to
prevent MPAA precipitation (5). Following reduction, the volume
was increased to 2.5 mL with 6 M GuHCl in 5% AcOH, and
then brought to a total volume of 5 mL with 5% AcOH (final
pH ∼2.0–3.0). Sample was then vortexed and sonicated thor-
oughly and clarified via centrifugation, and peptides were pu-
rified by HPLC.
Desulfurization. Desulfurization was based on ref. 6 with the
modification of replacing t-butylthiol with glutathione (7).
Desulfurization buffer [6 M GuHCl, 100 mM phosphate (pH
6.5)] was sparged with He and used to prepare a 550-mM stock
of TCEP (pH readjusted with NaOH to 6.5 after the addition of
TCEP) and a 53-mM stock of reduced glutathione. A 240-mM
stock of VA-044 was prepared in sparged water. Peptide was
dissolved in 230 μL of desulfurization buffer at a concentration
of ∼3 mM. Reagents were added to the peptide solution in the
following order: 204 μL glutathione stock, 204 μL VA-044 stock,
and 720 μL TCEP stock. The reaction was layered with argon
and incubated on a tube rotisserie overnight at 37 °C. Upon
completion, the reaction volume was increased to 2.5 mL with
6 M GuHCl in 5% AcOH, and then brought to a total volume of
5 mL with 5% AcOH. The sample was sonicated and clarified via
centrifugation, and peptides were purified by HPLC.
Acm Deprotection. Acm deprotection was performed as described
in ref. 8 by adding AgOAc to HPLC fractions containing Acm-
protected peptide to a final concentration of 20 mM, covering
with argon, and incubating overnight with gentle agitation at 25 °C.
DTT was added to 24 mM to quench the reaction, which resulted
in an immediate metal–DTT precipitate, followed by centrifuga-
tion to clarify the solution, dilution with 0.1% TFA in water (to
reduce acetonitrile concentration), and HPLC purification.
Enzyme Activity Assay. See main text.
Arginine-Assisted Folding. See main text.
Chaperone Refolding Assay. See main text.
DL-Aspartate-β-semialdehyde. DL-aspartate-β-semialdehyde (D/L–
ASA) for use in refolding assays was prepared essentially as
described by Black and Wright (9) from DL-allylglycine except
that the purification on Dowex resin was omitted and the com-
pound was aliquoted and stored in 1 M HCl at −80 °C. Stocks
were neutralized with NaOH immediately before preparation of
assay buffer. Racemic ASA was selected, because it has been
demonstrated that the recognition of ASA by DapA is stereo-
selective; the opposite chirality substrate is neither a substrate
nor an inhibitor of enzyme activity (10).
Circular Dichroism. All CD spectra were recorded on an AVIV
Model 410 spectrophotometer (AVIV) in 100 mM ammonium
bicarbonate buffer in a 1 mmQS quartz cuvette (Starna) at 25 °C.
Wavelength scans were performed at 1-nm resolution with 1-s
averaging time. Data from triplicate scans were averaged, blank
subtracted, and normalized to mean residue ellipticity by the
following equation: [θ] = 100 × θ/C × l × (n − 1), where C is
concentration of protein in mM, l is path length in centimeters,
and n is the number of residues in the protein. The concen-
trations of the protein samples used for CD experiments were
15.56 μM for recombinant DapA, 8.27 μM for synthetic D-DapA,
and 5.13 μM for synthetic L-DapA.
Sequence Analysis. BLAST analysis was performed using the
BLASTp algorithm with default parameters on the DapA protein
sequence from E. coli BL21(DE3) (GenBank accession no.
ACT44191.1). The sequences were aligned with the COBALT
Constraint-Based Multiple Protein Alignment Tool (11) and
analyzed with Jalview (12).
Structural Analysis. The crystal structure of DapA (PDB ID code
1DHP) was analyzed using the PyMolMolecular Graphics System
(Schrödinger, LLC).
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Fig. S1. Initial synthetic strategy for total chemical synthesis of 312-residue DapA, including peptide segments (DapA 1–4, green and DapA 5–8, blue) with
ligation hydrazide and cysteine residues indicated. Oxidation (hydrazide to azide), native chemical ligation (NCL), and acetamidomethyl (ACM) cysteine de-
protection steps are also indicated.




Fig. S2. Hydrolysis of DapA 2 thioester. Cys(ACM)-protected peptide hydrazides DapA 2 (A), 5 (B), and 7 (C) were dissolved in activation buffer at ∼0.4 mM
[6 M GuHCl, 100 mM sodium phosphate (pH 3.0)] and activated with NaNO2 (10 mM) at −20 °C for 20 min to generate active C-terminal azides (Top). Azide
groups were then converted to MPAA thioesters by equal-volume addition of ligation buffer (6 M GuHCl, 200 mM 4-mercaptophenylacetic acid, 200 mM
sodium phosphate, pH adjusted to 7.0–7.2) and pH readjusted to 6.8–7.0. Postmixing time-points at 30 and 60 min (Middle and Bottom) were collected,
quenched with 100 mM TCEP in 1% TFA, and analyzed by LC/MS. Significant hydrolysis of DapA 2 (histidine) thioester was observed in less than 60 min,
whereas DapA 5 and 7 thioesters were stable for several hours.





























































1.11 mg (by UV)
L-DapA Yields
Fig. S3. Yields obtained during the total chemical synthesis of 312 residue L-DapA, including peptide segments (DapA 1–4, green and DapA 5–8, blue) with
ligation hydrazide and cysteine residues. Oxidation (hydrazide to azide), NCL, and ACM cysteine deprotection steps are also indicated.




























































1.66 mg (by UV)
~20 mg ~5 mg
Fig. S4. Yields obtained during the total chemical synthesis of 312-residue D-DapA, including peptide segments (DapA 1–4, green and DapA 5–8, blue) with
ligation hydrazide and cysteine residues. Oxidation (hydrazide to azide), NCL, and ACM cysteine deprotection steps are also indicated.
0 20 40 60 80 100
% Activity (relative to native DapA)
Native
Fig. S5. Arginine-assisted refolding of DapA. Enzyme activity of recombinant DapA refolded with D-arginine or L-arginine (pre-SEC purification), normalized
to native DapA. Error bars indicate SD of at least three assays.



















Synthetic D (run 1)
Synthetic D (run 2)
Fig. S6. SEC purification of DapA following arginine-assisted folding. Chromatograph from purification of DapA tetramers after arginine-assisted folding:
synthetic L-DapA (one run) and synthetic D-DapA (two runs). Native recombinant DapA tetramer (normalized) is shown for comparison.
Table S1. Absorbance values (A562) at specified time points in refolding assays
Time, min
Recombinant DapA* Synthetic DapA A77C, pre-SEC Synthetic DapA A77C, post-SEC†
WT A77C L- D- L- D-
+GroEL/ES −GroEL/ES +GroEL/ES −GroEL/ES +GroEL/ES −GroEL/ES +GroEL/ES −GroEL/ES +GroEL/ES −GroEL/ES +GroEL/ES −GroEL/ES
1 0.097 0.045 0.012 0.006 0.028 0.000
2 0.192 0.146 0.045 0.007 0.084 0.008
3 0.230 0.001 0.184 0.000 0.063 0.000 0.012 0.000 0.126 0.003 0.034 0.003
5 0.265 0.210 0.078 0.025 0.138 0.072
7 0.272 0.225 0.085 0.033 0.150 0.090
9 0.277 0.004 0.225 0.000 0.088 0.002 0.039 0.002 0.155 0.001 0.096 0.000
13 0.275 0.005 0.231 0.000 0.094 0.003 0.041 0.008 0.155 0.103 0.004
16.5 0.274 0.230 0.097 0.046 0.156 0.107
21 0.292 0.241 0.100 0.046 0.153 0.109 0.002
30 0.293 0.008 0.248 0.000 0.110 0.005 0.047 0.003 0.168 0.000 0.115
44 0.302 0.253 0.106 0.053 0.170 0.135
58 0.293 0.012 0.250 0.003 0.108 0.008 0.053 0.011 0.172 0.000 0.120 0.004
Chaperone-mediated refolding of DapA recombinant WT vs. A77C, synthetic L- vs. D-A77C, pre-SEC purification, and synthetic L- vs. D-A77C, post-SEC
purification.
*In Fig. 2D, normalized to native recombinant DapA (WT): 0.363.
†In Fig. 5, normalized to highest point in GroEL/ES refolding of recombinant DapA (A77C): 0.253.
Other Supporting Information Files
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Abstract: Ebolaviruses are highly lethal filoviruses that cause hemorrhagic fever in humans and non-
human primates. With no approved treatments or preventatives, the development of an anti-
ebolavirus therapy to protect against natural infections and potential weaponization is an urgent
global health need. Here, we describe the design, biophysical characterization, and validation of pep-
tide mimics of the ebolavirus N-trimer, a highly conserved region of the GP2 fusion protein, to be
used as targets to develop broad-spectrum inhibitors of ebolavirus entry. The N-trimer region of
GP2 is 90% identical across all ebolavirus species and forms a critical part of the prehairpin interme-
diate that is exposed during viral entry. Specifically, we fused designed coiled coils to the N-trimer
to present it as a soluble trimeric coiled coil as it appears during membrane fusion. Circular dichro-
ism, sedimentation equilibrium, and X-ray crystallography analyses reveal the helical, trimeric struc-
ture of the designed N-trimer mimic targets. Surface plasmon resonance studies validate that the N-
trimer mimic binds its native ligand, the C-peptide region of GP2. The longest N-trimer mimic also
inhibits virus entry, thereby confirming binding of the C-peptide region during viral entry and the
presence of a vulnerable prehairpin intermediate. Using phage display as a model system, we vali-
date the suitability of the N-trimer mimics as drug screening targets. Finally, we describe the founda-
tional work to use the N-trimer mimics as targets in mirror-image phage display, which will be used
to identify D-peptide inhibitors of ebolavirus entry.
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Ebolaviruses are enveloped, negative-strand RNA
viruses that cause severe hemorrhagic fever.1 Since
its identification in 1976, there have been over 20
reported natural ebolavirus outbreaks, the majority
since 2000, and several accidental laboratory expo-
sures with an overall mortality rate >60%.2 Alarm-
ingly, in 2014 the largest known outbreak is
occurring in western Africa3 and has crossed inter-
national borders. Currently, no vaccines or therapeu-
tics are FDA approved. Because of ease of
transmission, high mortality, and potential for a
severe impact on public health, the CDC places ebo-
laviruses in its highest category of potential agents
of bioterrorism.4 There is a vital need for preventa-
tives and/or therapeutics to protect against future
natural, accidental, or deliberate outbreaks.
Ebolavirus entry into host cells, a critical step
to infection, is mediated by the viral surface glyco-
protein (GP), a class I fusion protein.5 GP comprises
two disulfide-linked subunits, one surface exposed
(GP1) and one embedded in the viral membrane
(GP2).6,7 Following binding to host cells via cell sur-
face attachment factors, the virus is endocytosed.
Endosomal cysteine proteases, cathepsins B and L,
cleave off much of GP1, exposing the binding site for
the receptor, endosomal NPC1.8–12 At this point, the
fusion mechanism is thought to mimic that of other
well characterized viral class I fusion proteins, such
as HIV-1 and influenza13–15 (Fig. 1). GP2 forms a
transient conformation (“prehairpin intermediate”)
embedded in both the virus (via the transmembrane
domain) and host cell (via the fusion loop) mem-
branes. This prehairpin intermediate exposes a tri-
meric coiled coil, formed by the N-terminal region
(N-trimer), and the C-terminal region (C-peptide).
Slow collapse of the intermediate into a very stable
trimer-of-hairpins structure, with the C-peptide
binding into the grooves on the N-trimer, juxtaposes
the virus and cell membranes, leading to membrane
fusion. In ebolavirus entry, the low pH of the endo-
some contributes to the stability of the trimer-of-
hairpins.16
In the case of HIV-1, the prehairpin intermedi-
ate has been exploited to develop highly potent viral
entry inhibitors (Fig. 1). Peptides and proteins that
bind with high affinity to either the N-trimer or C-
peptide regions prevent formation of the trimer-of-
hairpins, thereby halting viral entry [as reviewed in
Ref. (17)]. The most potent of the HIV entry inhibi-
tors, chol-PIE12-trimer, binds to the conserved
hydrophobic pockets of the HIV N-trimer and inhib-
its HIV entry with low picomolar potency.18 Since
filoviruses share a similar mechanism of entry as
HIV-1, they are likely vulnerable to inhibitors that
similarly target the prehairpin intermediate.
Figure 1. Model for membrane fusion mediated by enveloped virus surface glycoproteins. The HIV-1 and ebolavirus entry
events are predicted to be similar. First, the surface glycoprotein (Env for HIV-1, GP for ebolavirus) facilitates viral attachment
to the cell and, for ebolavirus, the virus is endocytosed and then cleaved by endosomal proteases. Engagement of the virus
receptors (CD4 and a chemokine receptor for HIV-1, NPC1 for ebolavirus) is followed by a conformational change in Env/GP,
and insertion of the fusion peptide/loop (brown) into the host cell membrane. At this stage, the virus is in a transient state that
bridges both membranes, termed the “prehairpin intermediate,” which is vulnerable to inhibition. In the absence of an inhibitor,
the Env/GP structure slowly resolves into the highly stable trimer-of-hairpins structure, juxtaposing the two membranes, and
leading to membrane fusion. The inset shows the high resolution structure of the ebolavirus trimer-of-hairpins (PDB: 2EBO).27 In
HIV, it has been shown that inhibitors that bind to either the N-trimer (blue) or C-peptide (yellow) regions are capable of inhibi-
ting entry [as reviewed in Ref. (17)].
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There are five known species of ebolavirus, four
of which are pathogenic to humans. The vast major-
ity of promising preventative and therapeutic candi-
dates with efficacy against ebolavirus in animal
models, such as vaccines, antibodies, and antisense
compounds (e.g.,19–23), are species-specific, resulting
in limited breadth and difficulty in combating
emerging species. The N-trimer of the prehairpin
intermediate provides a highly conserved target for
potential broad-spectrum inhibitors. Indeed,
although the overall sequence identity of GP across
all known ebolavirus species is only 42%, the
N-peptide region is 90% identical, and all changes
are conservative [Fig. 2(A)].
Here, we describe the development of ebolavirus
N-trimer mimics that will be useful in a variety of drug
discovery platforms to screen small molecule, antibody,
and peptide libraries for entry inhibitors that target
this conserved region. Specifically, we have designed
and characterized peptide mimics of ebolavirus N-
trimers, validated their use as drug discovery tools,
and explored conditions that can be applied directly to
phage display drug discovery endeavors. In addition,
using one of our N-trimers as an inhibitor itself (to
Figure 2. Conservation of the ebolavirus GP N-trimer and design of peptide N-trimer mimics. (A) Schematic of the primary
structure of ebolavirus GP2, indicating the fusion loop (brown), N-trimer (blue), C-peptide (yellow), and transmembrane domain
(TM, purple), all shown approximately to scale. The sequences of the N-trimer region (residues 558–596) and the C-peptide
region (residues 597–633) (Zaire ebolavirus species, representative Mayinga strain isolated in Zaire in 197660) contained in the
peptides described in this study are indicated. In the C-peptide, cysteine 609, which is proposed to disulfide bond with GP1,76
is mutated to alanine in our constructs (red). Below the Zaire N-trimer is an alignment of the sequences from the 4 additional
ebolavirus species plus Marburgvirus and Cuevavirus filoviruses. Genbank accession codes are indicated (right). Conserved
changes (score of 0 or higher in BLOSUM62 matrix77) are highlighted in gray, nonconserved in cyan. Notably, 3/5 and 5/5 ebo-
lavirus species are 100% identical in the N39 and N21 regions, respectively. The 2014 epidemic is caused by the Zaire ebolavi-
rus species and is 100% identical in this region.3 *Reston and likely Cuevavirus (Lloviu virus) are not pathogenic to humans. (B)
Schematics and sequences of the N-trimer mimics and their corresponding binding site mutants [eboIZN21 and eboIZN21(D2);
eboIZN39IQ and eboIZN39IQ(D3)]. The designed coiled coils, IZm and IQ, are shown in gray, while the ebolavirus N-trimer is
shown in blue. The a and d positions of the coiled-coil heptad repeats are indicated by a larger bolded font, including a stutter
at the N-terminal end of the ebolavirus N-trimer as seen in the crystal structures,27,28 where the coil is underwound, leading to
an atypical 3-4-4-3 pattern (instead of the standard 3-4, or a-g, periodicity of a heptad repeat). The alanine residues along the
C-peptide binding groove that are mutated to aspartate in the binding site mutants are shown (orange).
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target the C-peptide region of the prehairpin interme-
diate), we have confirmed the vulnerability of the ebo-
lavirus GP prehairpin intermediate to entry inhibition.
Results and Discussion
N-trimer mimic design
Based on our previous HIV-1 work,24,25 we set out to
design soluble peptide mimics of the N-trimer region
of the ebolavirus GP prehairpin intermediate by fus-
ing stable, soluble, designed trimeric coiled coils to
the N-trimer sequence [Fig. 2(B)]. As with HIV-1,
the ebolavirus N-trimer aggregates when produced
in isolation. We were interested in presenting the
entire N-trimer groove as well as a smaller, more
conserved region of the N-trimer to provide flexibil-
ity in drug screening. Our initial designs, in which
we fused the coiled coil IZm(24) to the N-terminus of
N-trimer segments of 29 and 39 amino acids, were
aggregated as determined by analytical ultracentri-
fugation (AUC) sedimentation equilibrium experi-
ments (data not shown). To overcome this problem,
we fused an additional trimeric coiled coil, GCN4-
pIQI’ (IQ)
26 to the C-terminus of the ebolavirus N-
trimer segment. The resulting peptide, eboIZN39IQ
presents the full ebolavirus N-trimer (determined
from available trimer-of-hairpins crystal struc-
tures27,28) as a trimeric coiled coil, as shown by cir-
cular dichroism (CD) [Fig. 3(A)] and AUC [Fig. 3(C)
and Table I]. eboIZN39IQ is very stable, as indicated
by similar CD spectra at 25, 37, and 50!C (Table I).
The ultimate goal for an ebolavirus N-trimer mimic
is to use it as a target in drug screening to identify
inhibitors of ebolavirus entry. Since these inhibitors
will bind to the virus in the endosome, all biophysi-
cal analyses were performed at pH 5.8 to mimic
endosomal pH.
To produce a smaller target that presents a
100% identical region of the N-trimer (across all ebo-
lavirus species), IZm was fused to the N-terminal 21
amino acids of the N-trimer, resulting in eboIZN21
(Fig. 2). Circular dichroism indicates that eboIZN21
is highly helical [Fig. 3(B)], and AUC and gel filtra-
tion studies show that it is largely trimeric with a
slight tendency to form higher order aggregates
(Table I and Supporting Information Fig. S1). X-ray
crystallography studies confirm the trimeric
Figure 3. Biophysical analyses of ebolavirus N-trimer
mimics. (A) CD spectra of 11.4 mM eboIZN39IQ and 11.1 mM
eboIZN39IQ(D3) at 25!C. Both spectra indicate a highly heli-
cal conformation with 81 and 83% helicity, respectively. (B)
CD spectra of 18.0 mM eboIZN21 and 25.3 mM eboIZN21(D2)
at 25!C, also indicate a highly helical conformation with 73
and 71% helicity, respectively. (C) Analytical ultracentrifuga-
tion (AUC) sedimentation equilibrium analysis of eboIZN39IQ,
shown as representative AUC data. 10, 5, and 2.5 mM pep-
tide solutions were centrifuged at 18,000, 21,000, and 24,000
rpm at 4!C on a Beckman XLA. All data were globally fit to a
single ideal species, and an observed molecular weight of
39,762 Da was determined for an Mobs/Mcalc of 3.31. The
data (open symbols) and fit (solid lines) are shown for the
lowest speed.
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coiled-coil structure of eboIZN21 (below). As seen with
eboIZN39IQ, eboIZN21 is very stable, showing similar
CD spectra at 25, 37, and 50!C (Table I). We also
attempted to produce mimics presenting the
C-terminal portion of the N-trimer, but they were not
soluble (data not shown) and were not studied further.
As negative controls for binding studies and
drug discovery efforts, we produced mutant
N-trimer mimics aimed at abolishing the C-peptide
binding site. Specifically, alanines found along the
C-peptide binding groove were mutated to aspartate,
introducing binding-disruptive charges along the
groove (Fig. 2). The resulting peptides are termed
eboIZN39IQ(D3) and eboIZN21(D2). Using CD and
AUC, we confirmed that these mutants maintained
the stable coiled-coil structure and trimeric nature
of their wild-type counterparts (Fig. 3 and Table I).
C-peptide binding characterization
To validate that eboIZN39IQ presents the native
conformation of the N-trimer found in the prehair-
pin intermediate, we characterized binding to its
native C-peptide ligand (Fig. 2), which binds along
the entire groove of the N-trimer in the postfusion
trimer-of-hairpins conformation. Surface plasmon
resonance (SPR) analysis (ProteOn XPR36, Bio-Rad)
of the interaction of the full-length C-peptide,
eboC37, with eboIZN39IQ showed a dissociation con-
stant of 14 nM (Fig. 4), with no binding to the D3
negative control. This tight binding affinity is of the
same magnitude as the HIV-1 N-trimer/C-peptide
interaction29 and indicates that eboIZN39IQ
presents a native N-trimer. A shortened C-peptide
(eboC24), missing the 13 N-terminal residues of
eboC37, bound to eboIZN39IQ with a dissociation
constant of "300 nM and did not bind to the D3 neg-
ative control (Supporting Information Fig. S2).
eboIZN21 was less well behaved on an SPR surface,
and we were unable to obtain reproducible data
using this target.
Crystal structure of eboIZN21
To visualize how the N-trimer is presented in the
absence of the native C-peptide ligand, as in our













eboIZN39IQ 229,400 227,900 227,100 3.24
eboIZN39IQ(D3) 230,400 229,300 228,400 3.22
eboIZN21 225,500 224,000 222,900 3.54
eboIZN21(D2) 224,800 222,800 221,800 3.15
CD scans were performed on the same samples of 11.4 mM eboIZN39IQ, 11.1 mM eboIZN39IQ(D3), 18.0 mM eboIZN21 and
25.3 mM eboIZN21(D2) in 50 mM sodium phosphate, pH 5.8, 150 mM NaCl at 25, 37, and 50!C. The peptides were allowed
to equilibrate at each temperature for 10 min, after which no change in signal was seen over time. Sedimentation equilib-
rium analysis was performed on each peptide at three concentrations each (a starting concentration and two twofold dilu-
tions, with typical starting concentrations between 10 and 30 mM) and a minimum of two speeds, but typically three speeds
(18,000, 21,000, and 24,000 rpm). Each data set was globally fit to a single ideal species. Each sedimentation equilibrium
analysis was performed 2–4 times and averaged for the above table.
Figure 4. Binding of the ebolavirus C-peptide to the N-trimer mimic. Sensorgram of eboC37 flowed over eboIZN39IQ in a
triplicate twofold dilution series starting at 60 nM, plotted with second-order second-neighbor-smoothing with a Savitzky–Golay
filter (Prism 6, GraphPad Software). Each replicate dilution series is shown as a distinct color. The kinetic fit of the raw data is
shown and yields ka 5 9.6 3 10
5 M/s1, kd 5 0.014/s
1, and a KD of 14 nM. Inset: The same eboC37 dilutions flowed over an
eboIZN39IQ(D3) surface. No binding was observed.
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mimics, we determined the X-ray crystal structure
of eboIZN21 to 2.15 A˚. eboIZN21 crystallized as a
symmetrical trimer in space group P321 with one
monomer in the asymmetric unit. The structure
reveals that eboIZN21 is a continuous trimeric coiled
coil, as designed [Fig. 5(A)]. Comparing our struc-
ture with the two previously reported structures of
the ebolavirus 6-helix bundle (PDB IDs: 1EBO28 and
2EBO27) revealed good overall agreement between
the N21 residues of our unliganded structure and
the C-peptide-bound structures, as indicated by root
mean square deviations (rmsd) of 1.2 A˚ (across 63
atoms, 1EBO) and 1.4 A˚ (across 61 atoms, 2EBO)
when trimers are aligned on Ca residues [Fig. 5(B)].
However, surface renderings show that a hydropho-
bic pocket in the N21 region of the 6-helix bundle
structures, which accommodates residues 619–626 of
the bound C-peptide, is collapsed in the isolated
eboIZN21 structure [Fig. 5(C–E)].
The collapse of this pocket in the unliganded
structure results from the side-chain conformations
of several residues that fill the pocket. Specifically,
in the absence of C-peptide, residues L569, L571,
F572, L573, and T576 adopt alternate rotamers to
pack together via hydrophobic interactions and thus
alter the surface contours of the ligand binding
pocket (Supporting Information Fig. S3). The side
chain of E564 also adopts an alternate conformation
to occupy a distinct portion of the pocket (toward the
top of the pocket in Fig. 5). Therefore, as seen with
the analogous hydrophobic ligand-binding pocket in
the HIV gp41 N-trimer [comparing structures in
Refs. (29–32), e.g., Supporting Information Fig. S4],
our eboIZN21 unliganded structure indicates that
the ebolavirus GP N21 pocket is induced by ligand
binding and can likely adopt various conformations
depending on the specific ligand.
We used the MONSTER protein interaction
server33 to calculate the solvent accessible surface
area (SASA) buried at the interface of the ebolavirus
and HIV hydrophobic pockets with their C-peptides.
The crystal structures of the ebolavirus27,28 and
HIV30,31 6-helix bundles reveal that in each case the
pocket interacts with 8 C-peptide residues (ITD-
KIDQI for ebolavirus and WMEWDREI for HIV)
[Supporting Information Fig. S4(A,C)]. The buried
SASA at the N21 pocket/8-mer C-peptide interface is
similar in the 1EBO and 2EBO structures at 393/348
and 387/325 A˚2, respectively. These values are compa-
rable to SASA buried at the HIV gp41 pocket/8-mer
Figure 5. Crystal structure of eboIZN21. (A) Cartoon rendering with a semitransparent surface of the unliganded eboIZN21
structure. The IZ trimerization domain (white) and N21 region (pink) are indicated. The N21 region of available ebolavirus
N-trimer structures is shown in isolation in panels B–E. (B) Overlay of the N21 region of the unliganded structure with the N21
region of the two previously solved ebolavirus GP2 core structures containing C-peptide (PDB IDs: 1EBO and 2EBO shown as
blue and green, respectively. This color scheme is maintained in panels C–E). Residues that line the N21 groove and have sig-
nificantly different rotamer conformations in the unliganded structure are shown as sticks and labeled. These residues occupy
some of the equivalent space occupied by C-peptide (not shown) in the liganded structures resulting in a less prominent hydro-
phobic pocket when viewed (in subsequent panels) as a surface. (C) Surface representation of the unliganded N21 region. The
bottom panel is the view of N21 from the bottom along its threefold axis and is rotated approximately 90! as compared to the
top panel. (D, E) Similar views to (C) of the N21 region from the structures containing C-peptide. The prominent hydrophobic
pocket in the 1EBO and 2EBO structures appears to be induced by ligand binding since the pocket is nearly absent in the
unliganded structure.
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C-peptide interface (349/310 A˚2).30 Finally, a similar
analysis between the HIV pocket and our D-peptide
entry inhibitor, PIE12 [Supporting Information
Fig. S4(B)], reveals that 416/391 A2 of SASA is bur-
ied at that interface.32 Given the comparable size of
the pocket/C-peptide interface in the ebolavirus and
HIV 6-helix bundle structures, combined with the
high anti-HIV potency of PIE12-trimer (a trimerized
version of PIE12, designed to bind all three pockets
of the prehairpin intermediate),32 it is reasonable to
expect that potent pocket-specific peptide inhibitors
of ebolavirus can also be discovered.
Phage display target validation
Phage display is a powerful screening technology
that is used to screen billions of peptides or antibod-
ies against a target of interest to identify specific
inhibitors of protein/protein interactions. Indeed,
HIV N-trimer mimics were successfully used in
phage display screens of both scFv antibodies and
D-peptides (see “Mirror-Image Phage Display”
below) to identify potent, broadly neutralizing HIV
entry inhibitors.25,29,32,34,35 To validate the ebolavi-
rus N-trimer mimics as discovery targets in the con-
text of phage display, we produced phage clones
expressing the native binding partners eboC37 and
eboC24 [Fig. 2(A)] and assayed their ability to bind
to our N-trimer mimics in phage clone binding
assays. These experiments were designed to verify
ligand binding and to define the best conditions for
future phage display discovery efforts.
Phage display selections can be conducted in
two formats: solid- and solution-phase. In solid-
phase selections, the target is bound to a solid sup-
port (here, biotinylated ebolavirus N-trimer mimic is
attached to streptavidin-coated magnetic beads), and
then the phage are incubated with the immobilized
target. Since common phage display libraries are
multivalent (multiple copies of the library molecule
are expressed on the surface of the phage, due to
fusion to multicopy coat proteins), avidity effects
improve the apparent binding constant of the library
clones. This avidity-induced affinity boost is benefi-
cial when screening na€ıve phage libraries, where ini-
tial binders typically have low target affinities. In
solution phase, where both target and phage are
incubated in solution, avidity effects are reduced.
Following incubation, the bound complexes are cap-
tured through a brief interaction with a solid sup-
port (again, in this case, through a biotinylated
target and streptavidin beads). At equivalent target
concentrations, solution-phase selection is more
stringent than solid-phase selection. The higher
stringency of solution-phase is useful when screen-
ing second-generation libraries for affinity matura-
tion (e.g., peptide binding consensus libraries or
antibody variable loop mutagenesis libraries), where
tight binders must be distinguished from a back-
ground of moderate binders.
Both eboC37 and eboC24 clonal phage bound to
eboIZN39IQ target significantly over background
(both empty beads and negative control eboIZ-
N39IQ(D3) beads) using solution-phase clonal phage
binding assays carried out at pH 5.8 to mimic the
endosomal environment (Fig. 6). Also, binding of
M13KE empty phage to both eboIZN39IQ and eboIZ-
N39IQ(D3) was minimal. These data validate eboIZ-
N39IQ as a phage display target. In addition, these
data demonstrate that eboIZN39IQ(D3) serves as an
effective negative control, as its clonal C-peptide
phage binding is comparable to that of blank beads.
In this format, both C-peptide clones bound at simi-
lar levels to eboIZN39IQ, although eboC37 had
greater background binding to both negative
controls.
Specific binding (over two orders of magnitude
over background) was seen when using eboIZN21 as
a target in a solid-phase eboC24 clonal phage bind-
ing assay, also validating eboIZN21 as a phage dis-
play target (Fig. 7). With the low level of eboC24
phage binding to eboIZN21(D2) (similar to eboC24
binding to blank beads), the binding site mutant is
also verified as a negative control. In addition, only
a very low level of M13KE empty phage binding to
eboIZN21 and eboIZN21(D2) was observed.
Low phage background binding to targets is
required in order to discern specific binding during
Figure 6. Validation of eboIZN39IQ as a phage display tar-
get. Clonal phage expressing ebolavirus C-peptides (eboC37
or eboC24) were incubated with biotinylated eboIZN39IQ in
solution followed by capture via magnetic streptavidin beads.
Negative target controls include the binding site mutant,
eboIZN39IQ(D3), and magnetic beads with no target (NT).
Binding of M13KE (phage with no peptide clone) to all targets
was also assayed. The fraction of phage bound is reported.
Error bars represent standard error across triplicate
experiments.
452 PROTEINSCIENCE.ORG Designed Ebolavirus Prehairpin Intermediate Mimics
! 37 
!!!!
phage panning rounds. To evaluate this property for
our two N-trimer mimics, we analyzed empty
M13KE phage binding to both targets under varying
conditions (Fig. 8). In both solid- and solution-phase
formats, M13KE phage showed significantly higher
binding to eboIZN39IQ beads than to blank beads.
For the eboIZN21 target, phage background binding
was drastically reduced in comparison to eboIZ-
N39IQ, and binding of M13KE phage was similar to
both target and blank beads in solid and solution
phase. Under stringent conditions (solution phase,
100 nM target) the M13KE background binding to
eboIZN39IQ was minimized, and a large affinity dif-
ference for eboC24 binding to eboIZN39IQ versus
eboIZN21 could be seen. This affinity difference is
likely to be biologically relevant because the trimer-
of-hairpins structures27,28 show that the binding site
of eboC24 extends past the C-terminus of N21.
These data indicate the importance of choosing
proper stringency conditions in performing phage
display selections.
The first step of a phage display discovery pro-
cess is to screen a na€ıve phage display library for
binding to the desired target. In such a first selec-
tion, where the library diversity only partially sam-
ples the large potential sequence space (e.g., a na€ıve
peptide 12-mer library has 2012 (>1015) possible
sequences, whereas the typical diversity of a phage
display library is <1010), the best binders identified
are usually modest, with low- to mid-micromolar
affinities. Therefore, the selection pressure applied
during phage panning must also be modest. Stand-
ard na€ıve phage display starting conditions are 10
mM target presented on solid-phase (i.e., 30 mL of 10
mM target immobilized onto magnetic beads).25 As
illustrated in Figure 8, M13KE binding to eboIZ-
N39IQ is nearly saturated at this condition, and
therefore it would not be possible to identify binding
over background. 10% phage binding is considered
saturating, as binding yields of even strong binders
do not generally exceed this level (likely due to
proteolysis of displayed peptides). Under the same
conditions, the eboIZN21 background binding is
>600-fold lower and similar to blank bead binding,
ideal starting conditions for na€ıve phage display.
Therefore, eboIZN21 is an optimized target for
phage display discovery efforts. Additionally, the
eboC24-phage can serve as an important positive
control during na€ıve phage display to validate the
conditions used to capture weak, but specific bind-
ers. Notably, in addition to having ideal behavior in
phage display, the N21 region is also identical across
all ebolavirus species and highly conserved among
filoviruses (95% conserved) [Fig. 2(A)]. eboIZN39IQ
is an ideal target for higher stringency solution-
phase phage display and could be used to screen sec-
ondary libraries for affinity optimization of ligands
identified from the na€ıve library. This could be espe-
cially useful for extending the binding interface of
the ligands further along the N-trimer groove.
Mirror-image phage display
Mirror-image phage display is an innovative adapta-
tion of standard peptide phage display and is used
to identify D-peptides that bind to a target of inter-
est25,36 (Supporting Information Fig. S5). D-peptides
are composed of D-amino acids and are the mirror-
image of naturally occurring L-peptides. D-peptides
have several important potential advantages as drug
candidates (as reviewed37). As peptides, they are
capable of blocking large protein/protein interac-
tions, which is generally not possible for small mole-
cules. In addition, because they are resistant to
protease degradation,38 D-peptides should possess a
longer in vivo half life and reduced immunogenic-
ity.39 In our HIV-1 entry inhibitor discovery pro-
gram,18,25,29,32 we used mirror-image phage display
and protein design to develop the highly potent and
broadly acting D-peptide entry inhibitor, chol-PIE12-
trimer, which is now in advanced preclinical studies.
Their resistance to endosomal proteases makes
D-peptides especially attractive as ebolavirus entry
inhibitors. Our future studies will therefore use the
N-trimer mimics to discover D-peptide inhibitors of
ebolavirus entry by mirror-image phage display.
In traditional peptide phage display, a library of
phage, each with a unique peptide displayed on its
surface, is screened against a target.40 In mirror-
image phage display, the target is chemically
Figure 7. Validation of eboIZN21 as a phage display target.
Clonal phage expressing an ebolavirus C-peptide (eboC24)
were incubated with biotinylated eboIZN21 bound to strepta-
vidin magnetic beads (solid-phase conditions). Negative
target controls include the binding site mutant, eboIZN21(D2),
and magnetic beads with no target (NT). Binding of M13KE
(phage with no peptide clone) to all targets was also
assayed. The fraction of phage bound is reported. Error bars
represent standard error for triplicate experiments.
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synthesized from D-amino acids and therefore forms
the mirror-image structure of the natural L-target
(Supporting Information Fig. S5). Phage display
using the D-target is performed, and identified
L-peptides that bind the D-target are then chemically
synthesized using D-amino acids. By the law of sym-
metry, these D-peptides bind the natural L-target.
Unlike with traditional phage display, mirror-image
phage display targets are limited in size to those
that can be chemically synthesized (although this
size limit is continually expanding with modern
chemical protein synthesis advances41.
In order to prepare ebolavirus N-trimers as
mirror-image phage display targets, we synthesized
them as D-peptides. At 48 amino acids each, D-
eboIZN21 and D-eboIZN21(D2) were synthesized
through standard solid-phase peptide synthesis
(SPPS) techniques. Importantly, even though the
101-residue length of eboIZN39IQ is beyond the
scope of standard SPPS, modern chemoselective liga-
tion techniques42 allow for its assembly from multi-
ple peptide segments. D-eboIZN39IQ, was assembled
using native chemical ligation43 and metal-free
desulfurization,44 in which cysteine residues are
Figure 8. Comparing the two ebolavirus N-trimer mimics as phage display targets. (A) Phage background binding is greater to
eboIZN39IQ than to eboIZN21. Phage binding assay showing M13KE control phage binding to biotinylated eboIZN39IQ and
eboIZN21 under both solid-phase (left) and solution-phase (right) conditions. Magnetic beads with no target (NT) were used as
a negative control. The fraction of phage bound is reported. Error bars represent the range for duplicate experiments (solid
phase) and standard error for four or more replicates (solution phase). (B) High stringency solution-phase binding shows an
affinity difference for the specific binding of eboC24 to the two N-trimer mimics. Clonal phage expressing eboC24 were
incubated with biotinylated N-trimer in solution followed by capture via magnetic streptavidin beads. Negative target controls
include the binding site mutants and magnetic beads with no target (NT). For NT, error bars represent standard error across
triplicate experiments. The remaining error bars represent the range for duplicate experiments.
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introduced at native alanine sites to facilitate liga-
tion and then converted back to alanine through
desulfurization [Supporting Information Fig. S6(A)].
D-eboIZN39IQ was assembled from three synthetic
segments of 27–41 residues. The production of
D-eboIZN39IQ(D3) required a different assembly
strategy, as one of the alanines used in D-eboIZN39IQ
as a ligation junction is mutated to aspartate. There-
fore, D-eboIZN39IQ(D3) was assembled from two
synthetic segments of 33 and 68 amino acids. The
final peptide products were confirmed by LC/MS
[e.g., Supporting Information Fig. S6(B,C)].
The law of symmetry dictates that D-peptides
will adopt the mirror-image structure of their
L-counterparts. CD analysis of D-eboIZN21 confirms
it possesses mirror-image helical structure compared
to its L-peptide counterpart [Supporting Information
Fig. S7(A)]. SPR analysis of D-eboC37 binding to
D-eboIZN39IQ shows a similar binding affinity
(6 nM) to the L-peptide interaction and validates the
functionality of D-eboIZN39IQ [Supporting Informa-
tion Fig. S7(B)]. Preliminary phage display experi-
ments with these D-targets demonstrate the same
M13KE binding properties as the L-versions (data
not shown), verifying the strategy of screening na€ıve
libraries with the D-eboIZN21 target and employing
D-eboIZN39IQ for subsequent affinity optimization
efforts when higher stringency is appropriate.
Vulnerability of the Ebolavirus prehairpin
intermediate to a high potency inhibitor
A prerequisite for the success of drug discovery
efforts targeting the ebolavirus N-trimer mimics is
the exposure of a vulnerable prehairpin intermedi-
ate during viral entry. Exogenous C-peptides derived
from the transmembrane subunit of the envelope
glycoprotein have been used to validate this vulnera-
ble prehairpin intermediate in a variety of viruses
(e.g., HIV, SARS, and many paramyxoviruses45–47).
For ebolavirus, an early report showed C-peptide
inhibition activity at mM concentrations,48 and more
recent reports describe improved inhibitory activity
(mid mM) of C-peptides with an endosomal localiza-
tion tag.49,50 Our ebolavirus N-trimer, eboIZN39IQ,
provides an additional tool with which to explore the
vulnerability of the prehairpin intermediate. In sup-
port of this strategy, peptide mimics of the HIV-1
N-trimer inhibit HIV entry at mid nM concentra-
tions by binding to the C-peptide region of the
exposed intermediate.24
Indeed, eboIZN39IQ inhibited entry in our pseu-
dovirus system in which ebolavirus GP (representa-
tive species, Zaire ebolavirus) is expressed on the
surface of an HIV particle [Fig. 9(A)], with an aver-
age IC50 of 320 nM. Importantly, the anti-ebolavirus
activity of our negative control, eboIZN39IQ(D3), is
!30-fold diminished, with an IC50 of 11 mM. It is dif-
ficult to determine the exact nature of the modest
eboIZN39IQ(D3) activity, as it is not seen against a
vesicular stomatitis virus glycoprotein pseudotype
(VSV), and no morphological changes (indicative of
Figure 9. Inhibition of filovirus entry by eboIZN39IQ. (A) A
representative pseudovirion assay looking at the inhibitory
activity of eboIZN39IQ and the negative control, eboIZ-
N39IQ(D3) against ebolavirus (EboV), marburgvirus (MarV),
and VSV retroviral pseudotypes. Each point represents the
average of quadruplicate measurements normalized to unin-
hibited control. Error bars represent normalized standard
errors. For this particular assay, eboIZN39IQ IC50s are 260
nM against ebolavirus and 5.4 mM against marburgvirus. The
eboIZN39IQ(D3) IC50s are 8.9 mM against ebolavirus and 11
mM against marburgvirus. (B) Data for the authentic filovirus
immunofluorescence inhibition assay. Each point represents
the average of quadruplicate measurements normalized to
vehicle control. Strong inhibition of ebolavirus is seen at 10
mM eboIZN39IQ, with an average 33% (64%) of infected
cells compared to vehicle control.
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toxicity) were observed. It is possible the modest
eboIZN39IQ(D3) activity could be due to residual
prehairpin intermediate binding activity. eboIZ-
N39IQ demonstrated modest activity against mar-
burgvirus pseudovirions (another member of the
filovirus family), at an IC50 of 5.7 mM, although this
was only !2-fold better than the eboIZN39IQ(D3)
anti-marburgvirus activity.
The ability of eboIZN39IQ to inhibit the entry of
wild-type ebolavirus and marburgvirus was also
assessed using a filovirus immunofluorescence assay
under BSL4 conditions [Fig. 9(B)]. Although eboIZ-
N39IQ was significantly less potent in this assay,
there is 67% inhibition of entry at the highest con-
centration tested (10 mM) and no inhibition by our
negative D3 control. Also, no activity was seen
against marburgvirus. Potency differentials between
pseudovirus systems and authentic filoviruses have
been seen for other fusion inhibitors [for example in
Ref. (51)]. Taken together, these data validate the
presence of a vulnerable prehairpin intermediate
during the ebolavirus entry process.
Unlike HIV-1, ebolavirus enters cells via endocy-
tosis and initiates membrane fusion late in the endo-
somal pathway. Therefore, ebolavirus entry
inhibitors will have to enter into and be active in
endosomes. Although eboIZN39IQ does not possess a
specific tag to localize it to endosomes, it is highly
charged on its surface (with both positive and nega-
tively charged side chains), and, interestingly, the
inhibitory activity we observed in both the pseudovi-
rus and authentic ebolavirus systems was dependent
on the presence of the standard viral assay additive
DEAE-dextran. It seems likely that the highly
charged N-trimer mimic associates with the anionic
cell membrane, especially in the presence of the
cationic DEAE-dextran that would reduce electro-
static repulsion between the negative charges of
eboIZN39IQ and the membrane, allowing it to access
the endosome more efficiently than C-peptides.50
As a structured peptide, eboIZN39IQ would also
likely resist proteolysis longer than unstructured
C-peptides.
Conclusion
In summary, we have designed and characterized
two mimics of the highly conserved ebolavirus GP
N-trimer region as it appears in the prehairpin
intermediate during viral entry. In addition, through
our clonal phage display experiments, we have func-
tionally validated eboIZN39IQ and eboIZN21 as
drug discovery targets, especially for phage display
screens. Finally, with the characterization of the
inhibitory activity of eboIZN39IQ, we have further
validated the vulnerability of the ebolavirus prehair-
pin intermediate by demonstrating potent inhibition.
These N-trimer mimics should be valuable for the
discovery of small molecules, antibodies and/or
peptides that inhibit ebolavirus entry. Specifically,
our group is interested in the discovery of D-peptide
inhibitors of ebolavirus using mirror-image phage
display, and with the two targets and their binding
site mutants synthesized in the D configuration, we
are now poised for those selections.
It is noteworthy that in addition to the remark-
able conservation of the N-trimer region across all
ebolavirus species, it is also highly conserved across
the filovirus family [see Fig. 2(A)]. Therefore, discov-
ery efforts will likely identify inhibitors with broad
filovirus activity. If such activity is suboptimal, it
should be possible to design analogous mimics of the
marburgvirus N-trimer region and use them in con-
cert with the ebolavirus targets. For example in
phage display, rounds of panning could alternate
between the ebolavirus and marburgvirus targets,
selecting specifically for an inhibitor of both viruses.
Although the vast majority of natural filovirus out-
breaks have been caused by ebolavirus, marburgvi-
rus still poses a risk both as a natural pathogen
(with three outbreaks in the last 10 years) and as a
bioterror agent,52 making the discovery of a broad-
spectrum inhibitor desirable.
In addition to serving as drug targets, the
ebolavirus N-trimer mimics should be useful as cell
biological tools. For example, fluorescently labeled
N-trimers could be used in cell culture experiments
to track the appearance of the prehairpin intermedi-
ate during the viral entry event. Such studies would
advance insight into filovirus entry dynamics.
Materials and Methods
Reagents
Plasmids and cells were obtained from the indicated
sources: pEBB-HXB2 (gift from B. Chen)53,
SV-ZeboGPDmuc and SVMarVGP (gift from M.
Farzan),54 BLR(DE3)pLysS E. coli (EMD Millipore,
Billerica, MA), BL21-Gold(DE3)pLysS E. coli and
XL-1 Blue E. coli (Agilent Technologies, Santa Clara,
CA). pNL4–3.Luc.R-E- (N. Landau)55,56 and HOS-
CD4-fusin (N. Landau)57,58 were obtained from the
NIH AIDS Research and Reference Program. Mam-
malian cells were propagated in standard tissue cul-
ture medium, Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal calf serum
and L-glutamate (Life Technologies, Grand Island,
NY).
Recombinant peptide production and
purification
The DNA encoding eboIZN39IQ and eboIZ-
N39IQ(D3) was produced via PCR gene synthesis.
The IZm and IQ fragments were PCR amplified from
plasmids encoding HIV-1 N-trimer mimics [e.g. in
Ref. (59)]. An NdeI site was included in the 50 PCR
primer for IZm, and a BamHI site was included in
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the 30 PCR primer for IQ. The ebolavirus N39
sequence from the species Zaire ebolavirus60 was
synthesized in two overlapping oligos with optimized
codons and companion primers. All internal primers
contained complementary sequences so the three
separate components, IZm, N39, and IQ could be
annealed and amplified together. The resulting DNA
fragment was cloned into the NdeI/BamHI cloning
sites of pKA8, validated by sequencing and
expressed in BLR(DE3)pLysS cells using an autoin-
duction protocol. Specifically, cultures were inocu-
lated from a single colony and grown overnight at
37!C in autoinduction media.61 The resultant pep-
tide has an N-terminal His tag (His8) followed by a
TEV cleavage site (ENLYFQG). A single tyrosine
was placed at the end of the sequence to facilitate
concentration determination via absorbance at 280
nm. The peptides were resuspended from inclusion
bodies using Ni-binding buffer (20 nM sodium phos-
phate pH 8.0, 300 mM NaCl, 10 mM imidazole) 1
6M GuHCl, and purified via gravity flow Ni affinity
chromatography (HIS-Select Nickel Affinity Gel,
Sigma Aldrich, St. Louis, MO). The purified peptides
were dialyzed into 5% acetic acid and further puri-
fied by reverse phase HPLC on a C18 column
(Vydac, Grace, Columbia, MD) and lyophilized. Pep-
tide powder was resuspended in water and diluted
to 0.2 mg/mL in 50 mM sodium phosphate pH 6.5,
0.5 mM EDTA, 1 mM DTT and digested with a
solubility-enhanced tobacco etch virus NIa protease
(TEVse, based on published modifications62,63) over-
night at 30!C. The digested peptide was dialyzed
into 5% acetic acid and then HPLC purified and




ERY, with IZm and IQ shown in bold, the ebolavirus
N-trimer in italics, and the three alanine positions
that are changed to aspartate in the D3 mutant in
parentheses.
Biotinylated eboIZN39IQ and eboIZN39IQ(D3)
for SPR analysis and phage display were expressed
from plasmids that are modified from those
described above. Using PCR, a CGG sequence was
added N-terminal to IZ (GHMCGGDIKK. . .). Expres-
sion and purification were as described above with
additional reduction steps included to keep the cys-
teine reduced during purification (100 mM DTT
treatment after Ni11 affinity chromatography and
50 mM TCEP treatment after TEV digestion). The
purified protein was biotinylated with EZ-link Mal-
eimide–PEG2–biotin (Thermo Scientific, Waltham,
MA). The purified lyophilized powder was resus-
pended at 1 mM in freshly prepared reaction buffer
(6 M GuHCl, 150 mM NaCl, 100 mM Na2HPO4, 5
mM TCEP) and the biotinylation reagent was added
at 5 mM and allowed to react for 4 h at RT. The
biotinylated peptides were purified by reverse phase
HPLC on a C18 column (Waters) and lyophilized.
The mass of the peptide was confirmed by LC/MS
(AB Sciex API 3000 LC/MS/MS system, Framing-
ham, MA).
Peptide synthesis
eboIZN21, eboIZN21(D2), eboC37 and eboC24 were
chemically synthesized using solid-phase peptide
synthesis (SPPS) with Fmoc-amino acids (AAPPTec,
Louisville, KY, and CBL Biopharma, Boulder, CO)
on a Prelude peptide synthesizer [Protein Technolo-
gies (PTI), Tucson, AZ]. A single tyrosine was placed
at the N-terminus of both eboIZN21 and
eboIZN21(D2) to facilitate concentration determina-
tion via absorbance at 280 nm. The peptides were
synthesized on TentaGel R RAM resin (Rapp Poly-
mere, Germany) to yield C-terminal amide peptides.
Standard synthesis scales were 25–32 mmol per pep-
tide. Standard amino acid coupling was as follows: 3
3 3 min deprotection with 20% piperidine in DMF
followed by 25 min couplings with 72.2 mM amino
acid (200 mM stocks in NMP), 71.5 mM HATU (198
mM stock in DMF), and 166.7 mM NMM (600 mM
stock in DMF). Biotinylation was achieved with N-
Biotinyl-NH-(PEG)2-COOH DIPEA (Novabiochem,
EMD Millipore) coupling for 2 h. N-terminal capping
was accomplished in 30 min with 2 mL acetic anhy-
dride and 2 mL 0.6M NMM. Peptide cleavage from
resin was accomplished offline with 92.5% TFA,
2.5% EDT, 2.5% TIS, 2.5% H2O when the peptide
contained Met or Cys residue(s) or with 95% TFA,
2.5% TIS, 2.5% H2O in the absence of any Met/Cys
residues followed by precipitation/washing with
diethylether. All peptides were purified by reverse-
phase HPLC on a Waters (Milford, MA) BEH
X-Bridge C18 column (10 lm, 300 A˚, 19 3 250 mm)
with a water/ACN gradient in 0.1% TFA. All pep-
tides were lyophilized and their molecular weight
verified by LC/MS.
D-eboIZN39IQ was assembled from three syn-
thetic peptide segments via native chemical ligation/
metal-free desulfurization (Supporting Information
Fig. S6). D-peptides were synthesized via Fmoc-
SPPS on a PTI PS3 peptide synthesizer at 100 mmol
scale. The C-terminal peptide was synthesized on
Rink Amide AM resin LL (Novabiochem) and the
other two segments were synthesized on Dawson
Dbz AM resin (Novabiochem). The C-terminal seg-
ment contained an N-terminal cysteine residue in
the place of a native alanine for use in native chemi-
cal ligation (CIDFLLQRMKQIEDKIEEIESKQKKIE-
NEIARIKKLIGERY). For the same reason, the
middle segment contained an N-terminal Boc-L-
thiazolidine-4-carboxylic acid (Boc-Thz-OH, Bachem,
Torrance, CA) as its N-terminal residue in place of
the native alanine at that position((Thz)-NETT-
QALQLFLRATTELRTFSILNRK). The N-terminus of
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the N-terminal peptide (GHMDIKKEIEAIKKE-
QEAIKKKIEAIEKELRQL) was biotinylated with
N-Biotinyl-NH-(PEG)2-COOH DIPEA (Novabiochem).
For peptides synthesized on Dawson Dbz AM resin,
the C-terminal linker was converted to the resin
bound N-acyl-benzimidazolinone (Nbz) according to
manufacturer instructions. Cleavage of all peptides
was performed according to standard procedures.
Peptides were purified by reverse-phase HPLC on a
Waters BEH X-Bridge C18 column (10 lm, 300 A˚, 19
3 250 mm) with a water/acetonitrile gradient in
0.1% TFA. Ligations were performed according to
Ref. (64) with peptide concentrations !2 mM. Fol-
lowing ligation between the C-terminal and middle
segments, the N-terminal Thz was converted to cys-
teine by dissolving the purified ligation product in
6M GuHCl, 200 mM sodium phosphate, 200 mM
methoxyamine HCl, pH 4. After Thz to Cys conver-
sion was achieved, the buffer was brought to 200
mM MPAA and 20 mM TCEP, the pH was adjusted
to 7, and the N-terminal peptide was added to the
solution for the final ligation. Following purification
of the ligation product by reverse-phase HPLC, the
cysteine residues at the ligation junctions were con-
verted to the native alanine residues via a metal-
free, radical-mediated desulfurization strategy
essentially as described in Ref. (44) except that
t-butylthiol was replaced with glutathione, and desul-
furizations were performed at 37"C. eboIZN39IQ(D3)
was synthesized in an analogous (though simplified)
manner using two peptide segments.
Preparation of peptide samples for biophysical
analysis
For biophysical analyses, peptide stocks were pre-
pared in water from lyophilized peptide at concen-
trations of 400 mM or greater for a minimum
absorbance at 280 nm of 0.1 in a 1 cm pathlength
cuvette. Stocks were centrifuged at 18,000g for 10
min to remove aggregates. Absorbance at 280 nm
(using e280 of 1408 M/cm
1 for tyrosine) was used to
determine stock concentrations.65 For eboIZN39IQ
and eboIZN39IQ(D3), both recombinant and syn-
thetic, UV absorbance consistently overestimated the
concentration of the stocks (as evidenced by an
unusually high 260/280 ratio as well as CD traces
whose shape depicted ideal coiled coils but whose
signal had a lower than expected absolute value).
This overestimation is likely due to peptide bond
absorbance contributing to the signal at 280 nm
(101 amino acids with only one near-UV absorbing
residue, a tyrosine). Therefore, the concentrations of
these stocks were determined via quantitative amino
acid analysis, which was performed using a Hitachi
L-8800 Amino Acid Analyzer (Hitachi High-
Technologies Corporation, Tokyo, Japan). Peptides
were hydrolyzed in 5.7N HCl overnight at 105"C in
sealed ampoules, and then analyzed via ion-
exchange chromatography and postcolumn derivati-
zation with ninhydrin using the Hitachi Analyzer.
The peptides were then diluted to the desired con-
centration in 50 mM sodium phosphate pH 5.8, 150
mM NaCl. For eboIZN21 and eboIZN21(D2), all
experiments described in this paper were performed
with biotinylated peptide. For eboIZN39IQ and
eboIZN39IQ(D3), CD, AUC and viral infectivity
were performed with nonbiotinylated material,
whereas SPR and phage display used biotinylated
material.
Circular dichrosim
Circular dichroism (CD) data were obtained using
an AVIV Model 410 spectrophotometer (AVIV, Lake-
wood, NJ). Samples were analyzed in a 1 mm path-
length quartz cuvette at 25, 37, and 50"C. Prior to
CD analysis, prepared samples (in 50 mM sodium
phosphate pH 5.8, 150 mM NaCl) were centrifuged
at 18,000g for 10 min to remove aggregates. CD
data were scanned in triplicate and buffer sub-
tracted. Final CD data were presented according to
mean residue ellipticity equation [h] 5 100 3 h/[(n 2
1) 3 (‘) 3 (c)], where h is the observed ellipticity, n
2 1 is the number of peptide bonds, ‘ is the path-
length in cm, and c is the peptide concentration in
mM. Percent helicity was calculated from the ellip-
ticity at 222 nm according to the Lifson–Roig-based
helix-coil model which defines the dependence on
chain length and temperature as described.66 Due to
aggregation observed with eboIZN39IQ and eboIZ-
N39IQ(D3) upon initial dilution in the CD buffer,
their final concentrations were corrected from the
original amino acid analysis values based on the




Using an Optima XL-A Analytical Ultracentrifuge
(Beckman Coulter, Brea, CA), sedimentation equilib-
rium analysis was performed on each peptide at
three concentrations (a starting concentration and
two 2-fold dilutions, with typical starting concentra-
tions between 10 and 30 mM). Dilutions were pre-
pared in matching buffer (50 mM sodium phosphate,
150 mM NaCl, pH 5.8), and the same buffer was
used for blanks. Each sample was spun until equilib-
rium, typically !24 h, at a minimum of two speeds,
but typically three speeds (18,000, 21,000 and
24,000 rpm). Each data set was globally fit to a
floating molecular weight single ideal species with a
nonlinear least squares algorithm as implemented in
HETEROANALYSIS.67 Fits are reported as the
observed (i.e., fit) molecular weight divided by the
calculated molecular weight of a monomer (Mobs/
Mcalc). Buffer densities and protein partial specific
volumes were calculated with SEDNTERP (version
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1.09).68 For the biotinylated peptides, partial specific
volumes were adjusted based on reported values for
PEG.69
Surface plasmon resonance
SPR analysis was conducted on the Bio-Rad (Hercu-
les, CA) ProteOn XPR36 instrument in PBS* run-
ning buffer (50 mM sodium phosphate, 150 mM
NaCl, pH 5.8) 1 0.1 mg/mL BSA and 0.01% Tween
20. Approximately 600 RUs of biotin-eboIZN39IQ (in
the presence of eboC37) and biotin-eboIZN39IQ(D3)
targets (200 nM stocks ultracentrifuged for 30 min
at 45,000 rpm) were loaded at 67 nM on to the NLC
neutravidin-coated chip (Bio-Rad), followed by block-
ing with 450 lM biotin. Using the one-shot kinetics
method, a twofold dilution series was performed in
triplicate at RT starting at 60 nM for eboC37 and a
threefold dilution series in triplicate at RT starting
at 800 nM for eboC24. 10 min dissociation time for
eboC37 and 5 min dissociation time for eboC24 were
used to ensure the response fully recovered to base-
line prior to the next injection. Data were corrected
by subtracting blank surface and blank buffer refer-
ence injections, and the kinetics (for eboC37) and
equilibrium (for eboC24) were globally fit to the
Langmuir model for 1:1 binding70 using ProteOn
Manager software (Bio-Rad).
Crystallization
eboIZN21 was dissolved in ddH20 to a concentration
of !10 mg/mL and centrifuged at 18,000g for 10
min. Sitting-drop vapor-diffusion crystal trials were
set up using a Phoenix crystallization robot (Art
Robbins Instruments, Sunnyvale, CA). Crystals
grew at 4"C in drops containing a 2:1 ratio of pep-
tide to well solution, which consisted of 30% (v/v)
1,2-propanediol, 100 mM HEPES pH 7.5, 20% (v/v)
PEG-400. The crystals were flash frozen in liquid
nitrogen without the need for additional cryoprotec-
tion and determined to be in space group P321 with
unit cell dimensions a 5 b 5 38.51 A˚, c 5 72.59 A˚.
Data collection, structure determination, and
refinement
A native dataset was collected at beam line 7-1 of
the Stanford Synchrotron Radiation Lightsource.
Data were integrated and scaled to 2.15 A˚ resolution
using HKL2000.71 In order to rule out the possibility
of twinning, data were initially scaled in space
group P3 and analyzed with the program Xtriage,71
which indicated that the data are untwinned and
that the correct space group is P321. A model that
consisted of a canonical helix appropriate to the size
and sequence of the IZ domain and the N21 region
of ebolavirus GP (PDB ID: 1EBO) was used for
molecular replacement using the program Phaser.72
A single eboIZN21 monomer was found in the asym-
metric unit with the trimeric structure generated by
the crystallographic threefold. Subsequent model
building, structure refinement, and validation were
performed with Coot,73 PHENIX Refine,74 and Mol-
Probity75 software, respectively. The final model was
refined to crystallographic R/Rfree values of 0.272/
0.294 with good geometry (Supporting Information
Table S1). Additional refinements were carried out
in space group P3 allowing all possible twin laws, to
further verify (by monitoring Rfree) that the correct
space group is P321 with a monomer in the asym-
metric unit. A composite omit map agreed well with
the final model, indicating good sidechain density
throughout. The atomic coordinates and structure
factors have been deposited in the Protein Data
Bank, http://www.pdb.org (PDB ID: 4R0R).
Clonal phage production
Forward and reverse sandwich oligonucleotides
encoding the C-peptide clones were designed based
on the primary sequence of each clone. The forward












cleotide sandwich was annealed with 5 mg of each
primer in 50 mL total volume in ddH2O by heating
to 95"C and slow cooling and then extended with
Klenow Fragment [New England Biolabs (NEB),
Ipswich, MA] according to the manufacturer’s pro-
tocol. The inserts and M13KE cloning vector back-
bone (NEB) were digested with Acc65I and EagI-
HF. The insert DNA was EtOH precipitated, gel
purified from a 6% TBE acrylamide gel, extracted
from the gel by incubating gel slices in a minimal
volume of extraction buffer (100 mM NaOAc pH
4.5, 1 mM EDTA, 0.1% SDS) for 16 h at 37"C, and
ethanol precipitated. The inserts and plasmid back-
bone were ligated and transformed into SS320 elec-
trocompetent cells and plated on LB/IPTG/X-gal
plates (LB agar, 25 mg/mL tetracycline, 1 mM
IPTG, 0.1 mg/mL X-gal). The DNA from specific
phage plaques was PCR amplified and Sanger
sequenced (Eton Bioscience, Durham, NC), and
those containing the correct DNA were subse-
quently amplified from a single plaque.
Phage amplification
A single plaque was added to XL-1 Blue cells (OD600
0.5–1), diluted to 40 mL of OD600 0.05 in LB 125 mg/
mL tetracycline, and shaken at 220 rpm at 37"C for
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4.5–5 h. Cells were pelleted by centrifugation, and
the phage supernatant was sterile filtered. Phage
were precipitated by adding 1/6th volume of PEG-
NaCl [20% w/v polyethylene glycol-8000 (Fisher Sci-
entific, Pittsburgh, PA), 2.5M NaCl] and incubating
overnight at 4!C. Precipitated phage were then pel-
leted via centrifugation and resuspended in TBS (50
mM Tris–HCl, 150 mM NaCl, pH 7.4). They were
PEG-precipitated again ("1 h on ice), centrifuged
and resuspended in 200 mL TBS. Aliquots were flash
frozen and stored at 220!C with a working stock
left at 4!C if imminent experiments were planned.
Clonal phage binding assay
For each phage binding reaction, 30 mL streptavidin-
coated magnetic beads (Life Technologies, Dyna-
beads MyOne, Streptavidin T1) at 10 mg/mL were
magnetically pelleted and washed with 3.33 bead
volume TBS. The beads were then blocked in 3.33
bead volume 100% SB (Thermo Scientific, Super-
Block Blocking Buffer in TBS, pH 7.4) for 10 min at
RT and rinsed with equal volume of 100% SB* (SB
adjusted to pH 5.8 with HCl). Solution-phase beads
were then resuspended in 3.33 bead volume of
100% SB* and stored at 4!C for up to 24 h. Solid-
phase beads were resuspended in 3.33 bead volume
PBS* 1 10% SB*. To load target on to solid-phase
beads, 13 bead volume of an appropriate target con-
centration (e.g., 10 mL of 10 mM target for 10 mL
beads) was added and incubated for 10 min followed
by addition of 3.33 bead volume 5 mM D-Biotin (in
PBS* 1 10% SB*) and incubation for an additional 5
min. For blank (no target) beads, 3.33 bead volume
of 5 mM D-Biotin was added and incubated for 5
min. All beads were then magnetically pelleted,
washed in PBS*, and resuspended in 13 bead vol-
ume PBS* 1 10% SB*.
Solid-phase binding reactions were incubated in
96-well format (Costar, sterile polystyrene, V-bottom,
nontreated, Corning, Corning, NY) with shaking at
700 rpm for 2 h at RT either as 30 or 100 mL reac-
tions in 13 PBST* (PBS* 1 0.01% Tween 20) 1 10%
SB* and 1010 plaque-forming units (pfu) of the
phage clone. All washes and elution were done on
the KingFisher Duo magnetic particle processor
(Thermo Scientific). The binding reaction was mixed
on the KingFisher for 1 min at medium speed and
the beads collected by 5 s dips of the magnet
through the sample, repeated five times (5 3 5 s).
All washes were done with PBST* (wash 1: 700 mL;
wash 2: 800 mL; wash 3: 900 mL; washes 4–7: 1000
mL), mixed at slow speed for 1.5 min, and beads col-
lected 3 3 3 s. Bound phage were eluted with 50 mL
EB (0.2 M glycine, pH 2.2) for 10 min, beads col-
lected 5 3 5 s, and neutralized with 7.5 mL NB (1 M
Tris, pH 9.1). Dilutions of eluted phage were used to
infect XL-1 Blue cells and then plated in top agar
(40% LB agar/60% LB) on LB/IPTG/X-gal plates.
Blue plaques were then counted to determine phage
titers.
Solution-phase binding reactions were per-
formed similarly to solid-phase 30 mL reactions.
Instead of adding target-loaded beads to the binding
reaction, an appropriate volume of 103 soluble tar-
get was added to the reaction (final 13 soluble tar-
get) just before phage were added. Additionally, on
the Kingfisher Duo, target and bound phage were
pulled down in a rapid 1 min magnetic pelleting
step (1 min slow mixing, 5 3 5 s bead collect). All
washes were done with PBST* except wash 1 which
contained 5 mM D-Biotin to block unoccupied strep-
tavidin sites (wash 1: 150 mL; wash 2: 700 mL; wash
3: 800 mL; wash 4: 900 mL; wash 5: 1000 mL), mixed
at slow speed for 25 s, and beads collected 3 3 3 s.
Pseudovirus infectivity assays
Single-cycle pseudovirions were produced with a
pNL4-3 HIV-1 genome (with firefly luciferase
inserted into the nef gene and frameshift mutations
in both Env and Vpr) and filovirus GP on their sur-
face (or VSV for a specificity control). These pseudo-
virions were produced by co-transfecting 293T
human embryonic kidney cells with the described
HIV-1 genome (pNL4-3.Luc.R-E-) and a plasmid
encoding the desired virus glycoprotein (SV-
ZeboGPDmuc for Zaire ebolavirus GP lacking the
mucin domain, SV-MarVGP for marburgvirus
(Musoke strain) GP and pMDG VSV-G for VSV) in
the presence of polyethylenimine (PEI) transfection
reagent (Polysciences, Inc., Warrington, PA).
Pseudovirus-containing supernatant was collected
and filtered through a 0.45 mM filter 38–43 h post-
transfection. For ebolavirus and marburgvirus, pseu-
dovirions were concentrated by centrifuging through
a 20% sucrose/TNE (10 mM Tris pH 7.6, 100 mM
NaCl, 1 mM EDTA) cushion (26,000 rpm, 2 h), and
the pellet resuspended in TNE, aliquoted and stored
at 280!C.
To measure inhibition of infectivity, 90 mL of
each inhibitor dilution and 8.9 mg/mL DEAE–dex-
tran were added to HOS–CD4–fusion cells in a 96-
well format. For each assay, a total of six inhibitor
dilutions were tested, each in quadruplicate. The
plates were transferred to BSL3, and 10 mL of pseu-
dovirus diluted in media was added to each well 30–
60 min after the inhibitor addition (final DEAE–dex-
tran concentration of 8 mg/mL). Virus was diluted in
order to yield a robust luciferase signal. 24 h later,
all wells were inspected under a light microscope to
check for gross morphological changes. Virus and
inhibitor were removed via aspiration, and fresh
media was replenished. 20–24 h later, the cells were
lysed, and the luciferase activity was measured
(Bright-Glo luciferase assay system, Promega, Madi-
son, WI). To determine IC50 values, the data from
each inhibitor concentration series were normalized
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to the noninhibitor control signal and fit to a Lang-
muir equation: y 5 1/(11[inhibitor]/IC50) (Kaleida-
graph, Synergy Software, Reading, PA). The curve
fit was weighted by the normalized standard error
of each concentration point (with a minimum error
allowed of 1%). Provided IC50s are averages of two
to four replicate experiments.
Filovirus immunofluorescence assays
Vero cells were seeded in 96 well black plates. Pep-
tides and vehicle control were diluted to 1.1X final
concentration in culture media [MEM, 5% FBS, gen-
tamicin (10 mg/mL)] and 90 mL/well were incubated
on the plate for 1 h at 37!C. In the BSL4 10 mL of
virus diluted in media and DEAE–dextran was
added to each well (final 8 mg/mL DEAE–dextran).
Ebola virus (Kikwit, a representative strain of the
Zaire ebolavirus species) and Marburg virus (Ci67)
were diluted in culture media to yield a robust sig-
nal in the assay ("20% infected cells). After 1 h at
37!C, the virus and peptides were removed, the
wells were washed with PBS and media with pep-
tide was used to replenish the wells. At 24 h postin-
fection, each well was visualized via light
microscope to look for any gross morphological
abnormalities. At 48 h postinfection, the wells were
washed with PBS and then the cells fixed with 10%
formalin. After blocking, the fixed cells were incu-
bated with GP-specific mAb (9G4 for Marburg virus,
KZ52 for Ebola virus) followed by incubation with
FITC-labeled secondary antibody (goat antimouse or
antihuman, respectively). Nuclei were stained with
Hoechst solution. Cells were imaged using an Oper-
etta high content device (PerkinElmer, Waltham,
MA) and images were analyzed using Harmony soft-
ware to determine percent of infected cells in a given
well. Data were plotted normalized to the vehicle
control.
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Figure S1: Gel filtration analysis of 240 µM eboIZN21 (red, recorded at 215 nm) in 50 mM 
sodium phosphate pH 5.8, 100 mM NaCl using a Superdex 200 column on an ÄKTApurifier (GE 
Healthcare Life Sciences) at room temperature with a 0.5 mL/min flowrate. Gel filtration 
standards (Bio-Rad) and their molecular weights are overlaid (grey, recorded at 280 nm). The 







Figure S2: Binding of the ebolavirus C-peptide to the N-trimer mimic. Sensorgram of eboC24 
flowed over eboIZN39IQ in a triplicate 2-fold dilution series starting at 800 nM (ProteOn XPR36, 
Bio-Rad), plotted with 2nd order 2-neighbor-smoothing with a Savitzky-Golay filter (Prism 6, 
GraphPad Software). Each dilution is shown as a distinct color. Equilibrium response data were 
averaged over one minute and fitted using non-linear least-squares analysis with Prism 6. The 
fit indicates a KD of 310 nM. Inset: The same eboC24 dilutions flowed over an eboIZN39IQ(D3) 








Figure S3: Hydrophobic interactions between N21 residues in the unliganded eboIZN21 
structure. Shown is an overlay of the N21 region of available ebolavirus N-trimer structures in a 
similar view to that in Fig. 5B. Residues L569, L571, F572, L573, and T576 adopt alternate 
conformations in the unliganded state compared to the structures containing C-peptide and form 
hydrophobic interactions among themselves in the absence of ligand (dotted black lines; 







Figure S4: Comparison of hydrophobic pockets in ebolavirus and HIV N-trimers. A) Surface 
representation of the N17 region comprising a hydrophobic pocket in the HIV gp41 N-trimer 
(orange) including a cartoon representation of the eight residues (8-mer, red) of the HIV C-
peptide that interact with the pocket. C-peptide residues that specifically contact pocket-forming 
residues are shown as sticks. The bottom panel is the same view as the top panel but without 
the ligand shown. B) A similar view of the HIV gp41 pocket but with the D-peptide ligand, PIE12 
(dark red), bound. A comparison of the C-peptide-bound and PIE12-bound pockets indicates the 
shape of the pocket is ligand induced. C) A similar view of the ebolavirus N21 region (blue) from 
the 1EBO crystal structure showing the hydrophobic pocket with and without the 8-mer region of 







Figure S5: Mirror-Image Phage Display. In mirror-image phage display, the peptide/protein 
target is synthesized with D-amino acids (D-target) and forms the mirror-image of the natural L-
target. Phage expressing a library of natural L-peptides (L-phage) are screened for binding to 
the D-target. The peptides from the specific phage clone binders are then synthesized with D-
amino acids (mimicking a D-phage), and by the law of symmetry, the D-peptides will bind the 








Figure S6: Synthesis of D-eboIZN39IQ. A) D-eboIZN39IQ (101 AA, with N-terminal biotin) was 
assembled using native chemical ligation and metal-free desulfurization. The native alanines 
and the residues used to replace them for native chemical ligation are indicated (red). B) HPLC 
analysis of final purified product D-eboIZN39IQ, using XBridge BEH130 C18 column, 2.1 x 50 








Figure S7: Biophysical characterization of the D-versions of the Ebola N-trimer mimics. A) CD 
spectrum of 10 µM D-eboIZN21 at 4 °C in 50 mM sodium phosphate pH 5.8, 150 mM NaCl is 
indicative of a highly helical conformation with 80% helicity. The positive values are as expected 
for this mirror-image helix. B) Analysis of binding of D-eboC37 to D-eboIZN39IQ via SPR 
(Biacore 3000). D-eboC37 was flowed over D-eboIZN39IQ (and D-eboIZN39IQ(D3); inset) in a 
7-member 2-fold dilution series starting at 60 nM in duplicate. The fit indicates a KD of 5.8 nM. 
No binding was observed to D-eboIZN39IQ(D3).   
 
SPR methods: SPR analysis was conducted on a CM5 sensor chip (GE Healthcare) loaded with 
~10,000 RU streptavidin followed by capturing ~400 RU biotin-D-eboIZN39IQ (at 40 nM in 
PBST* running buffer). Using Kinject, a 2-fold dilution series of D-eboC37 was flowed over the 
chip in duplicate at RT starting at 60 nM. A five minute dissociation time was used to ensure the 
response fully recovered to baseline prior to the next injection.  
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One of the most persistent, challenging problems in chemical peptide and 
protein synthesis is the handling of insoluble peptides. Although Native Chemical 
Ligation (NCL) has revolutionized peptide synthesis by providing a means to 
stitch together unprotected peptide segments, the handling of certain insoluble 
peptides remains a bottleneck to routinely preparing large proteins. Here, we 
introduce two new Solid Phase Peptide Synthesis (SPPS) building blocks, Fmoc-
Ddae-OH and Fmoc-Lys(N3-Dtpp)-OH, for incorporating and then selectively 
removing highly-solubilizing peptide sequences (“Helping Hands”) into difficult 
peptides. Two key design elements in this new strategy are (1) simple, on-resin 
attachment of the helping hand sequence at Lys residues, and (2) selective, in-
solution removal of the helping hand by gentle hydrazine treatment to regenerate 
the native Lys side chain. Introduction and selective removal of a helping hand 
sequence (Lys6) via the Fmoc-Ddae approach is demonstrated using a model 
peptide, C20. This method is then applied to the chemical synthesis of the 97-aa 
co-chaperonin GroES, assembled via NCL. The highly insoluble peptide 
comprising the C-terminal region of GroES is rescued by this solubilizing helping 
hand approach. Furthermore, we show that removal of the helping hand, with 
hydrazine, can be conveniently performed in a one-pot reaction with other 
synthetic steps. This robust and easy-to-use new tool will be broadly useful for 






4.2.1 Native Chemical Ligation and Protein Synthesis 
The development of Native Chemical Ligation (NCL)1 by Kent’s group was 
a critical discovery toward simplifying the total chemical synthesis of peptides 
and proteins. Using NCL, individual peptides containing N-terminal Cys and C-
terminal thioesters can be chemoselectively ligated to generate larger synthetic 
products. These starting peptide segments are usually prepared by solid-phase 
peptide synthesis (SPPS), using either Fmoc-2 or Boc-SPPS3 methods, and then 
purified by reverse-phase HPLC.  
Although this two-part strategy (SPPS of peptide segments followed by 
NCL) has been incredibly successful—including the total synthesis of the 312-
residue DapA protein4 and 166-residue, 50,825 Da polymer-modified EPO5—
very difficult challenges remain with handling poorly soluble and aggregation-
prone sequences. Based on these synthetic challenges, we reasoned that a very 
useful tool for the field would be an easy-to-use, reversible linker for introducing 
semi-permanent solubilizing groups (“helping hands”). Below, we document 
several previous efforts in the literature for addressing this solubility challenge, 
followed by an introduction to our new tool. 
 
4.2.2 Published Semi-permanent Solubilizing Methods 
One of the earliest demonstrations of attaching cationic residues (Lys and 
Arg) to improve peptide solubility and handling comes from research on 
solubilizing hydrophobic transmembrane peptides/proteins. Led by Deber’s 
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group, covalently installed poly-Lys and poly-Arg sequences on the termini of 
transmembrane helices greatly improved handling properties of these insoluble 
proteins6. These covalent strategies are not directly applicable in this work 
because the cationic sequences cannot be removed, but the key concept of 
using cationic groups to solubilize difficult/hydrophobic peptides has been 
established. Later, this same group employed a temporary solubilizing strategy 
via disulfide-bond attachment (Fig 4.1A); in this case, they developed a “PEG-a-
Cys” reagent for modifying Cys side-chains with polydisperse PEG7.  Although 
this disulfide strategy was very helpful in improving peptide solubility, it would be 
unstable under the highly reducing conditions present in NCL. 
One of the most prominent examples of a temporary solubilizing tag is the 
thioester Argn tag, first demonstrated by the Kent8 and Aimoto9 groups (Fig 
4.1B). In this method, the peptide of interest is directly prepared (on-resin) with a 
highly solubilizing thioester leaving group (Argn). This modification can be directly 
introduced by Boc peptide synthesis; incorporation via Fmoc-SPPS is more 
complicated due to the instability of thioesters to Fmoc deprotection10. However, 
a conceptually similar approach was recently demonstrated via Fmoc-SPPS 
using an ortho-aminoanilide cryptothioester method (Fig 4.1C)11. The thioester 
method has been used in several cases to endow peptides with greatly improved 
solubility and handling properties (see examples12). Unfortunately, the 
solubilizing tag is eliminated during the ligation reaction itself: it is either 
displaced by a more reactive thiol present in the reaction or eliminated during 
formation of the NCL product. Thus, the solubility enhancement cannot be 
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retained over the course of the synthesis. 
Another route for solubilizing tags (Fig 4.1D, E) employs C-terminal base-
labile linkers. In these cases, either glycolic acid (Fig 4.1D) or 
4.hydroxymethylbenzoic acid (HMBA) (Fig 4.1E) are used to create base-
sensitive ester linkages that are compatible with Boc13 or Fmoc-SPPS14, 
respectively. On the other end of the spectrum, an acid-labile (HF) linker (PAM, 
phenylacetamido) (Fig 4.1F) was recently used15 for solubilizing a difficult 
peptide produced by Fmoc-SPPS. Overall, these base and acid-sensitive linkers 
have been limited to peptide termini. 
Danifshefsky’s group developed an Allyl-based protection approach for 
introducing solubilizing groups16. Here, custom Fmoc-Glu and Fmoc-Lys building 
blocks were prepared with allylic ester and allylic carbamate linkers, respectively, 
containing solubilizing guanidine groups (Fig 4.1G). Deprotection of the allyl 
groups was achieved with tetrakis(triphenylphosphine) palladium(0) in DMSO in 
the presence of excess triphenylsilane to generate native peptide structure. 
Although these reagents were shown to be highly useful in solubilizing EPO 
peptide segments, their five-step syntheses were relatively complex, and only 
one Arg group was incorporated per building block. 
Lei Liu’s group recently developed a photosensitive linker for incorporating 
solubilizing sequences (Fig 4.1H)17. Here, an Fmoc-Gln building block was 
prepared that contains an Alloc group for Pd deprotection followed by on-resin 
incorporation of the solubilizing sequence. Later selective removal of the 
solubilizing sequence and restoration of a native Gln residue is achieved by 
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irradiation with UV light (proceeding through the ortho nitrobenzyl linker).  
Another very promising demonstration of solubilizing tags also comes from 
Liu’s group: GlyRBM, where RBM stands for removable backbone modification 
(Fig 4.1I)18. Here, an Fmoc-Gly building block was prepared that again uses 
Alloc protection for incorporation of the solubilizing sequence. An elegant 
approach was then developed for selective removal of the solubilizing 
sequence—inspired by Johnson’s N-(2-hydroxy-4.methoxy benzyl) (Hmb) 
group19. Protection of the 2-OH with an autocleavable linker (N-methyl-N-[2-
(methylamino)ethyl]carbamoyl group)20 provides a two-step deprotection 
mechanism: auto-elimination at pH 7 during the ligation reaction, followed by 
TFA-sensitive elimination of the Hmb group to restore a native Gly residue within 
the peptide. 
Lastly, two cases involving enzyme-cleavable linkers (Fig 4.1J, K) have 
been published for introducing solubilizing groups, using HIV-protease (Fig 
4.1J)12b and Carboxypeptidase (Fig 4.1K) 21.  
 
4.2.3 A New Helping Hand Approach 
These methods described above all address solubility problems with 
peptide segments; however in most cases, they are not sufficiently robust for 
routine use (e.g., due to their complex reagent synthesis, complex or 
uncontrolled cleavage conditions, limited placement within peptide sequences, or 
lability during NCL. Based on these challenges, we desire a new chemical tool 
(SPPS building block) with six important properties:  
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(1) Simple to prepare, low-cost, and usable in both L- and D-peptide syntheses, 
(2) Fully compatible and easy to incorporate in peptides using Fmoc-SPPS, 
(3) Compatible with NCL, desulfurization, hydrazide activation, and other 
methods used in assembly of peptide segments, 
(4) Provides a unique functional group to attach the desired solubilizing peptide 
sequence for improving solubility and handling properties, 
(5) Can be incorporated at diverse sites in nearly all peptide segments of the 
desired protein synthesis project (i.e., not limited to N- or C-termini), 
(6) After the solubilizing application is complete, the introduced sequence can be 
simply and selectively removed to generate the native peptide sequence. 
In response to this challenge, we describe the synthesis and application of 
Fmoc-Lys(N3-Dtpp)-OH (Fig 4.1L) and Fmoc-Ddae-OH (Fig 4.1M) for improving 
the solubility of difficult peptide sequences. Using these reagents (Fmoc-Ddae-
OH in particular), we can simply attach and remove, via gentle hydrazine 
treatment, highly solubilizing peptide sequences that we have termed helping 
hands (Fr. coup de main). We then applied a Lys6 helping hand to facilitate the 
synthesis and handling of a difficult region of the GroES chaperonin protein. 
Because these new tools possess the six properties listed above, we believe 








4.3.1 Failed Synthesis of GroES – a “Difficult Protein” that  
Needs a Helping Hand 
The Kay lab has a keen interest22 in developing mirror-image D-peptides 
as therapeutics23, as D-peptides have great therapeutic potential due to their 
resistance to natural (L-) proteases24. D-peptide inhibitors have been 
successfully developed using mirror-image phage display (MIPD)25; however, a 
key prerequisite for developing these inhibitors via MIPD is a D-protein target, 
which requires total chemical synthesis. Furthermore, we recognized an 
additional challenge in the preparation of large, complex mirror-image proteins: 
their precise folding in the absence of mirror-image chaperones. Accordingly, we 
showed that the E. coli GroEL/ES chaperone is ambidextrous (capable of folding 
both natural and mirror-image proteins)4. In order to generalize this observation, 
we are pursuing the total chemical synthesis of the E. coli GroEL/ES (538/97 
residues) chaperone, so that we can then use D-GroEL/ES to evaluate the cross-
chiral folding of a variety of recombinant L-client proteins. 
On the path to synthesizing GroEL/ES, we unexpectedly found the 
synthesis of the short GroES co-chaperonin to be highly challenging due to 
purification and solubility difficulties localized to its C-terminal region. In these 
exploratory studies, we pursued the chemical synthesis of GroES using three 
different synthesis strategies (via Fmoc-SPPS). First (Fig 4.2A), we attempted to 
synthesize the full 97-aa protein as a single peptide following a highly optimized 
synthesis SPPS strategy (several well-spaced pseudoproline dipeptides and low-
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density TentaGel R RAM resin). Although we were able to detect some correct 
full-length product, we were unable to cleanly isolate it by HPLC purification (Fig 
4.2B). At this point, it should be mentioned that one literature report has 
described the successful chemical synthesis of GroES using Boc-SPPS in one 
segment26, though neither HPLC nor MS data were provided to critically evaluate 
the quality of this material. 
We next pursued GroES using NCL strategies, by dividing the protein into 
two (Fig 4.2C, D) or three segments (Fig 4.2E, F). In this case, the thioester-
forming segments were prepared as C-terminal hydrazides for subsequent 
activation and in-situ thiolysis for NCL reaction27. However, these two strategies 
also proved very challenging—primarily due to difficulties with the C-terminal 
region of GroES. In the two-segment strategy, we obtained high-quality N-
peptide but found the C-peptide to be poorly soluble and practically unpurifiable 
as tested on three different HPLC columns of different chain lengths: C4, C12, 
and C18 (Fig 4.2D). With the three-segment strategy (Fig 4.2F), we found that 
the N- and middle peptides were of good quality, while the C-terminal peptide 
could not be dissolved for HPLC analysis and purification. 
These surprising challenges in our exploratory GroES syntheses 
prompted us to determine the nature of the problem and devise a chemical 
strategy to solve it. We speculate that the difficulty with the C-terminal region of 
GroES is due to its high density of acidic and hydrophobic residues. In fact, the 
N-terminal peptide possesses a pI of ~10.5, while the C-terminal peptide has a 
much lower pI of ~4.0. Based on this analysis, we decided to synthesize an 
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artificial version of the GroES-C protein with a covalent C-terminal Lys6 sequence 
(Fig 4.2G) in order to more appropriately balance its charge profile. Pleasantly, 
we found the crude HPLC profile of GroES-C-K6 (Fig 4.2H) to be much better 
resolved on three different columns, and the peptide solubility and handling to be 
greatly improved compared to unmodified control GroES-C.  
 
4.3.2 Attempt to Synthesize GroES Using Semi-permanent  
HMBA Linker 
Based on the promising results obtained with covalent attachment of poly-
Lys to GroES-C, we tested an already published method for semi-permanently 
modifying this peptide—via HMBA linker14—in order to synthesize the full-length 
protein. Fig 4.3A, B outline this two-segment approach. The N-peptide was  
prepared on hydrazine resin, while the C-peptide was prepared on TentaGel R 
RAM resin. For the difficult GroES-C peptide, a C-terminal Lys6 sequence was 
first installed on-resin, followed by an HMBA linker, a Cys(ACM) for attachment 
of fluorescent probes in future mechanistic studies, and then the remaining 
peptide sequence. The two starting peptides were purified by HPLC (Fig 4.3C), 
and then NCL was performed to generate a full-length construct (Fig 4.3D). Next, 
desulfurization of the ligation junction Cys42 was achieved using a free radical 
method28, generating the correct product (Fig 4.3D).  
After generating this full-length material (more soluble than the individual 
C-terminal segment), we tested removal of the Lys6 using the published base-
mediated method. Unfortunately, we encountered challenges with maintaining 
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the solubility of our full-length construct in denaturing conditions at the high pH 
required to completely remove the solubilizing group. Further, overnight 
incubation at pH ~8.5 (highest pH that we could maintain soluble sample) 
showed incomplete removal of the Lys6 sequence. These complications with 
cleaving the HMBA linker under denaturing conditions encouraged us to pursue 
another route to synthetic GroES.  
 
4.3.3 Synthesis of GroES Using Permanent C-terminal Poly-His 
Our ultimate goal in the synthesis of GroES is to prepare the native protein 
sequence for future mechanistic studies. Thus, we were initially hesitant to 
prepare a version modified with a permanent C-terminal Lys6 sequence due to 
the potential impact on chaperone assembly and activity. However, from 
literature, we found a C-terminal His6 version of GroES was active. In this SPR 
study29, a Ni-NTA SPR chip was used to immobilize GroES-His6, which was then 
used to demonstrate an ATP-dependent association with GroEL. Based on these 
data, we pursued the synthesis of GroES using our two-segment strategy (Fig 
4.4A, B), but retaining a permanent C-terminal His6 in the final construct. 
Although we were able to purify the GroES-C-H6 peptide (Fig 4.4C), we 
found that its solubility and handling properties were worse than our original C-
terminal Lys6 version. Specifically, the dissolution of GroES-C-H6 was more 
challenging compared to GroES-C-K6; with the poly-Lys version, this peptide (at 
30 µmol scale) can be dissolved relatively straightforwardly in ~12 mL of HPLC 
buffer, whereas 30 mL of HPLC buffer was inadequate for dissolving the poly-His 
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version. Additional rounds of dissolution were needed using 6 M GuHCl to fully 
dissolve the batch of GroES-C-H6. Nevertheless, we ligated purified GroES-C-H6 
with GroES-N to generate full-length product (Fig 4.4D). Similar to the previous 
approach, this product was then desulfurized at Cys42 to generate GroES with an 
additional C-terminal His6 (Fig 4.4E). 
The lyophilized synthetic GroES-His6 was then dissolved in 6 M GuHCl, 25 
mM Tris, 50 mM NaCl, pH 7.5 and refolded by overnight dialysis at 4 °C (MWCO 
3500, two exchanges) into this same buffer without GuHCl. In collaboration with 
George Lorimer (University of Maryland), the dialyzed material was then tested in 
an activity assay. Specifically, the ability of synthetic GroES-H6 to inhibit steady-
state ATPase activity of a single-ring mutant of GroEL (termed SR1) was 
evaluated (Fig 4.4F)30. Here, GroES-H6 demonstrated SR1 binding and inhibition 
of ATPase activity similar to recombinant controls: GroES and H6-GroES. 
However, the profile of the concentration dependence was slightly different in the 
synthetic sample compared to recombinant controls. This difference could be due 
to an altered monomer/heptamer equilibrium in GroES-H6 compared to WT and 
H6-GroES, as has been suggested in the literature31. However, this discrepancy 
might also be due to defects in the synthetic sample. Based on these somewhat 
vague activity data and the undesirable solubility properties of the GroES-C-H6 
peptide, we decided to attempt synthesis of native GroES using a scar-free 





4.3.4 Development of Helping Hand Using the C20  
Model Peptide 
A simple model peptide, C20 (Ac-DWTKNITDKIDQIIHDFVDK-NH2), was 
used to develop the Helping Hand solubilizing strategy. C20 is derived from the 
C-terminal heptad repeat region (CHR) of the Ebola GP2 protein32, which serves 
a critical role in viral entry33. A Tat-modified form of the extended Ebola C24 
peptide (YGRKKRRQRRR-GSG--IEPHDWTKNITDKIDQIIHDFVDK) was recently 
shown to inhibit viral entry34. The C20 peptide has several properties that make it 
an appealing model peptide for developing our new Helping Hand strategy: 
(1) It possesses good solubility in HPLC buffer (0.1% TFA in water/acetonitrile), 
and 6 M GuHCl, in order to cleanly develop our new approach; 
(2) The purity of the crude synthetic product is high, and it resolves well by RP-
HPLC on several different columns, simplifying data interpretation; 
(3) The peptide sequence contains several important residues: one Trp for 
accurate concentration determination, three Lys as potential insertion sites for 
helping hands, and good sequence diversity (ten different residues). 
 Accordingly, we prepared crude C20 peptides that incorporated either 
Fmoc-Lys(Dde) or Fmoc-Lys(N3-Dtpp) as reference points to develop our helping 







4.3.5 Implementation of the Fmoc-Lys(N3-Dtpp) Approach 
 The inspiration behind the two new building blocks, Fmoc-Lys(N3-Dtpp) 
and Fmoc-Ddae-OH, described in this work and synthesized in the Aucagne lab 
comes from the reaction of nitrogen-containing nucleophiles (primary amines) 
with 2-acylcyclohexane-1,3-diones  (see detailed review35) (Fig 4.5A). The 
formed enamine bonds can then be selectively cleaved by treatment with 
hydrazine, regenerating the original primary amine; importantly, these enamine 
bonds are stable to Fmoc and Boc deprotection conditions. This strategy has 
been used by Bycroft36 to develop the well-established amine-protecting group 
Dde, (4,4.dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde), which is used in Fmoc-
Lys(Dde) and Dde-Lys(Fmoc) building blocks offered by several commercial 
suppliers. 
 Our first attempt to install helping hands involved the new building block 
Fmoc-Lys(N3-Dtpp) (1-azido-5-[1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidine-5-
ylidene]pentyl) (Fig 4.1L). The N3-Dtpp linker was recently shown37 to be stable 
to a variety of conditions used in chemical protein synthesis projects (including 
HPLC and NCL). In this published work, the linker was cleaved with 1 M 
hydrazine, pH 9.5 or more mild conditions with 1 M hydroxylamine, pH 8.5. Next, 
N3-Dtpp-Val-OH was used to assemble, on solid-phase beads, a human mucin 
(MUC1) glycoprotein of 160 residues by applying a series of copper-catalyzed 
azide-alkyne “click” reactions, resulting in ~15 kDa (non-glycosylated) and ~20 
kDa (glycosylated) proteins.  
 We prepared C20 and C20(N3-Dtpp) peptides and observed clean 
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incorporation by SPPS (Fig 4.5B, C). We also performed preliminary copper-
catalyzed azide-alkyne cycloaddition with 4.pentynoic acid to demonstrate 
successful on-resin reaction with the azide group (Fig 4.5B, C). Having 
established that the reagent could be incorporated and participate in a click 
reaction, we considered various strategies for introducing and removing 
solubilizing sequences (Fig 4.5D-G), with the goal to identify the most efficient 
and useful method. In our first strategy (Fig 4.5D), we attempted to use a click 
reaction to attach an unprotected poly-Lys peptide (Lys6) to the on-resin C20(N3-
Dtpp) peptide. Here, poly-Lys was prepared on an amide resin, and the N-
terminus was modified with 4.pentynoic acid to generate an N-terminal alkyne. 
Cleavage with TFA then produced an unprotected peptide with C-terminal amide. 
Unfortunately, we were unable to achieve observable poly-Lys click products, 
which we attributed to a phase separation issue between the hydrophobic 
protected on-resin peptide and the highly charged unprotected poly-Lys in 
solution. 
 In our second strategy (Fig 4.5E), we looked to overcome the phase 
separation issue by using protected poly-Lys (in contrast to unprotected peptide 
used above). In this case, the poly-Lys peptide (Lys6) was prepared on 2-
chlorotrityl-chloride resin and cleaved using two different conditions: 1% TFA in 
DCM and 20% TFA in DCM, to prepare protected forms. Although these 
protected peptides were easily synthesized, their poor handling properties made 
this approach non-ideal due to the unpredictable nature of working up, storing, 
and solubilizing protected peptide fragments. Although this approach may be 
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feasible in the future, we did not pursue it further as it steers away from our goal 
of making a helping hand approach that is easy to incorporate. 
 In our third strategy (Fig 4.5F), we recognized that the unique azide group 
could be directly reduced to an amine38, thus providing a primary amine for 
simple introduction of Lysn via Fmoc-SPPS. Unfortunately, reduction of the azide 
led to elimination of the linker (likely by formation of a six-membered ring 
intermediate), ultimately generating the native Lys side chain before any 
additional modifications could be performed. This reduction strategy could likely 
be tried again by synthesizing a new reagent with a longer side chain, in order to 
minimize cycle formation and subsequent self-elimination. 
 In our fourth strategy (Fig 4.5G), we designed an “adaptor approach” via 
copper-catalyzed azide-alkyne “click” reaction. In this design, the azide group 
was reacted with Fmoc-propargylamine to generate a distant primary amine for 
subsequent Fmoc-SPPS introduction of Lysn. Although we were able to 
successfully generate C20(Fmoc-triazole-Dtpp) on-resin, we eventually decided 
against this approach because some on-resin sequences were found to be highly 
sensitive to oxygen damage when performing copper-click reaction. In particular, 
we observed minor histidine oxidation byproducts (+16 Da) in cases when strict, 
inert procedures were not carefully followed39. For our new helping hand 
approach to be generally useful to the community, it should be clean and simple-





4.3.6 Implementation of the Fmoc-Ddae-OH Approach 
 Based on our experience with Fmoc-Lys(N3-Dtpp), we wished to design a 
new, more user-friendly approach for installing helping hands sequences. This 
approach (Fig 4.6) employs our second new building block: Fmoc-Ddae-OH, (N-
Fmoc-1-(4,4.dimethyl-2,6-dioxocyclohexylidene)-2-[2-(2-aminoethoxy)ethoxy]- 
ethan-1-ol). Here, we were again inspired by the Dde-work from Bycroft36a. In this 
case, we designed an approach that involves the already commercially available 
(in both L- and D-) reagent Fmoc-Lys(Dde). We first synthesized C20 model 
peptide with a central Lys(Dde) (Fig 4.7A), creating C20(Dde). Next, we 
deprotected the Dde group with 3% hydrazine, producing C20 peptide (Fig 
4.7B). Fmoc-Ddae-OH was then added to the peptide resin to react with the 
newly revealed unique primary amine, producing C20(Fmoc-Ddae) (Fig 4.7C), 
which was right-shifted on RP-HPLC due to the hydrophobic Fmoc and 
(4,4.dimethyl-2,6-dioxocyclohexylidene) groups. Time course studies showed this 
reaction to be nearly complete after 2 h. On-resin Fmoc-SPPS was then 
performed to prepare C20(K6-Ddae) (Fig 4.7D), which showed a dramatic left-
shift on HPLC, as expected. The full batch of C20(K6-Ddae) peptide was then 
cleaved from the resin using standard TFA cleavage conditions. 
 This new strategy for producing C20 with a (K6-Ddae) helping hand was 
very simple to employ using standard coupling and deprotection conditions. We 
next evaluated the selective removal of the (K6-Ddae) helping hand via hydrazine 
treatment. Here, we conducted a time-course study (Fig 4.7D) to measure the 
conversion of C20(K6-Ddae) into native C20. C20(K6-Ddae) (~5 mM) was 
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dissolved in 6 M GuHCl, 100 mM phosphate, pH 7.5. Cleavage of the (K6-Ddae) 
group was achieved by addition of 1 M hydrazine to the solution (final pH 
adjusted to 7.5). Clean elimination of the (K6-Ddae) group was achieved with a 
t1/2 of ~1 h. 
 These results with C20 validated our new tool for introducing helping 
hands. This tool possesses the six properties listed in the introduction: simple-to-
prepare, easy-to-incorporate, stable to assembly conditions, provides a unique 
functional group, diverse sequence placement (at common Lys residues), and 
simple, selective removal of the solubilizing sequence.  
 
4.3.7 Successful Synthesis of GroES Using Fmoc-Ddae  
Approach 
 The best metric for the general utility of our new Fmoc-Ddae Helping Hand 
approach would be to synthesize and rescue a difficult peptide. In this case, we 
returned to the challenging GroES synthesis, especially the intractable GroES-C 
peptide. Accordingly, we designed a revised GroES synthesis strategy that 
employed the new Fmoc-Ddae approach (Fig 4.8A,B). GroES-C(K6-Ddae) 
peptide was synthesized and purified (Fig 4.8C), and then ligated to purified 
GroES-N via NCL to generate full-length GroES(K6-Ddae) (Fig 4.8D). We next 
desulfurized the ligation site Cys42 (Fig 4.8E) and removed the helping hand 
sequence after 2 h treatment with 1 M hydrazine (Fig 4.8F) to create native 
GroES. Interestingly, the desulfurization and hydrazine steps were done in a one-
pot reaction. Specifically, desulfurization of the peptide was first performed using 
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the free radical method (6 M GuCl, pH 6.5, 20 mM reduced glutathione, 30 mM 
VA-044, 300 mM TCEP) for 4 h. Second, in the same reaction (without an 
intervening purification), 1 M hydrazine was added to the solution (pH adjusted to 
7.5) to remove the helping hand. This one-pot capability for helping hand removal 
is another appealing attribute of this method. 
 In conclusion, we were finally able to achieve synthetic GroES protein 
using this new, simple helping hand strategy. 
 
4.4 Discussion and Future Plans 
The new Fmoc-Ddae-OH approach for introducing and removing helping 
hands was demonstrated in a simple C20 model peptide, as well as the highly 
challenging GroES protein. The introduced helping hand sequence (K6) was 
sufficient to assist in solubilizing the difficult GroES-C terminal peptide, enabling 
synthesis of the full-length product. Importantly, the entire procedure for 
introducing Fmoc-Ddae-OH and the helping hand sequence, as well as the later 
removal with 1 M hydrazine, was very simple to perform using standard peptide 
synthesis procedures. This simple method will be amenable to automation for 
future synthesis projects.  
 The possibility of using an azide-alkyne click approach with the Fmoc-
Lys(N3-Dtpp) reagent is also still feasible for future research projects. The four 
options described above with this reagent, although not yet generalizable for 




 The immediate next steps with this helping hand approach are to repeat 
the procedure on a large scale (including yields at all synthetic steps) and 
generate sufficient material for activity testing in collaboration with the Lorimer 




Xiang Ye and George Lorimer (University of Maryland) for performing 
GroES activity testing; M.S.K.(University of Utah Research Foundation Seed 
Grant and AI076168). 
 
4.6 Materials and Methods 
4.6.1 Peptide Characterization 
All peptides were prepared on a Prelude commercial peptide synthesizer 
(Protein Technologies, Inc.) Peptides with C-terminal amides were prepared on 
TentaGel R RAM resin (0.19 mmol/g, RAPP Polymere). Peptides with C-terminal 
hydrazides were prepared on in-house modified hydrazine-chlorotrityl resin 
based on published protocol27c. 
Peptides were analyzed on the following columns (from Phenomenex): 
• Jupiter 5u C4 300A, 4.6 x 150 mm 
• Jupiter 4u C12 Proteo 90A, 4.6 x 150 mm 
• Aeris WIDEPORE C4 3.6u, 2.1 x 50 mm 
Peptides were purified on the following column (from Phenomenex): 
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• Jupiter 5u C4 300A, 10 x 250 mm 
Mass spectrometry characterization of peptides was performed using an AB 
Sciex 3000 LC/MS/MS system. 
 
4.6.2 Native Chemical Ligation and Desulfurization 
NCL reactions were performed according to standard protocols in the 
field40, with specific adjustments for peptide hydrazides27, 41. Desulfurization 
reactions were performed according to the established free-radical protocol28, 
using reduced glutathione as the thiol scavenger. 
 
4.6.3 Cleavage of Helping Hands with 1 M Hydrazine 
Cleavage of helping hands was performed in 6 M GdnHCl in 100 mM 
phosphate, 50 mM DTT, pH 7.5, with addition of 1 M hydrazine. Careful attention 
should be made to adjust the solution pH after adding hydrazine. 
 
4.6.4 Copper Catalyzed Azide-Alkyne Cycloaddition  
Reactions 
Copper-catalyzed azide-alkyne was performed under inert conditions 
using three-way valve set-up. Several cycles of vacuum-argon degassing is 
performed on all buffers before use. Copper bromide dimethyl sulfide complex 
(Sigma) is used as the catalyst. Typical reaction conditions (small-scale testing) 
used ~2 µmol of peptide resin, ~5 µmol of alkyne, ~10 µmol copper, and ~20 





















































































Peptide Peptide Peptide 
A B C 
Peptide Peptide Peptide 
D E F 
G H I 




Figure 4.1: Semi-permanent solubilizing methods. (A) PEG-a-Cys; (B) 
Thioester tag; (C) o-aminoanilide cryptothioester tag; (D) Base-sensitive 
glycolamide-linked tag; (E) Base-sensitive HMBA-linked tag; (F) Acid-sensitive 
PAM-linked tag; (G) Allyl-linked Arg tags; (H) Photocleavable tag; (I) pH-sensitive 
autocleavable tag; (J) HIV protease-sensitive tag; (K) Carboxypeptidase-sensitive 











C [GroES-N]: MNIRPLHDRVIVKRKEVETKSAGGIVLTGSAAAKSTRGEVL-NHNH2 
[GroES-C]: CVGNGRILENGEVKPLDVKVGDIVIFNDGYGVKSEKIDNEEVLIMSESDILAIVEA-NH2 
[GroES] on C4a 





[GroES-N-S] on C12 [GroES-Middle] on C12 F [GroES-C-S] 
Insoluble 
[GroES-C-K6]: CVGNGRILENGEVKPLDVKVGDIVIFNDGYGVKSEKIDNEEVLIMSESDILAIVEAKKKKKK-NH2 G 
H 
[GroES-C-K6] on C4 [GroES-C-K6] on C12 [GroES-C-K6] on C18 
Figure 4.2: The challenging GroES synthesis. (A) Full-length GroES 
sequence; (B) HPLC analysis of crude GroES on C4a column; (C) 
GroES-N and GroES-C peptide sequences; (D) HPLC analysis of crude 
GroES-N and GroES-C peptides on C4, C12, and C18 columns. (E) 
GroES-N-s, GroES-Middle, and GroES-C-s peptide sequences; (F) 
GroES-N-s, GroES-Middle, and GroES-C-s peptides on C12 column; (G) 
GroES-C-K6 peptide sequence; (H) GroES-C-K6 on C4, C12, and C18 
columns. C4 column is Phenomenex Jupiter (4.6 x 150 mm); C4a is 
Phenomenex Aeris (2.1 x 50 mm); C12 is Phenomenex Proteo (4.6 x 150 
mm); and C18 is Waters (4.6 x 50 mm). The incorporations of 
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Calc: 11496.2  
Obs: 11496.0 Calc: 11464.1 Obs: 11464.0 
Figure 4.3: HMBA-based method to prepare GroES. (A) GroES-N and 
GroES-C peptide sequences; (B) Assembly strategy; (C) C12 
(Phenomenex Proteo, 4.6 x 150 mm) HPLC and MS data on the purified 
GroES-N and GroES-C peptides (D) MS data on the purified ligation 
product; (E) MS data on the purified desulfurization product. The 
incorporations of pseudoproline dipeptides are indicated in bold and 






























































































Figure 4.4: Permanent poly-His method to prepare GroES. (A) GroES-N 
and GroES-C peptide sequences; (B) Assembly strategy; (C) MS data on 
the purified GroES-C peptide; (D) Mass spec data on the purified ligation 
product; (E) Mass spec data on the purified desulfurization product; (F) 
ATPase activity assay for GroES constructs. Pseudo-proline dipeptides and 
N-substituted Gly residues, used to improve synthesis quality, are indicated 
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Figure 4.5: Fmoc-Lys(N3-Dtpp) approaches to helping hand. (A) 
Reaction of 2-acylcyclohexane-1,3-diones with primary amine; (B) 
Crude [C20], [C20(N3-Dtpp)], and [C20(click)] on C12 column (4.6 x 
150 mm); (C) Mass spec data on [C20], [C20(N3-Dtpp)], and 
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Figure 4.6: Fmoc-Ddae helping hand approach. Fmoc-Ddae-OH method 
for introducing helping hands proceeds using an Fmoc-Lys(Dde) 
intermediate, which is then deprotected with hydrazine. The single primary 
amine is reacted with Fmoc-Ddae-OH to generate a unique anchor for 
introducing helping hand sequences by Fmoc-SPPS. Cleavage of the 

























































































































































Figure 4.7: Fmoc-Ddae-OH method using C20. (A) HPLC and MS analysis 
of C20(Dde); (B) HPLC and MS analysis of C20; (C) HPLC and MS analysis of 
C20(Fmoc-Ddae); (D) HPLC and MS analysis of C20(KKKKKK-Ddae); (E) 
Overlay of HPLC traces; (F) Time-course study on helping hand cleavage. 













NCL 1. Desulfurization (C
42->A42) 




































































































































Figure 4.8: Synthesis of GroES using Fmoc-Ddae-OH approach. (A) 
GroES-N and GroES-C peptide sequences; (B) Assembly strategy; (C) MS 
data on the purified GroES-C peptide; (D) MS data on the purified ligation 
product; (E) MS data on the purified desulfurization and hydrazine-treated 
product. The incorporation of pseudoproline dipeptides and N-substituted Gly 
residues, used to improve synthesis quality, are indicated in bold and 
underline within the peptide sequences. Note: an Ile/Leu deletion byproduct is 
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This chapter describes our efforts to synthesize a 352-residue DNA 
polymerase: Dpo4 (DNA polymerase IV) from Sulfolobus solfataricus. The total 
chemical synthesis of a DNA polymerase has long been an interest of the 
synthetic biology and chemical protein synthesis fields. An entirely synthetic 
polymerase would provide unmatched access to specific modifications for 
mechanistic studies and an important first step toward generating mirror-image 
life, as a D-polymerase would be an excellent tool for amplifying mirror-image L-
DNA. In this study, we selected Dpo4 as our synthetic target because 1) it is one 
of the shortest thermostable DNA polymerases found in Nature; 2) it has been 
well-characterized both structurally and functionally; 3) it possesses lesion 
bypass ability; and 4) a mutant form (Y12A) can extend RNA in addition to DNA. 
In this chapter, we detail the rational design of a six-segment strategy for 
synthesizing this enzyme. Several design optimizations were validated using a 
PCR assay for screening different mutants in recombinant Dpo4. In addition to 
the various synthetic tools and optimizations described here, we formally 
introduce the DOPPEL (Diversity-based Optimization of Peptide Properties to 
Enhance Ligations) concept. DOPPEL is the introduction of subtle sequence 
changes that can be made to greatly simplify chemical synthesis. With this 
approach, we identified a Dpo4 “DOPPELganger” (C31A/I101M) that has robust 
activity, but is much more synthetically tractable. We also introduce a TEV-
cleavable Lys tag to improve solubility and the overall synthesis. Currently, we 
have prepared micro quantities of the full-length construct, and are scaling up. 
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5.2 Introduction 
5.2.1 Selection of Dpo4 Polymerase 
Dpo4 (DNA polymerase IV), 352 residues, was identified in 2001 using a 
homology search of the published Sulfolobus solfataricus genome2. S. 
solfataricus is a thermophilic archaeal bacterium that was discovered in the 
Solfatara volcano crater near Naples, Italy3. Dpo4 is a thermostable DNA 
polymerase that is capable of performing PCR4. In fact, a blend of Dpo4 and Taq 
was capable of amplifying UV-irradiated DNA that could not be amplified by Taq 
alone5.  
Similar to all known DNA polymerases, the structure of Dpo4 has been 
described as a right hand composed of “thumb”, “palm”, and “finger” domains1, 6 
that wraps around the DNA. The palm domain is generally well-conserved across 
polymerases and provides three carboxylic acid groups that are key to catalysis 
(in Dpo4, these are Asp7, Asp105, and Glu106, which are conserved throughout the 
Y-family)1. The thumb and finger domains are more structurally variable and are 
generally associated with other important functions: translocation, DNA 
positioning, and processivity6. However, unlike most other DNA polymerases, 
Dpo4 also possesses a fourth domain termed the “little finger” or wrist/pad (Fig 
5.1). The suggested function of the little finger is primarily to facilitate DNA 
association upstream of the active site via electrostatic interactions7. Additionally, 
domain-swapping studies between different Y-family polymerases suggest that 
the little finger influences processivity and the response to different types of DNA 
lesions8. A key structural feature of Dpo4 (and all Y-family members) is its 
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solvent-accessible active site that provides the ability to bypass DNA lesions. 
Specifically, in Y-family members, the thumb and finger domains are 
significantly smaller compared to the other polymerases7. In all other families, the 
active site is much tighter9, as a protein conformational change occurs upon 
binding of the correct complementary nucleotide. A variation of an “induced fit” 
mechanism has been used to describe this concept10. In fact, the error rate of Y-
family DNA polymerases11 is several orders of magnitude higher compared to 
polymerases in all other families12. However, it should be emphasized that this 
large difference in error rate is also influenced by other proofreading and 
mismatch repair activities—not just due to this active site accessibility13. On the 
other hand, the active site accessibility and subsequent translesion synthesis 
ability of Y-family DNA polymerases provide a critical role in Nature, as these 
enzymes prevent stalling of higher fidelity enzymes that perform most cellular 
DNA replication13.  
Another interesting feature of Dpo4 is its potential to perform not just DNA 
polymerase activity, but also RNA polymerase activity. In this case, a mutant of 
Dpo4 (Y12A) showed significant RNA polymerase activity, in contrast to WT14. 
However, the Y12A mutant showed less efficient overall DNA/RNA polymerase 
activity compared to WT. This result has been explained by a steric gate 
hypothesis15, where the Y12A mutation leads to decreased discrimination at the 
2’-OH group—as was shown in two crystal structures of this mutant16. 
Interestingly, nonspecific ribonucleotide incorporation by DNA polymerases, as a 
general phenomenon to all polymerase families, has recently attracted great 
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interest17. 
In conclusion, the relatively short Dpo4 is a very appealing synthetic target 
based not only on its DNA polymerase activity, but also on its other interesting 
capabilities: translesion synthesis and potential for RNA polymerase activity. 
 
5.2.2 Dpo4 (352 aa) from the Perspective of Chemical  
Protein Synthesis 
Total chemical protein synthesis (CPS) is an exciting field of chemistry 
that is dependent on the optimized application of two established procedures: 
solid-phase peptide synthesis (SPPS)18 and native chemical ligation (NCL)19. In 
most cases, peptide segments are prepared by SPPS, using either Fmoc20 or 
Boc21 methods, and then these segments are chemoselectively ligated together 
using NCL. 
Our recent synthesis of 312-residue DapA in both L- and D- chirality was 
an impressive achievement that extended the length record for CPS, as well as 
providing an interesting biological insight into chaperone-mediated protein 
folding22. Size limits in protein chemical synthesis have recently been reviewed23. 
Prior to DapA, the longest reported synthetic protein was the iterative synthesis 
of isopeptide-linked tetraubiquitin of 304-aa24. Most major CPS projects are in the 
range of 100 – 200 aa25, with only these two published examples >300 aa. The 
routine production of proteins >300 aa is still a significant challenge. 
The proposed synthesis of 352-aa Dpo4 would push this limit even further. 
Based on our experience with DapA, the two primary limitations to synthesizing 
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long proteins are (1) cumulative sample losses over sequential purification steps, 
and (2) handling of poorly soluble synthetic intermediates. Thus, the total 
chemical synthesis of Dpo4 will require a highly optimized strategy and 
introduction of new tools to address these limitations, as detailed throughout the 
chapter. 
 
5.2.3 Synthesis Strategy and DOPPEL 
Our previous synthesis of 312-residue DapA was a laborious, difficult 
process that required a strong intellectual partnership with a high degree of 
persistence (over 2 years). Although we were able to achieve this mega-
synthesis twice (in L- and D- chirality), there were some aspects of the synthesis 
that were suboptimal. Ultimately, these challenges must be addressed for the 
chemical synthesis of large proteins to become routine. Some of these 
challenges with DapA included: 
• Several inefficient and ultimately failed synthesis strategies were pursued 
before the final optimized route was selected. For many of these 
strategies, several 30 µmole batches of purified peptide were required, 
and many rounds of ligation (NCL) and HPLC purification were needed to 
determine the viability of a particular strategy. 
• The quality of the synthetic L- and D- proteins (pre- and post-folded) was 
not ideal. Although the biological question in the DapA paper could be 
answered with these materials, the synthetic quality was lacking at two 
stages. First, the final synthetic proteins, prior to an orthogonal SEC 
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purification, were poorly active (~15.30% compared to recombinant 
protein). Second, even after an SEC purification of this material that 
isolated foldable tetrameric material, it was only ~80% active compared to 
recombinant protein. The quality of our synthetic material must be 
improved for future mega-synthesis projects. 
• Significant yield losses accumulated over the course of the synthesis 
process that would be problematic in longer and more complex synthesis 
projects. Many of the peptides in the chemical synthesis of DapA required 
several batches (~100 µmol) of starting material. Thus, projects that 
involve more handling steps would require even more starting material 
(purified peptides), ultimately becoming resource-prohibitive. 
Based on these challenges from the DapA project, we wished to pursue 
the synthesis of the longer Dpo4 protein using a more methodical strategy. We 
identified two important design criteria before pushing forward on this total 
chemical synthesis: 
(1) We need to scout and then develop a highly optimized synthesis strategy 
to obtain high yield and quality, as well as highly functional material; 
(2) We wish to introduce a new tool that can be used to routinely simplify and 
improve the overall synthesis process.   
Concerning the first criterion (an optimized synthesis strategy), we made 
extensive use of pseudoproline dipeptides and 2,4-dimethoxybenzyl (Dmb) 
backbone amide protecting groups, low-density resins, diverse HPLC column 
chemistries, and strategic optimizations at all steps of the SPPS and NCL 
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processes to produce the highest quality peptides and assembly strategy. These 
exact optimizations are detailed in the sections below. 
Concerning the second criterion (a new tool), in addition to using several 
state-of-the-art protecting groups and assembly strategies that helped enhance 
the overall synthesis, we desire a tool that can generally assist in all major 
synthesis projects. Here, we formally introduce a new tool termed DOPPEL:  
Diversity-based Optimization of Peptide Properties to Enhance Ligations. The 
key concept of DOPPEL is the introduction of synthesis-friendly mutations (“quiet 
mutations”) that do not significantly perturb the structure and function of the 
desired synthetic target. In other words, we look to make well-informed, subtle 
sequence changes that can significantly improve the chemical synthesizability 
(quality and/or yield) of the target protein. These changes should not have a 
major impact on the function of the target protein and are first validated using 
recombinant protein, as will be shown below.  
The DOPPEL concept, like many of the ideas in this chapter, originated 
from our previous challenges with the DapA synthesis. To achieve DapA, we 
made a single sequence change, A77C, which aided the synthesis by eliminating 
two synthetic handling steps: desulfurization and ACM-removal. In fact, without 
this change, we were unable to assemble the N-terminal half of DapA. The 
rationale for making the A77C version of DapA included analysis of a BLAST 
sequence alignment and inspection of the published crystal structure. Ultimately, 
the mutant was validated by recombinant protein activity testing that showed 
negligible effects on either DapA activity or refolding by GroEL/ES.  
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In this Dpo4 synthesis, we formalize this idea into the more 
comprehensive DOPPEL concept by evaluating several different mutants or 
DOPPEL versions of Dpo4 (“DOPPELgangers”). The justifications behind these 
mutations are described below, including both rationale for why the mutation 
would assist in the synthesis and why it is predicted to have minimal impact on 
structure/function. We then evaluated the effects of these mutations on enzyme 
activity via recombinant expression methods. 
 
5.3 Results 
5.3.1 Exploratory Synthesis and Peptide Scouting of Dpo4 
As the 352-residue Dpo4 construct is 40 residues longer than our previous 
highly challenging synthesis of 312-residue DapA, we reasoned that a very 
efficient synthesis strategy would be needed. Therefore, before attempting the 
total synthesis of the entire Dpo4 protein, we decided to first scout the properties 
(synthesis quality and solubility) of the individual regions within the protein—to 
inform the final synthesis strategy. In other words, the peptides that make up the 
Dpo4 protein sequence can be individually synthesized and analyzed to identify 
any highly challenging sequences. Accordingly, the Dpo4 protein sequence was 
then divided at potential NCL junction sites into nine contiguous peptides ranging 
from 26 – 49 residues (Figure 5.2 A, B, peptides [s1] to [s9]). Peptides [s1] to 
[s8] were prepared as C-terminal hydrazides for exploratory testing of ligation 
reactivity, while peptide [s9] was prepared as C-terminal amide. Peptide N-
termini were prepared with either Cys or Pen (Penicillamine, a thiolated version 
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of Val26) to explore ligation reactivity. All peptides were synthesized by standard 
Fmoc-SPPS (30 µmol scale). 
HPLC and MS were then used to characterize the crude peptides (Figure 
5.3 A-I, Table 5.1). Preliminary scouting of peptide solubility was also performed 
in the buffers used for HPLC purification (0.1% TFA in acetonitrile/water) and 
NCL reactions (6 M GuHCl, pH 7).  
Fortunately, all nine peptides showed a major product with the correct 
mass (Figure 5.3 A-I, Table 5.1). Across all peptides, the most common 
byproducts were: Ile/Leu/Val/Pen deletions (-113/-113/-99/-130 Da), aspartimide 
formation (-18 Da), and various adducts typically observed to a small degree in 
crude peptides: TFA (+97 Da), OtBu/tBu (+56 Da), and an unresolved +40 Da 
modification. 
Overall, we found that peptides comprising the C-terminal half of Dpo4 
([s5], [s6], [s7], [s8], and [s9]) showed slightly higher synthesis quality compared 
to the N-terminal half. These C-terminal peptides are rich in synthesis-friendly 
(“kinky”) Pro residues and potential pseudoproline sites27 (Xaa-Ser and Xaa-Thr), 
which encouraged us to pursue longer combined segments in our final synthesis 
strategy. In contrast, we found peptide [s3] to be highly challenging due to a 
significant degree of aspartimide formation (-18 Da aspartimide and +67 Da 
piperidine adduct byproducts), as well as Ile/Leu (-113 Da) deletions. 
The C-terminal region of peptide [s3] contains four potential aspartimide 
sites (Asp-Glu, Asp-Ile, Asp-Lys, and Asp-Tyr)28. Indeed, synthesis of a short 
peptide ([ASIDE], Figure 5.4 A, B) containing just this region already showed 
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measurable aspartimide formation29. To address this challenge, we considered 
troubleshooting a series of different aspartimide-preventing additives in our Fmoc 
deprotection solution (e.g., HOBt, Oxyma-based additives30, or formic acid31); 
however, we reasoned that we could reduce this problem by simply revising our 
final synthesis strategy. In this case, the difficult region (-DEAYLDISDKVRD-) 
should be repositioned from the C- to the N-terminus of a peptide segment so as 
to reduce the cumulative piperidine (base) exposure time and subsequent 
aspartimide formation. This repositioning of the ASIDE sequence greatly reduced 
the aspartimide problem, as observed in the final peptides. 
During our initial peptide scouting, we also found peptide [s1] to be poorly 
soluble under ligation conditions (<1 mM in 6 M GuHCl). This could be 
problematic during the subsequent assembly of our protein, as it would be 
difficult to drive any reactions containing this peptide by increasing the 
concentration of [s1]. Furthermore, any post-ligation purifications involving this 
segment are likely to be complicated by this solubility challenge. In response, we 
prepared a His6-tagged version of this peptide ([His-s1]), reasoning that the His6 
sequence would provide a permanent solubilizing function (Figure 5.4 C, D). 
Model peptide testing showed that the His6 addition greatly improved peptide 
solubility (>1 mM) (data not shown). Installation of an N-terminal His6-tag would 
also facilitate the expression of our recombinant Dpo4 constructs used below. 
Fortunately, the quality of the [His-s1] peptide was not significantly impacted by 
the His6-tag addition. Furthermore, the C-terminal peptide [s9] was adequately 
soluble (>1 mM) in 6 M GuHCl, providing additional support to place a His6 
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sequence at the N-terminus. 
In addition to scouting the synthesis quality and solubility of these 
peptides, we also used them to perform exploratory testing on their ligation 
kinetics. This testing is highly informative, as it will assist in identifying the most 
reactive and reliable ligation junctions for connecting individual peptide 
segments. In the course of this testing, we observed slow ligations (>8 h to obtain 
a major product peak) for segments associated with the C-terminal half: Leu 
thioester between [s5] + [s6], Leu thioester between [s6] + [s7], and Thr thioester 
between [s8] and [s9]. These observations are consistent with Dawson’s 
published thioester reactivities32. We also unfortunately observed prohibitively 
slow NCL kinetics in all reactions involving N-terminal Penicillamine (Pen) 
groups. Pen (β,β-dimethylcysteine) is a β-thiol derivative of Val that is used to 
ligate at Val residues33 by a ligation-desulfurization strategy34. We found that 
even reactions involving Ala thioesters (e.g., reaction of [s1] with [s2]) were very 
slow, with negligible product after 24 h. This result was surprising, as Pen was 
reported to ligate with sluggish32 Val thioesters (i.e., forming a Val-Val junction)33. 
However, the general utility of Pen in NCL has since been questioned35. 
Ultimately, we decided to avoid Val junctions, using only Ala-based junctions (via 
Cys junctions). It should be mentioned that many custom cysteine surrogates 
have been developed for ligating at other residues, as recently reviewed36. 
However, most of these cysteine surrogates are commercially unavailable and 
are still synthetically challenging to produce (>7 steps), although Payne’s recent 
work is highly encouraging on this front37. 
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5.3.2 Six-Segment, Convergent Assembly Strategy 
Based on the lessons from our peptide scouting, we selected our six 
peptide segments, ranging from 45 – 72 residues, for assembling Dpo4 (Fig 5.5 
A, B). However, a brief note on the peptide nomenclature is needed before 
further discussion. The final six peptides are combinations of the initial nine 
scouting peptides. 
Although these new peptides are relatively long (thus more difficult to 
synthesize and purify compared to shorter peptides), we rationalized that more 
difficult initial HPLC purifications are preferred over the losses and complexities 
associated with additional HPLC purifications of synthetic intermediates. Based 
on our experience, each additional HPLC purification adds at least three potential 
challenges: 
(1) An additional complexity associated with maintaining solubilized peptide 
during the transition from NCL reaction buffer (6 M GuHCl, 200 mM 
phosphate, plus other additives) to purification conditions (0.1% TFA in 
water/acetonitrile), and  
(2) The development of a high-resolution HPLC purification method that can 
sometimes be very difficult, due to closely eluting reactants and products. 
(3) A decrease in yield (typically >20%) simply due to HPLC contact. 
Considering this issue of balancing peptide length with the number of 
intermediate purifications more quantitatively, we recognized a simple 
relationship between number of peptide segments and minimum total number of 
purifications: p = (n*2) – 1, where p is the minimum total number of purifications 
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and n is the number of peptide segments (Fig 5.6). Fig 5.6a shows the minimum 
number of purifications required for a particular number of peptide segments 
based on this relationship. 
 To simplify the calculations, one-pot strategies38 are omitted, as well as 
desulfurizations and various deprotection steps that add complexity as the 
number of segments increases. Thus, by decreasing the number of starting 
peptide segments from nine (Fig 5.6b) to six (Fig 5.6c), we have decreased the 
overall complexity by reducing the minimal number of purifications from 17 to 11. 
Importantly, this design concept—using longer peptides with fewer 
purifications versus shorter peptides with more purifications—required us to 
employ optimized Fmoc-SPPS and HPLC purifications to generate high-quality 
peptides. HPLC traces of the six crude peptides are provided in Fig 5.7. HPLC 
and MS data demonstrate that very high-quality purifications of these peptides 
could be achieved (Fig 5.8, 5.9, 5.10, 5.11, 5.12, and 5.13)  
We made extensive use of pseudoproline dipeptides in all six peptides 
(Fig 5.5) to improve overall synthesis quality27, 39. Asp-Ser and Asp-Thr 
pseudoproline dipeptides were especially important, as they prevent aspartimide 
formation. In general, as many pseudoprolines as possible were used in the 
assembly, with two exceptions:  
(1) In Pro and pseudoproline-rich peptides, over-incorporation was avoided 
(e.g., Arg-Thr and Glu-Thr pseudoprolines were not used in the already 
kinky [8-9] peptide),  
(2) Ile-based pseudoprolines were avoided as D-Ile (ultimately needed to  
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synthesize D-Ile-Ser and D-Ile-Thr pseudoprolines) is unusually 
expensive, and we plan to synthesize D-Dpo4 for mirror-image 
polymerase studies using the same synthetic route employed here.  
In addition to the extensive incorporation of pseudoproline dipeptides, we 
strategically introduced 2,4-dimethoxybenzyl (Dmb) N-substituted Gly40 to 
improve synthesis quality in peptides [1-2] and [5-6]. In the case of [1-2], we 
prepared a truncated version of this peptide and showed that insertion of (Dmb)-
Gly greatly reduced His deletion byproducts associated with the N-terminal His6 
sequence (Fig 5.14 A). Based on this result, we then incorporated (Dmb)-Gly in 
the full [1-2] sequence.  
In the case of [5-6], we found the crude peptide to be relatively low quality 
(Fig 5.7 D and 5.14 G), although a clearly isolated correct peak was observed. 
The relatively low quality of [5-6] is not entirely surprising due to its low density of 
Pro and pseudoproline residues compared to the other peptides. To address this 
problem, we simplified it by focusing on a truncated version: peptide [6] (Fig 5.14 
B). This peptide was then prepared with Asp-Thr pseudoproline dipeptide (Fig 
5.14 C). Impressively, early insertion of a single (Dmb)Gly greatly improved 
quality (Fig 5.14 D). 
Alternatively, we investigated the effect of alternative Lys side-chain 
protecting groups to improve synthesis quality. In this case, we substituted three 
Lys(Boc) in the sequence with one of two alternatives: Lys(Mtt) or Lys (Dde) (Fig 
5.14 E, F). We hypothesized that the more bulky protecting groups Mtt and Dde 
could reduce on-resin aggregation compared to the more compact Boc protecting 
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group. It has been reported in the literature that these protecting groups can 
improve synthesis quality in short peptides. However, as can be seen in Fig 5.14 
E & F, these substitutions did not improve synthesis quality, and thus Boc 
protection was retained at all Lys positions 
The dramatic synthesis improvement seen in [6] with one (Dmb)Gly was 
then expanded to the more difficult context of full-length [5-6]. Again, the overall 
quality of the longer full-length crude peptide was significantly improved 
(compare Fig 5.14 G & H). 
However, outside these two cases in [1-2] and [5-6], we avoided further 
incorporation of (Dmb)Gly throughout the project due to difficulty in coupling the 
next (N-terminal) residue40. The other Gly residues are located in positions not 
ideal for incorporating (Dmb)Gly protection for a variety of reasons:  
(1) They precede a difficult-to-couple hindered residue,  
(2) They are located next to an already introduced pseudoproline dipeptide, 
which makes them likely to be unnecessary, 
(3) They are too late (too N-terminal) in the peptide to have a measurable 
effect on overall synthesis quality.  
Nevertheless, we note one particular appeal of the commercially available 
(Dmb)Gly in improving synthesis quality: it can be directly used in both L- and D- 
synthesis projects, as Gly is an achiral residue. In contrast, the established 
pseudoproline dipeptides (Xaa-Ser and Xaa-Thr, detailed above) are 
commercially limited to L-chirality, so these must be custom-prepared in mirror 
image for future D- synthesis projects (an effort already underway with Mark 
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Petersen). 
Lastly, we wish to emphasize the importance of performing Fmoc-SPPS at 
very low densities (~0.2 mmol/g) for improving synthesis quality. Fig 5.15 shows 
the crude synthesis quality of an exploratory version of peptide [2] when 
prepared at two different densities: ~0.5 (Fig 5.15 A) and ~0.2 mmol/g (Fig 5.15 
B). Based on this result, all peptides were subsequently synthesized at densities 
<0.25 mmol/g. We could then outline the assembly strategy, applying two rules:  
(1) Employ a convergent assembly to maximize overall efficiency41,  
(2) Plan the order of assembly so that the last ligation reaction utilizes a 
highly reactive and reliable thioester.  
Concerning the order of assembly, there are five thioesters to consider: 
Lys, Ile, Ala, Lys, and Lys (Fig 5.5 B, Fig 5.15 C). The highly reactive Ala 
junction32 between peptides [4] and [5-6] was selected for the final ligation 
reaction. Our logic is that because the last ligation uses the most precious 
synthetic material, this reaction should be performed under the most favorable 
conditions, i.e., using the most optimal available thioester. Further, although Lys 
thioesters are highly reactive, they have recently been found to form unreactive 
thiolactone species42—another reason to avoid Lys as the final thioester. 
Thus, our assembly strategy was split into two halves centered on the Ala 
junction (Fig 5.15 C): N-terminal half with peptides [1-2], [3], and [4] and C-
terminal half with peptides [5-6], [7-8], and [8-9]. Starting with this framework, we 
describe the challenges that we encountered in the total synthesis of these two 
halves, followed by the necessary DOPPEL changes. These five sections 
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described below include: 
(1) N-terminal Half: How to Handle the His tag? 
(2) N-terminal Half: The C31 Conundrum 
(3) N-terminal Half: I101-Inspired Precipitation 
(4) C-terminal Half: Desulfurization Dilemmas 
(5) C-terminal Half: Taking a Step Back in Ligations. 
 
5.3.3 (1) N-terminal Half: How to Handle the His tag? 
An important observation during the peptide scouting stage was the poor 
solubility of the [s1] peptide, which was remedied by installation of an N-terminal 
His6 tag. Thus, our recombinant Dpo4 construct was produced with an N-terminal 
His6 tag (WT construct, Fig 5.16 A), which was also used to facilitate the 
purification via Ni affinity resin. 
 Our first efforts to perform PCR using this WT construct were relatively 
unsuccessful. Fig 5.16 B shows the results of a PCR assay using M13KE 
plasmid template, and two short 20 nt primers with the following PCR conditions: 
15 seconds denaturation at 86, 89, 90.6, or 92 °C, 30 seconds annealing at 56°, 
and 1 minute extension at 60°, repeated over 25 cycles (generating a product 
~200 nt). The positive control (“NEB”) is a commercially available Dpo4 protein 
from a similar thermophile, Sulfolobus islandicus. Here, the NEB sample was 
active up to 92 °C, while the WT sample was only active at 86 °C. To determine 
this discrepancy in activity between our S. solfataricus and the NEB S. islandicus 
samples, we first identified the sequence variations. Based on the published 
! 108 
molecular weight of the NEB reagent, we were able to deduce the likely S. 
islandicus strain from a BLAST search of the reference S. solfataricus. 
Compared to our S. solfataricus sequence (WP_009993137.1), the S. islandicus 
strain (WP_014513455.1) contained 24 sequence changes (out of 352 residues) 
although most of these changes are relatively conservative: Lys/Arg, Ile/Val (Fig 
5.16 C). However, we decided against engineering our vector to mimic the S. 
islandicus sequence due to significant peptide scouting that had already been 
performed on our native sequence. 
In addition to the protein sequence differences (Fig 5.16 C), our construct 
contained an additional N-terminal His6 tag. To determine if the His-tag interfered 
with activity, we generated a new construct containing a TEV-cleavable site 
between the His6 tag and the protein sequence (TEV construct, Fig 5.16 A). This 
construct allowed us to purify the protein using a Ni affinity column and then 
remove the N-terminal His6 tag by TEV protease digestion (courtesy of the Hill 
lab). Unfortunately, we were unable to digest this particular construct with TEV, 
likely due to limited accessibility of the TEV site. To overcome this issue, we 
generated a new Dpo4 construct containing an extended GG insert between the 
His6 tag and the protein sequence (TEVX construct, Fig 5.16 A). Using very high 
concentrations of TEV (~0.1 mg/mL per ~1 mg/mL Dpo4) for an extended 
digestion period (>12 h), we were able to achieve nearly complete TEV cleavage 
to generate the His-tag free protein (Naked WT, NWT construct, Fig 5.16 A). 
Pleasantly, we found that the His-tag-free Dpo4 construct showed PCR ability 
similar to the NEB sample (Fig 5.16 B). 
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Unfortunately, chemical synthesis of His-tag-free Dpo4 would be more 
difficult without the solubilizing N-terminal His6 tag, as described in the peptide 
scouting sections above. Therefore, we then wondered if the inhibitory effect of 
the His6 tag is strictly dependent on (a) the simple presence of an N-terminal His6 
sequence, or (b) the location of our N-terminal His6 being directly abutted against 
the N-terminus of Dpo4. To address this question, we evaluated the PCR ability 
of our TEVX construct (Fig 5.17 A) prior to TEV cleavage. To our surprise, the 
TEVX construct is nearly as active as the NWT Dpo4 protein (Fig 5.17 A). This 
important result means that we can maintain the N-terminal His6 in our synthesis 
strategy by simply distancing it from the Dpo4 protein via TEV linker. 
Alternatively, the tag could still be cleaved by TEV digestion following total 
synthesis (though this would involve a handling step that would diminish yield).  
During the course of our investigation of WT Dpo4 polymerase activity, we 
also developed more gentle conditions that allowed for robust activity of the 
original WT construct (Fig 5.17 B): 5 sec denaturation at 84, 84.9, 86, or 87.2 °C, 
30 sec annealing at 56°, and 1 min extension at 60°, for 25 cycles. 
These conditions employ a shorter denaturation time and lower 
denaturation temperatures compared to our original method. These gentle 
conditions were used to evaluate our DOPPEL changes in the next sections. 
One last design optimization was developed during this stage of testing. 
Based on the data showing that the TEVX and NWT constructs were significantly 
more active than the original WT construct, we recognized that this could be 
exploited to further assist the chemical synthesis. Instead of incorporating a His6 
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sequence, we reasoned that any solubilizing sequence could be introduced in the 
synthetic construct N-terminal to the TEV site for two reasons: 
(1) The His6 sequence is not important for purification of synthetic constructs, 
so any solubilizing sequence could be introduced, and 
(2) The final synthetic construct can be cut with TEV to generate NWT 
sample, so the temporary solubilizing group could be removed before 
activity testing. 
Thus, we modified our synthesis plan to incorporate a Lys7-TEV site at the 
N-terminus instead of the original His6 sequence. Based on solubility data from 
GroES in Chapter 3, poly-Lys is more solubilizing than the corresponding poly-
His. 
 
5.3.4 (2) N-terminal Half: The C31 Conundrum 
Dpo4 (Fig 5.2, 5.5) possesses only one native Cys residue: C31. 
Unfortunately, this one single Cys adds significant complexity to the overall 
assembly. In order to effectively explain this added complexity, it is best to first 
consider the assembly strategy as if there were no native Cys residues, as 
shown in Fig 5.18 A. Here (with no Cys constraints), the six segments can be 
assembled in the most optimal manner (based on solubility, preferred protecting 
groups, and thioester method), and then one single global desulfurization 
reaction is performed at the last step to eliminate the five junction cysteines. 
However, the presence of one native Cys constrains the overall assembly 
strategy. Specifically, there are two different approaches that can be used to 
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retain Cys31.  In the first approach (Fig 5.18 B), the C31 position is internal. 
After the whole protein has been assembled and desulfurized using the 
same approach as Fig 5.18 A, an extra deprotection step would then be 
required. However, obtaining a high-resolution purification between the protected 
Cys protein and deprotected Cys protein in the final full-length product would 
likely be extremely challenging within the context of a 352-aa protein (i.e., ~100 
Da change within a ~42,000 Da protein or ~0.2% difference). Moreover, this 
deprotection step adds an extra handling step at the end of a major synthesis 
project—an undesirable prospect. In the second approach (Fig 5.18 C), the C31 
position is incorporated as a terminal orthogonally-protected Cys. The protein 
would then be assembled maintaining this orthogonally-protected Cys C31. After 
desulfurizing all Cys that are C-terminal to C31, a separate handling step to 
deprotect C31 would be required. This step would then be followed by ligation of 
a short 30-aa peptide that is N-terminal to C31. In addition to adding two extra 
handling steps, this approach would require a high-resolution purification 
between 362-aa and 332-aa proteins, which would also likely be challenging. In 
summary, both “one Cys” approaches are limiting for three reasons:  
(1) An additional Cys deprotection step, associated purification, and loss in 
yield would be required, 
(2) Very challenging, hard-to-resolve purifications would be introduced, and 
(3) These extra steps decrease the overall convergency of the approach. 
Thus, we reasoned that mutation of C31 to any other residue would 
greatly simplify the overall synthesis strategy. To consider this possibility, we 
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employ DOPPEL. 
To evaluate potential changes at position C31, we first performed a 
BLAST search of the top 500 sequences in the NCBI “Reference Proteins 
(refseq)” database. Intriguingly, selection of the Reference Proteins Database 
greatly reduced redundancy compared to the default database entry: “Non-
redundant protein sequences (nr)”. The top 500 hits were aligned using the NIH 
COBALT tool43 and then exported to Jalview44 for further analysis. Within 
Jalview, a redundancy filter was applied at 95%, which reduced the number of 
hits to 312. These data were then imported into the Weblogo program45 for 
presenting sequence alignment data. Based on these data, Gly was surprisingly 
favored at position 31 (Fig 5.19 A). Investigation of the crystal structure produced 
two interesting results: first, C31 is found within a beta-sheet structure and does 
not possess any direct polar contacts with neighboring residues (Fig 5.19 B), and 
second, it is relatively buried within neighboring hydrophobic residues. Finally, a 
preliminary investigation via Rosetta simulation ranked Phe as the least 
disruptive mutation at this position. Based on these data, we evaluated three 
different single mutants: C31F (hydrophobic change supported by crystal 
structure and Rosetta), C31S (classic isosteric mutation), and C31A (another 
isosteric mutation). The C31G mutant was not prepared due to its likely 
disruptive effect within a beta-sheet structure. 
During preliminary studies using DNA extension assays, we found that the 
C31F mutant was the most disruptive mutant (data not shown), and it was not 
further studied. The other two mutants, C31S and C31A, were then evaluated 
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using gentle PCR conditions (5 seconds denaturation at 84, 84.9, 86, or 87.2 °C, 
30 seconds annealing at 56°, and 1 minute extension at 60°, for 25 cycles). Fig 
5.19 C, D shows the less disruptive effect of C31A compared to C31S. Thus, 
C31A was selected as the favored mutation at this position. 
 
5.3.5 (3) N-terminal Half: I101-Inspired Precipitation 
The assembly of the N-terminal half of Dpo4 can be performed in an N->C 
(Fig 5.20 A) or C->N (Fig 5.20 B) direction. Our initial attempt proceeded via the 
N->C pathway. Here, peptides [1-2], [3], and [4] were prepared as C-terminal 
peptide hydrazides, while peptides [3] and [4] were equipped with N-terminal 
Cys. During this initial trial, we found that the [1-2] plus [3] ligation proceeded in a 
straightforward manner, with minimal difficulties associated with either the 
ligation kinetics or the purification step. However, we surprisingly encountered a 
severe aggregation problem when attempting to ligate [1-3] to [4].   
This difficult ligation involves a poorly reactive Ile thioester32, and the 
reaction kinetics we observed were therefore very slow, requiring overnight 
reactions (>12 h) to observe significant product (>30%). However, during the 
reaction, significant and irreversible precipitation occurred despite the denaturing 
conditions (6 M GuHCl). Unfortunately, this precipitation could not be rescued: 
DMF, 8 M GuHCl, water/acetonitrile, nor elevated temperature (~50 °C) had a 
significant effect. Furthermore, based on the reaction input, we found that the 
precipitation contained both ligation product [1-4] and reactant [4], whereas most 
of the unreacted [1-3] remained in solution. This difficulty forced us to reconsider 
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our assembly strategy.  
In response to the N->C challenge, we tested a C->N direction assembly 
strategy (Fig 5.20 B). Here, some issues with protecting group compatibilities 
must first be introduced. Although the peptide hydrazide method is a significant 
advance for accessing thioesters via Fmoc-SPPS46, it is incompatible with the 
most common N-terminal protecting group, Thz (Thiazolidine)47. Unfortunately, 
an easy-to-use, high yield, and commercially viable alternative to Thz, which is 
compatible with hydrazides has not yet been established, although many 
alternatives are under development38c, 48. The incompatibility of Thz with 
hydrazides originates at the activation step (Fig 5.20 C); here, the NaNO2-
mediated activation converts a hydrazide (-NHNH2) into a reactive acyl azide (-
N3) intermediate that can then be displaced by a thiol to generate the active 
thioester for NCL. However, this activation procedure disables the Thz protecting 
group by converting it into a Cys and other unidentified byproducts (data not 
shown). Thus, an alternative protection scheme must be used for N-terminal 
protection in combination with peptide hydrazides for N->C ligations.  
However, it is important to note that peptide hydrazides are compatible 
(Fig 5.20 D) with Thz-ring opening conditions (conversion of Thz -> Cys), via 
methoxyamine hydrochloride treatment (MeONH2). Thus, peptide hydrazides can 
be used for C->N ligations when used in combination with other thioester 
methods. 
Therefore, we used Dawson’s Dbz method49 (Fig 5.20 E) for preparing 
peptide [3] as a thioester. Specifically, peptide [3] was assembled on Dawson 
! 115 
Dbz NovaSyn TGF resin (Novabiochem, 0.22 mmol/g) to prepare a C-terminal 
Dbz (diaminobenzoate) on-resin. Next, the Dbz was activated by addition of p-
nitrophenyl chloroformate and base to generate an Nbz product (N-acyl-
benzimidazolinone). Following peptide cleavage, the [3]-Nbz peptide was purified 
and used for subsequent conversion to a thioester. With purified peptides [3]-Nbz 
and [4] in hand, we again attempted to prepare the N-terminal half. Unfortunately, 
this reaction was again very slow (incomplete after >18 h at 37 °C using 2-3 mM 
peptide concentrations), and precipitation became visually obvious under ligation 
conditions in 6 M GuHCl. Due to the slow reaction kinetics and poor peptide 
solubility, we were unable to isolate a usable amount of product.  
Based on the results using both N->C and C->N assembly strategies, the 
synthetic difficulty of the N-terminal half is likely due to two compounding factors: 
(1) Slow ligation kinetics at the Ile junction between peptides [3] and [4], 
(2) The aggregation propensity of peptide [4] under ligation conditions. 
We reasoned that this challenge offers another case for DOPPEL. The 
aggregation problem could be solved by simply changing the ligation junction 
residue (I101) to a more reactive thioester. The application of a more reactive 
thioester will accelerate NCL kinetics and minimize aggregation simply by 
reducing the reaction time. 
To evaluate potential changes at position I101, we utilized the sequence 
alignment data and crystal structure data from the C31 analysis (above). For 
I101, we found via alignment that Pro was the most statistically favored residue 
(Fig 5.21 A). This substitution would not be helpful, as Pro is the least reactive 
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thioester32. After further evaluating the crystal structure, we found that I101 was 
located within a hydrophobic pocket along a beta-sheet (Fig 5.21 B, C). Based 
on this information, we decided to make two conservative mutations: I101M and 
I101F, both of which would significantly increase thioester reactivity. 
Preliminary DNA extension data led us to remove I101F from 
consideration, as it was very disruptive. In contrast, I101M was found to be 
minimally disruptive compared to WT (Fig 5.21 D) as demonstrated in a PCR 
experiment (5 sec denaturation at 84, 84.9, 86, or 87.2 C, 30 sec annealing at 
56, and 1 min extension at 60, for 25 cycles). Thus, I101M was selected at this 
favored mutation at this position. Preliminary testing of with a [3]-Met thioester 
peptide confirmed accelerated reactivity and significantly less precipitation 
compared to [3]-Ile (data not shown).  
At this stage, two mutations have been identified, using DOPPEL, to 
enhance the Dpo4 synthesis: C31A/I101M. Fig 5.22 shows the activity testing 
data on this new double mutant, confirming minimal effect on activity under 
gentle PCR conditions. 
  
5.3.6 (4) C-terminal Half: Desulfurization Dilemmas 
The success of our Dpo4 design hinges on our ability to perform global 
desulfurization at the last step of the synthesis. In this case, we will be converting 
five Cys to Ala within a >300 residue protein. However, Brik’s group reported24 
significant challenges in desulfurizing seven Cys in their final synthetic 304-aa 
tetraubiquitin. Ultimately, they had to redesign their synthesis strategy to include 
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intermediate desulfurization steps. For our Dpo4 synthesis, we would like to 
avoid this problem. After expending considerable effort preparing the full-length 
construct, it would be extremely disappointing not to be able to desulfurize the 
final ligation junctions. Thus, in order to investigate this potential problem before 
consuming precious synthetic material, we recombinantly engineered artificial 
constructs of Dpo4 with varying numbers of Cys residues to predict the degree of 
desulfurization difficulty. Here, three artificial Dpo4 constructs were prepared, 
with the Cys locations indicated:  
• Multi-Cys construct: 31, 57, 102, 121, 155, 222, 283;  
• N-Cys construct: 31, 57, 102, 121; and  
• C-Cys construct: 31, 155, 222, 283.  
Multi-Cys was generated to create the most challenging desulfurization 
construct, while N-Cys and C-Cys were prepared to localize any challenging Cys 
to either the N- or C-terminal halves of the full-length protein. From our 
preliminary testing, we found the desulfurization of seven Cys to be highly 
challenging, whereas desulfurization of either three or four Cys residues was 
feasible. Although we have concluded that two desulfurizations should be 
employed to favor success in our total Dpo4 synthesis, further studies are 
underway. More broadly (outside of the current Dpo4 project), these constructs 
will be used to inform the most ideal conditions for performing desulfurizations, 
as previous cases in the Kay lab have been relatively simple: one or two Cys per 
short peptide (<150 aa). 
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5.3.7 (5) C-terminal Half: Taking a Step Back in Ligations 
Similar to the N-terminal half, the C-terminal half can be assembled in two 
different ways: N->C (Fig 5.23 A) or C->N (Fig 5.23 B). Although this choice may 
seem inconsequential, it ultimately has a significant effect on the overall yield of 
the C-terminal half—and consequently the entire protein 
Using peptide hydrazides, the N->C assembly of this half must be 
performed using a Cys(ACM) protection at the N-terminus (Fig 5.23 A). 
Unfortunately, this approach would require at least three synthetic steps, with the 
last step being silver-mediated ACM deprotection, which we have found to be 
highly challenging (and low yielding) when handling long poorly-soluble synthetic 
intermediates. In contrast: note that in the synthesis of the N-terminal half 
described above (Fig 5.20), no protection is needed for the unreactive (non-Cys) 
N-terminus. 
On the other hand, the C-terminus could also (theoretically) be assembled 
using a method that does not include peptide hydrazides, but rather exploits the 
benefits of a traditional NCL approach using Thz-protection. Here, Thz-peptide 
thioesters could be used to prepare [5-6] and [7-8]. Then, peptide [8-9] can be 
prepared with N-terminal Cys and C-terminal amide/acid. Using this approach, 
the C-terminal half could be assembled in either one or two steps (Fig 5.23 D, 
E)—with both strategies avoiding ACM deprotection. This is an exciting prospect 
from two perspectives: 
(1) The overall efficiency of the synthesis would be greatly improved, 
(2) This elegant approach entails an appealing combination of classical and 
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modern thioester methods. The classical thioester assembly (C->N) would 
be used to assemble the C-terminal half, while the modern peptide 
hydrazide method (N->C) would be used to assemble the N-terminal half.  
Based on this potentially improved synthesis strategy, we decided to 
prepare peptides [5-6] and [7-8] as Thz-peptide thioesters using the older 
Dawson Dbz method49. Fig 5.24A shows the crude HPLC and MS data on 
peptide [Thz-5-6-Nbz], while Fig 5.24B shows data for the peptide hydrazide 
[Cys(ACM)-5-6- NHNH2]. 
Unfortunately, the quality of the Nbz-produced peptide is clearly worse 
than the peptide hydrazide. The [Cys(ACM)-5-6-NHNH2] peptide shows a clearly 
isolated peak, whereas the [Thz-5-6-Nbz] peptide is a complex mixture that will 
be highly challenging to purify. Fig 5.24C and 5.24D show the crude HPLC and 
MS data for the [Thz-7-8-Nbz] and [7-8-NHNH2] peptides. In this case, the 
decreased quality with the Nbz peptide is even more pronounced, with a 
significant -1997 Da byproduct appearing as the main species. Most of the 
byproducts observed with the Dawson Dbz method were one of three types: (1) 
inadequate conversion of Dbz->Nbz; (2) nonspecific peptide modification with p-
nitrophenyl chloroformation; or (3) impurities likely due to branching at the Dbz 
core. Based on lower quality of the Nbz-peptides, we postponed this approach 





5.3.8 Final Strategy and Pilot Synthesis of Dpo4 
Based on all of the scouting data and DOPPEL work described above, we 
identified our synthesis strategy and DOPPEL changes: 
• Six-piece, convergent assembly strategy (Fig 5.25) 
• C31A and I101M DOPPEL changes 
• Introduction of an N-terminal polyLys sequence, cleavable with TEV 
protease 
We next pursued a pilot total chemical synthesis of Dpo4 using this 
strategy. Due to the convergency of this approach, we were able to 
independently assemble the two protein halves. First, peptide [1-2] was reacted 
[3] generating [1-3] (Fig 5.26 A), which was then reacted with [4] to generate the 
N-terminal half: [1-4] (Fig 5.26 B). Introduction of the I101M mutation was 
essential to assembling the N-terminal half, as the [1-3] plus [4] ligation was 
complete after only 2 h. The N-terminal half was then desulfurized at positions 
C57 and C102 to generate [1-4]-desulfurized (Fig 5.26 C).  
For the C-terminal half of the protein, [ACM-5-6] was ligated to [7-8] to 
generate [ACM-5-8] (Fig 5.27 A), which was then reacted with [8-9] to generate 
the C-terminal half of the protein: [ACM-5-9] (Fig 5.26 B). Removal of the ACM 
protecting group produced the ligation-competent [5-9] (Fig 5.26 C). 
With both halves purified (see Fig 5.28 A, B for closer analysis of the 
Mass Spec data), the final, full-length ligation could be performed. In this case, 
very limited material was available (<1 mg of each half); nevertheless, the final 
ligation showed traces of full-length product by MS (Fig 5.28 C). Unfortunately, 
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insufficient material was obtained for further testing due to limited starting 
material in this pilot synthesis.  
 
5.4 Future Plans 
Push Forward the Dpo4 Synthesis: The Dpo4 synthesis will be scaled-up 
in order to produce usable quantities of functional protein. Some of this work has 
been performed as batches of peptides in the C-terminal have already been 
synthesized. In parallel with the synthesis scale-up, optimized work-up conditions 
for the full-length recombinant product will be performed. Here, recombinant 
Dpo4 will be dissolved in ligation/desulfurization buffer (6 M GuHCl), and different 
conditions will be evaluated for improving the yields of purification via HPLC. The 
transition from 6 M GuHCl to HPLC conditions (0.1% TFA in water/acetonitrile) 
has proven to be a difficult, low-yield step of the assembly process. This can be 
optimized using more recombinant material. 
Further Optimize the Dpo4 Synthesis: Two new Thz-based protecting 
groups are under development for simplifying the assembly of the C-terminal half 
([5-9]). These groups were designed to be peptide hydrazide compatible. See 
Fig 5.29 for details. Here, we found that Meoc-Thz-OH (a simpler version of the 
published Tbeoc-Thz-OH47) reagent was stable to peptide hydrazide activation. 
We also found that the conversion of Meoc-Thz into Thz was greatly accelerated 
by adjusting pH to >8, which overcomes a previous limitation of this reagent50. 
We have also begun preliminary investigations into using pNB(p-nitrobenzyl)-
Thz-OH as an alternative to the Thz-protecting group; this group is theoretically 
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stable to hydrazide activation and can be selectively reduced to the acid-labile 
pAB(p-aminobenzyl)-Thz-OH (ultimately forming Thz-OH) using reducing 
conditions51, such as Pd-based hydrogenation52 or Zn reduction53. 
 
5.5 Acknowledgments 
Dave Kemble, Frank Whitby, Katherine Ferrell, Vish Chandrasekaran 
(University of Utah) for advice and help with cloning and protein expression. 
Katherine Ferrell for providing TEV stocks. 
 
5.6 Materials and Methods 
5.6.1 Peptide Characterization 
All peptides were prepared on a Prelude commercial peptide synthesizer 
(Protein Technologies, Inc.) Peptides with C-terminal amides were prepared on 
TentaGel R RAM resin (0.19 mmol/g, RAPP Polymere). Peptides with C-terminal 
hydrazides were prepared on in-house modified hydrazine-chlorotrityl resin 
based on published protocol46b. Peptides with C-terminal Dbz/Nbz on Dawson 
Dbz NovaSyn TGF resin (0.22 mmol/g, Novabiochem). 
Peptides were analyzed on the following columns (from Phenomenex): 
• Jupiter 5u C4 300A, 4.6 x 150 mm 
• Jupiter 4u C12 Proteo 90A, 4.6 x 150 mm 
• Luna 5u C18(2) 100 A, 4.6 x 250 mm 
• Aeris WIDEPORE C4 3.6u, 2.1 x 50 mm 
Peptides (following ligations, desulfurizations, and ACM-deprotections) were 
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purified on the following semiprep-scale columns (from Phenomenex): 
• Jupiter 5u C4 300A, 10 x 250 mm 
• Jupiter 10u C4 300A, 10 x 250 mm 
• Jupiter 4u C12 Proteo 90A, 10 x 250 mm 
Crude peptides were purified on the following prep-scale columns (from 
Phenomenex): 
• Jupiter 10u C4 300A, 21.2 x 250 mm 
• Jupiter 4u C12 Proteo 90A, 21.2 x 250 mm 
Mass spectrometry characterization of peptides was performed using an AB 
Sciex 3000 LC/MS/MS system. 
 
5.6.2 Native Chemical Ligation and Desulfurization 
NCL reactions were performed according to standard protocols in the 
field54, with specific adjustments for peptide hydrazides46-47, 55. Desulfurization 
reactions were performed according to the established free-radical protocol56, 
using reduced glutathione as the thiol scavenger. 
 
5.6.3 Cloning and Protein Expression 
Dpo4 S. solfataricus sequence (WP_009993137.1) was cloned into 
pEXP5.CT vector. Mutant versions of Dpo4 were produced either by 
Quickchange strategy or ‘round-the-horn’ PCR methodology. All mutants were 
confirmed by sequencing using T7 primers. Dpo4 was expressed using either 
BL21(DE3) pLysS (all constructs except for TEV-containing constructs) or BL21-
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CodonPlus (DE3)-RIPL cells (for TEV-containing constructs). Proteins were 
expressed by autoinduction method. After overnight expression, cells were 
pelleted and then lysed with lysosome and sonication. The lysed material 
(soluble fraction) was collected by centrifugation and applied to Ni-NTA beads for 
purification, followed by overnight dialysis (4 °C) into 50 mM Tris pH 8, 50 mM 
NaCl, 1 mM DTT. After dialysis, samples were purified by HPLC on a 
Phenomenex C4 column and then lyophilized. 
 
5.6.4 Refolding Protocol 
Lyophilized Dpo4 powder was suspended in denaturation buffer (6 M 
GuHCl, 50 mM Tris pH 8, 50 mM NaCl) to ~25 µM and then dialyzed overnight at 
4 °C, using Slide-a-Lyzer dialysis cassettes 3,500 MWCO, into the same buffer 
without GuHCl. Sampels were then spun to remove any precipitation and protein 
concentration was measured using an extinction coefficient of 19,200 cm-1 M-1. 
 
5.6.5 PCR Protocol 
PCR activity assays (for comparing activity of our Dpo4 recombinant 
constructs) was performed on a Biorad C1000 Touch Thermal Cycler. For each 
25 µl reaction, 140 ng of M13KE plasmid template DNA  and 1 µM 
concentrations of two primers: 
• M13 1470: cgcaactatcggtatcaagc 

















Figure 5.1: Dpo4 crystal structure. Crystal structure shows the four key 
polymerase domains: thumb (green), palm (red), finger (blue), and little 













        10         20         30         40         50         60         70 
MIVLFVDFDY FYAQVEEVLN PSLKGKPVVV AVFSGRFEDS GAVATANYEA RKFGVKAGIP IVEAKKILPN 
        80         90        100        110        120        130        140 
AVYLPMRKEV YQQVSSRIMN LLREYSEKIE IASIDEAYLD ISDKVRDYRE AYNLGLEIKN KILEKEKITV  
       150        160        170        180        190        200        210 
TVGISKNKVF AKIAADMAKP NGIKVIDDEE VKRLIRELDI ADVPGIGNIT AEKLKKLGIN KLVDTLSIEF  
       220        230        240        250        260        270        280 
DKLKGMIGEA KAKYLISLAR DEYNEPIRTR VRKSIGRIVT MKRNSRNLEE IKPYLFRAIE ESYYKLDKRI  
       290        300        310        320        330        340        350 
PKAIHVVAVT EDLDIVSRGR TFPHGISKET AYSESVKLLQ KILEEDERKI RRIGVRFSKF IEAIGLDKFF 
352      
 DT 
Segment Length Sequence 
[s1] 31 MIVLFVDFDYFYAQVEEVLNPSLKGKPVVVA 
[s2] 40 VFSGRFEDSGAVATANYEARKFGVKAGIPIVEAKKILPNA 
[s3] 49 VYLPMRKEVYQQVSSRIMNLLREYSEKIEIASIDEAYLDISDKVRDYRE 
[s4] 44 AYNLGLEIKNKILEKEKITVTVGISKNKVFAKIAADMAKPNGIK 
[s5] 38 VIDDEEVKRLIRELDIADVPGIGNITAEKLKKLGINKL 
[s6] 26 VDTLSIEFDKLKGMIGEAKAKYLISL 
[s7] 39 ARDEYNEPIRTRVRKSIGRIVTMKRNSRNLEEIKPYLFR 
[s8] 43 AIEESYYKLDKRIPKAIHVVAVTEDLDIVSRGRTFPHGISKET 
[s9] 42 AYSESVKLLQKILEEDERKIRRIGVRFSKFIEAIGLDKFFDT 
A 
B 
Figure 5.2: Initial breakdown of the 352-residue Dpo4. (A) Protein sequence 
of Sulfolobus solfataricus Dpo4, NCBI reference: NP_343798.1 (B) Breakdown 
of the protein sequence into nine peptides for exploratory synthesis and 
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[s1] [s2] [s3] 
[s4] [s5] [s6] 
[s7] [s8] [s9] 
A B C 
D E F 
G H I 
Figure 5.3: HPLC of the initial nine peptides. (A) – (I) Crude HPLC traces 
of the nine initial scouting peptides covering the Dpo4 sequence. Samples 














Segment Length Full Peptide Sequence Calc Mass (Da) 
Obs Mass 
(Da) Major Byproducts 
[s1] 31 MIVLFVDFDYFYAQVEEVLNPSLKGKPVVVA-NHNH2 3545.1 3545.2 
3431.5 (-Ile/Leu), 
3413.8 (-Met), 3446.2 (-
Val) 
[s2] 40 PenFSGRFEDSGAVATANYEARKFGVKAGIPIVEAKKILPNA-NHNH2 4268.8 4267.9 
4136.7 (-Pen), 4307.5 
(+40), 4490.5 (+Fmoc) 
[s3] 49 PenYLPMRKEVYQQVSSRIMNLLREYSEKIEIASIDEAYLDISDKVRDYRE-NHNH2 6001.8 6002.5 
5889.3 (-Ile/Leu), 
5986.1 (aspartimide), 
5872.6 (-Ile/Leu + 
aspartimide) 
[s4] 44 CYNLGLEIKNKILEKEKITVTVGISKNKVFAKIAADMAKPNGIK-NHNH2 4846.8 4846.7 
4733.1 (-Ile/Leu), 
4718.4 (-Glu), 2456.5 
(truncation)   
[s5] 38 PenIDDEEVKRLIRELDIADVPGIGNITAEKLKKLGINKL-NHNH2 4275.9 4275.1 
4315.1 (+40 Da), 
4300.7 (+26 Da), 4260 
(aspartimide) 
[s6] 26 PenDTLSIEFDKLKGMIGEAKAKYLISL-NHNH2 2929.4 2928.8 
2798.2 (-Pen), 2968.9 
(+40 Da), 2839.9 (-90 
Da) 
[s7] 39 CRDEYNEPIRTRVRKSIGRIVTMKRNSRNLEEIKPYLFR-NHNH2 4852.6 4852.1 
4948.1 (TFA adduct), 
2889.9 (Truncation), 
4909.6 (OtBu adduct) 
[s8] 43 CIEESYYKLDKRIPKAIHVVAVTEDLDIVSRGRTFPHGISKET-NHNH2 4929.6 4928.9 
4968.9 (+40 Da), 
4852.2 (-77 Da), 4913.1 
(aspartimide) 
[s9] 42 CYSESVKLLQKILEEDERKIRRIGVRFSKFIEAIGLDKFFDT-NH2 5020.8 5020.7 
4907.5 (-Ile/Leu), 
4892.3 (-Gln/Lys), 4921 
(-Val) 
Table 5.1: Mass spec summary of the initial nine peptides. Mass Spec 
of the initial nine peptides, including the observed (deconvoluted) masses 
and major byproducts for each peptide. Sites of pseudoproline dipeptides 
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Retention time (min) 
Segment Length Full Peptide Sequence Calc Mass (Da) 
Obs Mass 
(Da) Major Byproducts 
[His-s1] 37 HHHHHHMIVLFVDFDYFYAQVEEVLNPSLKGKPVVVA-NHNH2 4368.0 4367.7 
4254.2 (-Ile/Leu/Asn), 
4230.7 (-His) 
Segment Length Full Peptide Sequence Calc Mass (Da) 
Obs Mass 
(Da) Major Byproducts 










Figure 5.4: Analysis of two additional scouting peptides. (A) HPLC 
analysis of crude [ASIDE] peptide; (B) Mass Spec summary of [ASIDE] 
peptide; (C) HPLC analysis of [His-s1]; (D) Mass Spec summary of [His-s1] 
peptide. * and # indicate -18 Da aspartimide and +67 Da piperidine adduct 
byproducts. [ASIDE] was analyzed on C4-Aeris column (2.1 x 50 mm) and 









         2         12         22         32         42         52         62 
MHHHHHHGGI VLFVDFDYFY AQVEEVLNPS LKGKPVVVCV FSGRFEDSGA VATANYEARK FGVKAGIPIV  
        72         82         92        102        112        122        132 
EAKKILPNAV YLPMRKEVYQ QVSSRIMNLL REYSEKIEIA SIDEAYLDIS DKVRDYREAY NLGLEIKNKI  
       142        152        162        172        182        192        202 
LEKEKITVTV GISKNKVFAK IAADMAKPNG IKVIDDEEVK RLIRELDIAD VPGIGNITAE KLKKLGINKL  
       212        222        232        242        252        262        272 
VDTLSIEFDK LKGMIGEAKA KYLISLARDE YNEPIRTRVR KSIGRIVTMK RNSRNLEEIK PYLFRAIEES  
       282        292        302        312        322        332        342 
YYKLDKRIPK AIHVVAVTED LDIVSRGRTF PHGISKETAY SESVKLLQKI LEEDERKIRR IGVRFSKFIE 






































VT, VS, ES, FS, 
DT 
n/a 
Figure 5.5: Final six-segment breakdown of the 352-residue Dpo4. (A) 
Protein sequence of Sulfolobus solfataricus Dpo4, NCBI reference: 
NP_343798.1; (B) Breakdown of the protein sequence into six peptides for the 
total synthesis. Sites of pseudoproline dipeptides and (Dmb)Gly are indicated 
in bold and underline. 
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p = (n*2) - 1 































Figure 5.6: Relationship between peptide segments and minimum total 
number of purifications. (A) Table summarizing the relationship between 
peptides and purifications; (B) Optimal assembly strategy starting with nine 






















































Figure 5.7: HPLC on the final six crude peptides. (A) Peptide [1-2]; (B) Peptide 
[3]; (C) Peptide [4]; (D) Peptide [5-6]; (E) Peptide [7-8]; (F) Peptide [8-9]. All 





























































Figure 5.8: Analysis of pure [1-2] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 




















































Figure 5.9: Analysis of pure [3] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 






















































Figure 5.10: Analysis of pure [4] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 



















































C Calc: 7449.5 
Obs: 7449.1 
Figure 5.11: Analysis of pure [5-6] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 

























































Figure 5.12: Analysis of pure [7-8] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 























































Figure 5.13: Analysis of pure [8-9] peptide. (A) HPLC on C4-Aeris column; (B) 
Observed ions (charge states); (C) Deconvoluted Spectra. Calculated theoretical 
mass is based on the peptide sequence, while observed mass is the mass average 




















































































*" *" *" *" *" *"
Figure 5.14: Optimization of [1-2] and [5-6] crude peptides. (A) [1-2], 
with (Dmb)Gly position indicated in blue; (B) [6]-only; (C) [6] with DT-psi; 
(D) [6] with DT-psi and (Dmb)Gly; (E) [6] with DT-psi and select Lys(Mtt) 
incorporation; (F) [6] with DT-psi and select Lys(Dde) incorporation; (G) [5-
6] with DT-psi; (D) [5-6] with DT-psi and (Dmb)Gly. HPLC of [1-2] peptide 
analyzed on C4-Aeris column (2.1 x 50 mm); [6] and [5-6] peptides were 
analyzed on C12-column (4.6 x 150 mm). * indicates sites of alternative 





















































Figure 5.15: Optimization of [2] and convergent assembly. HPLC 
analysis of (A) [2] at 0.5 mmol/g density; and (B) [2] at 0.2 mmol/g. Peptides 
were analyzed on C12-column (4.6 x 150 mm). (C) Summary of the 
















A WT construct:         MHHHHHHGGIVLFVDFDYFY........ 
TEV construct:    MHHHHHHENLYFQGIVLFVDFDYFY........ !
TEVX construct: MHHHHHHENLYFQGGGIVLFVDFDYFY........ !
NWT construct:            GGGIVLFVDFDYFY........  !
1!
2! 3! 4,5! 6,7!
8!






86° 89° 90.6° 92° 
WT 
86° 89° 90.6° 92° 
NWT 
86° 89° 90.6° 92° 
Figure 5.16: Identification of the His tag issue. (A) N-terminal 
sequences of various Dpo4 constructs; (B) 1% agarose gels on PCR 
activity assays; (C) Sequence comparison of the WT and NEB samples. 
Note that the PCR activity data were run on the same gel, but lanes have 










86° 89° 90.6° 92° 
TEVX 
86° 89° 90.6° 92° 
B WT NEB 
84° 84.9° 86° 87.2° 84° 84.9° 86° 87.2° 
Figure 5.17: Additional PCR on recombinant constructs. (A) 1% 
agarose gel on PCR activity assays using original denaturation conditions; 
(B) 1% agarose gel on PCR activity assays using gentle denaturation 
conditions. Note that PCR activity data were run on the same gel, but lanes 



















A No Native Cysteines 
Global 
Desulfurization 
B One Native Cysteine – Approach #1 


















Figure 5.18: Assembly strategies for handling one cysteine. (A) No Cys 
assembly strategy; (B) One Cys assembly strategy – approach #1; (C) One 
Cys assembly strategy – approach #2. Red stars indicate junction site Cys 
that need to be desulfurized. Blue dagger indicates the one native Cys that 












84° 84.9° 86° 87.2° 84° 84.9° 86° 87.2° 
C31S 
84° 84.9° 86° 87.2° 
C31A 
Figure 5.19: DOPPEL analysis at Cys31. (A) Sequence alignment data, 
with position 31 indicated with red arrow; (B, C) Analyses of the crystal 
structure at position 31 (1JXL.pdb) Sulfur residue at C31 is shown in orange. 
(D) 1% agarose gel on PCR activity assays using gentle denaturation 
conditions. Note that WT and C31S PCR activity data were run on the same 
gel, but lanes have been repositioned to simplify data presentation. C31A 



















A N->C Direction Assembly C->N Direction Assembly B 
Hydazide Incompatibility C 





[A] -N3 Cys- +"
+" [A] -N3 ???- 
[A] -NHNH2 Thz- 
MeONH2 
[A] -NHNH2 Cys- 
[B] -SR 
[A] -NHNH2 [B] 
NaNO2 
pH 3 
[A] -N3 [B] 
[C] Cys- 
[A] [B] [C] 
Thiols, pH 7 
Thiols, pH 7 
Hydazide Compatibility D 
Dawson Dbz method E 




[A] -Nbz Thz- [A] -SR Thz- 
Thiols, pH 7 
Figure 5.20: Chemical assembly strategies for N-terminal half. (A) N-
>C direction assembly; (B) C->N direction assembly; (C) Demonstration 
of the hydrazide-Thz incompabibility; (D) Demonstration of the hydrazide-
Thz compatibility; (E) General activation method for Dawson Dbz/Nbz 














84° 84.9° 86° 87.2° 
C 
I101M 
84° 84.9° 86° 87.2° 
Figure 5.21: DOPPEL analysis at Ile101. (A) Sequence alignment data, with 
position 101 indicated with red arrow; (B, C) Analyses of the crystal structure 
at position 101 (1JXL.pdb) In right panel, residue at I101 is shown in pink. (D) 
1% agarose gel on PCR activity assays using gentle denaturation conditions. 
Note that PCR activity data were run on the same gel, but lanes have been 















84° 84.9° 86° 87.2° 
C31A+I101M 
84° 84.9° 86° 87.2° 
Figure 5.22: Activity analysis of the double mutant (C31A/I101M). 1% 
agarose gel on PCR activity assays using gentle denaturation conditions. Note 













ACM-based Design: 3 purifications 
















Thz-[7-8] -Lys [5-6-7-8-9] 
A N->C Direction Assembly 















Figure 5.23: Chemical assembly strategies for C-terminal half. (A) N->C 
direction assembly; (B) C->N direction assembly; (C) ACM-based approach; (D) 





































































































Obs: 5495.0 & 
          7492.3 
Figure 5.24: Synthesis of [5-6] and [7-8] by Dawson and hydrazide 
methods. (A) HPLC and MS of [Thz-5-6-Nbz]; (B) HPLC and MS of [ACM-5-
6-NHNH2]; (C) HPLC and MS of [Thz-7-8-Nbz];  (D) HPLC and MS of [7-8-






























1. Oxidation ([5-6]) 
2. NCL([5-6]+[7-8]) 
(ACM) 





1. Oxidation ([1-4]) 
2. NCL([1-4]+[5-9]) 
1. Oxidation ([1-3]) 
2. NCL([1-3]+[4]) 
M---A154-NHNH2 






































































































Figure 5.26: MS on the N-terminal intermediates. (A) Peptide [1-3]; (B) 

































































































Figure 5.27: MS on the C-terminal intermediates. (A) Peptide [ACM-5.8]; 














































Figure 5.28: MS on the key intermediates and final product. (A) 
Magnified MS trace on peptides [1-4] and [1-4]-desulfurized; (B) 
Magnified MS trace on peptides [5.9] and [ACM-5.9]; (C) Magnified MS 







































































































Figure 5.29: Dpo4 future directions. (A) Deprotection mechanism for Tbeoc-
Thz; (B) Deprotection mechanism for pNB-Thz; (C) Time-course of Meoc-Thz-
RWSTEVEA-NHNH2 peak area under different pH values; (D) Time-course of 
Thz-RWSTEVEA-NHNH2 peak area under different pH values. 
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